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1 Introduction 
1.1 The hallmarks of cancer - Functional capabilities of 
tumor cells 
Cancer, as a leading cause of death worldwide, is a global health problem and its occurrence is 
increasing due to demographic changes and unhealthy lifestyle behaviors1. 
The multistep process of tumor formation and progression is accompanied by the acquirement of 
several functional features, known as hallmarks of cancer (Figure 1-1), which ensure survival, 
proliferation and dissemination of tumor cells2.  
 
Figure 1-1. The hallmarks of cancer 
Scheme of the functional capabilities of tumors acquired during tumorigenesis. (Modified from Hanahan and 
Weinberg, Cell 20112) 
Genome instability and mutation is causal for tumorigenesis. While the accumulation of 
spontaneous mutations during cell replication is very low, due to high efficiency and accuracy of 
deoxyribonucleic acid (DNA) repair mechanisms in normal cells, cancerous cells develop 
numerous mutations. This results from a compromised DNA repair system by inactivating 
mutations and/or epigenetic repression via DNA methylation and histone modifications2. Loss of 
function of the genes ATM (ataxia telangiectasia mutated), BRCA1 (breast cancer 1), BRCA2, 
BAP1 (BRCA1-associated protein 1), MLH1 (mutL homolog 1), MSH2 (mutS homolog 2), MSH6 
and STAG2 (stromal antigen 2), which are involved in DNA damage control, were demonstrated in 
several tumors and thereby behave as tumor suppressor genes3.  
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The accumulation of mutations is further accelerated by impaired surveillance systems that 
normally safeguard genomic integrity. Loss of tumor suppressor TP53 (tumor protein p53), known 
as the guardian of the genome, is the most prominent example. It plays a crucial role in triggering 
cell death as a response to DNA damage3 and is said to be the most frequently mutated gene in 
human tumors4. Other tumor suppressor genes involved in cell survival or fate, which show a loss 
of function in several types of cancer, are PTEN (phosphatase and tensin homolog), TET2 (tet 
oncogene family member 2) and VHL (von Hippel-Lindau). Besides, several oncogenes implied in 
cell survival or fate are activated in tumors, including AKT (v-akt murine thymoma viral oncogene 
homolog 1), BCL2 (B cell CLL/lymphoma 2), BRAF (v-raf murine sarcoma viral oncogene 
homolog B1), EGFR (epidermal growth factor receptor), HRAS (v-Ha-ras Harvey rat sarcoma viral 
oncogene homolog), KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog), NRAS 
(neuroblastoma RAS viral oncogene homolog), IDH1 (isocitrate dehydrogenase 1), IDH2 and 
MYC (v-myc avian myelocytomatosis viral oncogene homolog)3. Additionally, in premalignant 
lesions, decreased telomerase expression leads to the loss of telomers and successive 
chromosomal aberrations. Resulting amplification or deletion of chromosomal segments also 
favors tumor-promoting mutations2. 
The most essential characteristic and thereby important hallmark of cancer is sustained 
proliferative signaling. In normal tissues, cell growth and cell division are elaborately regulated 
by the production and release of growth factors in order to maintain cell homeostasis and normal 
tissue function. In cancer, this signaling is deregulated. The production of growth factor ligands by 
tumor cells themselves or by stroma cells after stimulation with tumor-derived signals leads to 
tumor cell proliferation. Upregulation of growth factor receptors on tumor cells renders them 
hyperresponsive and allows proliferation, also in the presence of otherwise insufficient amounts of 
growth factor ligands. Alterations in the structure of growth factor receptors of tumor cells even 
permit ligand-independent activation and thereby growth factor independence. Furthermore, also 
independent of ligand-receptor interactions is a constitutive activation of downstream signaling 
pathways2. Structural changes of the BRAF protein by activating mutations, which were observed 
in a multitude of melanoma patients, for instance, result in constitutive signaling of the RAF to 
mitogen-activated protein (MAP)-kinase pathway5. Similarly, a wide range of tumors exhibit 
mutations in phosphoinositide 3-kinase (PI3K) isoforms, which leads to the hyperactivation of the 
AKT signal transducer. The loss of negative feedback mechanisms further supports constant 
proliferation of tumor cells. Prominent examples are the compromised RAS GTPase activity due 
to oncogenic mutations in RAS genes and loss-of-function mutations in the tumor suppressor 
PTEN, which counteracts PI3K in non-malignant cells, leading to amplified PI3K signaling in tumor 
cells6,7. 
In support of sustained proliferative signaling is the evasion of growth suppressors. This cancer 
hallmark implies the circumvention of mechanisms that negatively regulate cell proliferation. 
Thereby tumor suppressor genes play critical roles. The RB (retinoblastoma-associated) and 
TP53 proteins are potent inhibitors of proliferation. In case of stress or abnormality signals, TP53 
can arrest cell-cycle progression until normalization or trigger apoptosis in the event of irreparable 
damage. Thus, the inactivation of these tumor suppressor genes results in ablation of cell-cycle 
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control. Additionally, the orchestration of contact inhibition, meaning the suppression of cell growth 
upon cell-to-cell contact in dense populations, serves to overcome proliferative barriers2. 
Another hallmark of cancer is the resistance to cell death. Apoptosis, which is programmed cell 
death, has been recognized as a protective mechanism for cancer development. Hereby, 
extracellular death-inducing signals, involving, e.g., Fas receptor/Fas ligand (FAS/FASL) 
interactions, or intracellular signals result in the activation of caspase 8 or 9, initiating proteolysis 
by effector caspases and the subsequent disassembling and phagocytosis of the cell. Important 
pro-apoptotic triggering proteins are BAX (BCL2-associated X protein) and BAK (BCL2 
antagonist/killer) which are inhibited by anti-apoptotic proteins like BCL2. Tumors developed a 
multiplicity of apopotosis-evasion strategies, including the loss of TP53 as a damage-sensing and 
apoptosis-inducing factor, the upregulation of anti-apoptotic regulators like BCL2, along with the 
downregulation of pro-apoptotic factors like BAX and the avoiding of extrinsic ligand-induced 
death pathways2. 
Replicative immortality, which enables tumor cells to generate macroscopic tumors, is also 
regarded as a hallmark of cancer. Telomeres, which are responsible for the protection of 
chromosome ends and which shorten during cell replication, are thought to be centrally involved in 
the trait of unlimited proliferation of tumor cells. The upregulation of telomerase expression and 
subsequent maintenance of telomeric DNA, thus, secures integrity of chromosome ends and 
allows tumor outgrowth2. 
In a later stage of tumor formation, a trait that was thought to be important was the generation of 
neovasculature by the process of angiogenesis. The fact that recent data revealed a critical role 
of angiogenesis also in premalignant neoplastic growth cemented its status as an integral 
hallmark of cancer. Vasculature, which is in charge of nutrient- and oxygen-supply for tissues as 
well as the elimination of metabolic waste products and carbon dioxide, develops during 
embryogenesis and becomes largely quiescent in adults. Contrarily, in tumor cells, established 
vasculature grows new vessels (angiogenesis). This process is mostly controlled by the 
upregulation of vascular endothelial growth factor A (VEGF-A) in areas of inadequate oxygen 
supply (hypoxia) or via oncogenic signaling2. 
Another hallmark of cancer is tumor-promoting inflammation2. This is described by the 
expression that tumors are wounds that never heal8. Practically every tumor is infiltrated by 
immune cells, which secrete growth factors, survival factors and pro-angiogenic factors, and 
thereby contribute to tumor growth and metastasis. By the supply of mentioned bioactive 
molecules, tumor-promoting inflammation can, therefore, contribute to multiple hallmark 
capabilities2. 
Activating invasion and metastasis is the last step in tumor progression for many types of 
cancer. This hallmark implies the dissemination of primary tumor cells to distant sites. A key 
molecule involved in metastasis is the cell-to-cell adhesion protein E-cadherin, whose 
downregulation and inactivation was frequently observed in human cancer2. 
The eight hallmarks mentioned above have been shown to be fundamental acquired capabilities 
in most types of tumors, elucidating, in part, the complex biology of cancer. Yet, two other striking 
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traits of tumors came into focus during the past years: deregulated energy metabolism and 
evasion of immune destruction2.  
In the following chapters, these two novel aspects will be further highlighted. 
1.2 Tumor metabolism 
Tumors show alterations in their metabolism to fulfill the demands of hyperproliferation. Besides 
orchestrated glutamine pathways, the most prominent changes occur in glucose metabolism, 
which is mainly responsible for energy production, but also important for the generation of building 
blocks for cell proliferation9. Alterations in glucose metabolism, as well as alterations regarding 
amino acid and lipid metabolism, will be described in detail in the following chapters. 
1.2.1 Glucose metabolism 
In the presence of oxygen, non-malignant cells take up glucose via glucose transporter 1 (GLUT1) 
and convert it to pyruvate, which is then transported into the mitochondria to fuel oxidative 
phosphorylation (OXPHOS) and maximize energy yield in form of adenosine triphosphate (ATP) 
production. Contrarily, in most cancer cells, pyruvate is metabolized to lactate by lactate 
dehydrogenase 5 (LDH-5), even in the presence of oxygen. Lactate is exported from the cell via 
monocarboxylate transporters (MCTs) to allow constant glycolytic activity. This process is known 
as aerobic glycolysis or “Warburg effect” after its discoverer, Nobel prize laureate Otto Warburg 
(Figure 1-2)10.  
 
Figure 1-2. Tumors are characterized by accelerated aerobic glycolysis (Warburg phenotype) 
Glucose transporter 1 (GLUT1) enables glucose uptake into the cell which is followed by the conversion to 
pyruvate. In tumor cells, instead of introducing glucose-derived pyruvate into the mitochondria for efficient 
energy generation, pyruvate is metabolized to lactate by means of lactate dehydrogenase 5 (LDH-5), 
regardless of the presence of oxygen (O2), and exported from the cell via monocarboxylate transporters 1 
and 4 (MCT1/4). 
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The considerable lower ATP yield of glycolysis compared to OXPHOS in cancer cells is 
counterbalanced by an upregulation of GLUT1, leading to increased glucose uptake and an 
increased flux rate to fulfill the tumor’s energy demand11-13. 
Glucose uptake serves as a potent tool for tumor diagnosis and staging: positron emission 
tomography (PET) measures the uptake and accumulation of the non-metabolizable glucose 
analog 18F-fluorodeoxyglucose (18F-FDG) by tumor cells. Nowadays, the availability of a wide 
range of radiotracers also facilitates the investigation of various other aspects of aberrant tumor 
metabolism, like amino acid uptake, fatty acid and nucleotide synthesis14. 
At first sight, it seems contradictory that cancer cells prefer the inefficient aerobic glycolysis to 
generate ATP. However, ATP levels in highly proliferating cells relying on aerobic glycolysis seem 
to be sufficient12,15.  
Otto Warburg attributed the accelerated glycolysis to a disturbed mitochondrial function in tumor 
cells10, which today is disproved by several groups, showing that glycolysis is also performed by 
tumor cell lines with unimpaired mitochondrial capacity16. Furthermore, it has been shown recently 
that some tumor cells even depend on mitochondrial activity17. 
Another hypothesis was that aerobic glycolysis provides a selection advantage in hypoxic areas of 
tumors, where oxygen supply is insufficient18. However, studies by Vander Heiden and colleagues 
demonstrated that the accelerated glycolysis is not only important for energy production but also 
needed for the generation of building blocks. Glycolytic intermediates fuel the synthesis of non-
essential amino acids and lipids, and serve for the generation of nucleotides via the pentose 
phosphate pathway (PPP), thereby providing increasing biomass to support rapid cell division 
(Figure 1-3)9. 
1.2.1.1 Molecular mechanisms of metabolic reprogramming 
70% of all human tumors display overexpression of glycolysis-related genes19. The glycolytic 
switch and increased flux of glucose and also glutamine by cancer cells is regulated by hypoxia-
inducible factor (HIF), oncogenes and tumor suppressor genes, in order to maximize the synthesis 
of substrates for membranes, nucleic acids and proteins required for cell growth and division20. 
The HIF family comprises three transcription factors, HIF-1, HIF-2 and HIF-3, which are 
heterodimers consisting of a stable β-subunit and an unstable α-subunit. Under normoxic 
conditions, the α-subunit is degraded by oxygen-dependent prolyl hydroxylases (PHDs) and by 
the von Hippel-Lindau (VHL) ubiquitin ligase. In hypoxia, which frequently occurs in advanced 
tumors21, the α-unit is stabilized and assembles with the β-unit22. Activation of HIF-1 leads to its 
binding to hypoxia response elements in the nucleus and to the transcription of several glycolysis-
associated genes like GLUT1, HK1 (hexokinase 1), HK2, LDHA and MCT423,24. Additionally, 
pyruvate dehydrogenase kinase 1 (PDK1) is activated and reduces the conversion of pyruvate to 
acetyl coenzyme A (acetyl-CoA) by inhibiting pyruvate dehydrogenase (PDH)25. Together, these 
alterations compromise OXPHOS, accelerate glycolysis and drive tumor cells into a Warburg 
phenotype.  
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Moreover, oncogenes and tumor suppressor genes regulate tumor metabolism and HIF activation 
independently of oxygen supply. The loss of the tumor suppressor gene PTEN augments nutrient- 
and mitogen-sensing PI3K/AKT and mTOR (mammalian target of rapamycin) activity, which in 
turn activate HIF20. Impairment of PHD activity through accumulation of tricarboxylic acid (TCA) 
cycle intermediates like succinate due to mutations of genes coding for the TCA cycle proteins 
succinate dehydrogenase (SDH) and fumarate hydratase (FH) represent another oxygen-
independent pathway of HIF stabilization and activation26. 
HIF-1α stabilization is associated with poor prognosis in gastric cancer and linked to decreased 
chemo- and radiosensitivity27,28. HIF is not only upregulated in cancer cells but also in cells of the 
tumor stroma. In myeloid-derived suppressor cells (MDSCs), which accumulate in many tumor 
types, HIF-1 was found to regulate their function and differentiation29.  
Furthermore, HIF interacts with other transcription factors like MYC30. Oncogenic MYC activates 
transcription of more than 1,000 genes involved in proliferation and metabolism, like glutaminase-
1, which converts glutamine to glutamate. MYC is also responsible for the transcription of genes 
for ribosomal RNA and proteins assuring protein synthesis and increase in biomass20. Another 
MYC-responsive gene is LDHA, which is highlighted in Chapter 1.2.1.231. The tumor suppressor 
TP53 represents the most frequently mutated gene in human tumors4. It positively regulates 
OXPHOS via upregulation of the synthesis of the cytochrome C oxidase 2 gene. Accordingly, loss 
or mutation of TP53 accelerates glycolysis32. Furthermore, Bensaad et al. identified a TP53-
inducible gene named TIGAR (TP53-induced glycolysis and apoptosis regulator), which directly 
inhibits glycolysis and redirects glucose to the PPP33. Activated TP53 also induces the 
transcription of PTEN, which negatively modulates the AKT-mTOR pathway, resulting in the arrest 
of cell growth and division34. Likewise, TP53-directed apoptosis and activation of autophagy can 
occur, e.g., in case of DNA damage35. 
In summary, a network of transcription factors, upregulated oncogenes, like MYC, and loss of 
tumor suppressors, like TP53 or PTEN lead to cancer-associated modifications in glucose 
metabolism resulting in a Warburg phenotype accompanied by alterations in amino acid 
metabolism (Figure 1-3)23.  
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Figure 1-3. Energy metabolism of cancer cells is controlled by alterations in oncogenes and tumor 
suppressor genes 
Scheme depicting the interconnections of glycolysis, oxidative phosphorylation (OXPHOS), glutaminolysis 
and the pentose phosphate pathway (PPP). Metabolites generated during glycolysis and the tricarboxylic 
acid (TCA) cycle fuel the synthesis of nucleotides, amino acids and lipids. The influence of HIF-1 (grey), 
tumor suppressor TP53 (green) and oncogenes MYC and PI3K/AKT (orange) on a variety of enzymes and 
transporters of metabolic pathways is illustrated. Dotted arrows represent positive and bars represent 
negative impacts. Glucose-6-P, glucose-6-phosphate; 6-P-GL, 6-phosphogluconolactone; 6-P-G, 6-
phosphogluconate; Ribose-5-P, ribose-5-phosphate; GLUT1, glucose transporter 1; HK, hexokinase; PKM2, 
pyruvate kinase M2; LDH-5, lactate dehydrogenase 5; MCT1/4, monocarboxylate transporter 1 and 4; MPC, 
mitochondrial pyruvate carrier; PDH, pyruvate dehydrogenase; PDK1, pyruvate dehydrogenase kinase 1; α-
KG, α-ketoglutarate; GLS, glutaminase; IDH1, isocitrate dehydrogenase 1. (Adapted from Vander Heiden et 
al., Science 20099) 
1.2.1.2 Lactate dehydrogenase 
LDH is a major enzyme involved in the Warburg effect. It is a tetramer and composed of two 
different protein subunits, LDHA (LDH-M, muscle) and LDHB (LDH-H, heart), encoded by the 
LDHA gene and LDHB gene, respectively. Subunit A and B can form five possible 
tetramers/isoenzymes: LDH-1 (B4), LDH-2 (B3A1), LDH-3 (B2A2), LDH-4 (B1A3) and LDH-5 
(A4). LDHs catalyze the interconversion of pyruvate and lactate, dependent on the composition of 
the protein subunits. The LDH-1 enzyme, which is present in oxygenated tissues, e.g., the heart 
muscles, predominantly catalyzes the conversion of lactate to pyruvate. Conversely, the LDH-5 
enzyme, mainly found in the skeletal muscle, catalyzes the conversion of pyruvate to lactate, 
coupled with the restoration of NAD+ (nicotinamide adenine dinucleotide), which in turn fuels 
glycolysis36. 
Early analyses of various human tumors revealed a higher prevalence of LDH-M subunits 
compared to adjacent non-malignant tissue37. In renal cell carcinoma and gastric cancer, 
overexpression of LDHA correlates to the clinical disease stage and is linked with aggressiveness 
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and poor prognosis, suggesting that LDHA holds promise as a prognostic marker38,39. In 
melanoma patients, where serum LDH levels are predictive of prognosis and response to 
treatment, overexpression of LDH-5 in tumor tissues is related to reduced overall survival40. 
Moreover, LDH-5 is a direct target of HIF-1 and the proto-oncogene MYC (Figure 1-4)41,42. In 
pancreatic tumor cells, increased expression of forkhead box protein M1 (FOXM1) led to an 
upregulation of LDHA via direct binding to the promoter region43. In contrast, LDHA was repressed 
by miR-34a (microRNA 34a)44. MicroRNAs, a group of small endogenous, non-coding RNAs, bind 
to the 3’ untranslated region of mRNAs, promote mRNA degradation and/or inhibit translation. 
Thereby they regulate gene expression, which makes them important players in tumorigenesis45. 
Besides transcriptional and post-transcriptional regulation, LDHA is controlled by post-
translational modifications. Tyrosine phosphorylation and lysine acetylation of LDHA were shown 
to control LDH-5 activity and thereby seem to be involved in the Warburg effect46-48. 
Fantin et al. demonstrated that downregulation of LDHA by means of shRNA (short hairpin RNA) 
resulted in an increase in OXPHOS in tumor cells and under hypoxia, tumor proliferation was 
diminished49. Accordingly, downregulation of LDHA by siRNA (small interfering RNA) or a small 
molecule inhibitor FX11 reduced ATP levels, elevated oxygen consumption and reactive oxygen 
species (ROS), and finally led to cancer cell death50. Consistently, after LDHA disruption in human 
renal cancer cells, non-small cell lung cancer cells or mouse breast cancer cells and subsequent 
inoculation into mice, tumors showed reduced growth and delayed metastatic spread51-53. In line 
with these findings in mouse models, Wang et al. described a positive correlation between LDHA 
expression and tumor size in human breast cancer specimen54.  
 
Figure 1-4. Mechanisms and impact of LDHA regulation 
HIF-1, MYC and FOXM1 are transcription factors for the LDHA gene leading to LDHA mRNA expression 
after binding to the LDHA promoter region. LDHA mRNA is translated to LDHA proteins, which form the 
homotetrameric enzyme LDH-5. LDHA is post-transcriptionally regulated by the repressor miR-34a and post-
translationally by acetylation and subsequent proteolysis. In contrast, phosphorylation enhances LDH-5 
tetramer formation. LDH-5 catalyzes the conversion of pyruvate to lactate, and lactate export via MCT1 and 4 
(MCT1/4) leads to accumulation of lactic acid (Lactate− H+), which in turn facilitates metastasis, angiogenesis 
and immunomodulation. (Adapted from Augoff et al., Cancer Letters 201555) 
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1.2.1.3 Lactate and lactic acid 
The Warburg phenotype of tumors is characterized by aerobic glycolysis which leads to the 
excessive generation of lactate10. Several publications demonstrate that the production of lactate 
is favorable for the tumor (Figure 1-4). Walenta et al. described a positive correlation of high 
lactate levels in primary human tumors (up to 40 µmol/g) and the incidence of distant 
metastases56,57. In addition, tumor-derived lactate has been shown to fuel OXPHOS in 
oxygenated tumor cells in heterogeneous tumors58. It increases cancer stemness and 
metastases59 as well as migration of tumor cells, while inhibiting monocyte motility60. Consistently, 
downregulation of lactate production by LDHA siRNA abrogated the migration of glioma cells and 
attenuated TGF-β2 (transforming growth factor β2) secretion, which is important for extracellular 
matrix (ECM) remodeling61. Lactate also promoted the migration of endothelial cells by increasing 
their production of VEGF62. VEGF, in turn, is an important factor implicated in angiogenesis. 
Furthermore, lactate induced the upregulation of hyaluronan, a component of the ECM which 
enables cell movement, and its receptor CD44 (cluster of differentiation molecule 44) on 
melanoma cells, resulting in an aggressive phenotype63. Hyaluronan and CD44 expression was 
also fostered on fibroblasts when they were cultured with lactate64. Tumor-associated fibroblasts 
are known to take up lactate which leads to lactate “recycling”, as they convert it to pyruvate and 
use it for the TCA cycle and OXPHOS. So it seems that tumor and stroma cells complement each 
other, recycle products of glycolysis and thereby buffer the tumor environment65. 
In tumor xenografts of head and neck squamous cell carcinoma, lactate levels positively 
correlated with radioresistance66. These results underline the importance of glycolysis and 
subsequent lactate production for tumor progression and metastasis. 
Lactate is exported from the tumor cell in co-transport with protons via MCT1 and MCT467, where 
it accumulates as lactic acid and leads to a subsequent acidification of the tumor environment68. 
While the extracellular pH value in normal tissues is around pH 7.5, the tumor microenvironment 
can exhibit values between pH 6.5 and pH 6.069-71. This tumor acidosis leads to enhanced 
degradation of the ECM, thereby increasing the invasiveness of tumors18. Thus, normalizing the 
pH by means of buffering or proton pump inhibitors (PPI) counters spontaneous metastasis and 
tumor growth71-73. Moreover, acidification upregulates the expression of VEGF in brain tumors74. 
Importantly, lactic acid suppresses the anti-tumor immune response in the tumor 
microenvironment, which is described in detail in Chapter 1.4. 
1.2.2 Amino acid metabolism 
Besides glucose, glutamine, as the most abundant amino acid in the body, is a crucial nutrient for 
cell proliferation. In fast growing tumor cells, the uptake of glutamine is increased, followed by the 
conversion to glutamate or lactate, a process called glutaminolysis (Figure 1-3)75. Increased 
glutamine metabolism is linked to MYC expression76 and upregulation of glutaminase in cancer 
patients77. The resulting increase in glutamate levels has been shown to inhibit T cell activity78. 
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Other amino acids that play important roles in tumor metabolism are tryptophan and arginine, 
which will be discussed more in detail in the following chapters. 
1.2.2.1 Tryptophan metabolism 
Tumors often show a deregulation in tryptophan metabolism in order to evade immune control79. 
Mechanisms and outcomes for the tumor will be explained in the following chapter. 
Tryptophan is converted to kynurenine by indoleamine 2,3-dioxygenase (IDO). IDO 
overexpression, of both the classic form IDO1 as well as a novel form IDO2, has been described 
in several types of cancer80,81. Decreased serum tryptophan levels are linked to poor prognosis in 
melanoma82. In colorectal cancer, increased malignancy was related to overexpression of IDO 
and subsequent diminution of tumor infiltrating lymphocytes. As T cell activation depends on 
tryptophan uptake, the depletion of tryptophan by excessive IDO activity of cancer cells, leads to 
an unresponsiveness of T cells83. However, T cell function is not only impaired due to 
overexpression of IDO by tumor cells but also by IDO expression of macrophages and dendritic 
cells84. Besides the immunosuppressive properties of tryptophan depletion, kynurenine, the 
primary product of tryptophan metabolism by IDO, exerts negative effects on T cell activity. Opitz 
et al. further discovered that tryptophan 2,3-dioxygenase, a liver enzyme which was not yet 
reported to be involved in cancer biology, is overexpressed in glioma cells and leads to tryptophan 
degradation in brain tumors85. Treatment with IDO inhibitors and IDO silencing by siRNA improved 
T cell responses and anti-tumor immunity, diminished tumor formation and augmented responses 
to chemotherapy86-89. 
1.2.2.2 Arginine metabolism 
Arginine is important for polyamine synthesis, which is essential for cell growth and differentiation. 
It is metabolized by arginase (ARG) to ornithine and urea. Ornithine is a precursor of polyamine 
synthesis and also serves as precursor for proline synthesis, which is involved in collagen 
production. In mammals, two different genes code for the two arginase isoforms ARG1 and 
ARG290. ARG1 is found in the cytosol of hepatocytes, where it plays an important role in the urea 
cycle and is also expressed in granulocytes91, while ARG2 is constitutively expressed in 
mitochondria of different cell types like, e.g., renal cells, neurons, macrophages and enterocytes90. 
In various types of cancer, an increased ARG activity was observed92. Therefore, the availability 
of ARG and the expression of ARG1 and ARG2 seem to be of crucial importance for tumors due 
to the supply with polyamines and negative effects on T cell function93, as described in Chapter 
1.3.2.1.1. 
Alternatively, nitric oxide synthase (NOS) converts arginine to citrulline and nitric oxide (NO). NOS 
comprises a family of enzymes: NOS1 (nNOS) is expressed mainly in neuronal tissue, NOS2 
(iNOS) is inducible in various immune cells and NOS3 (eNOS) is present primarily in endothelial 
cells. After full activation via assembly with calmodulin and several co-factors, NOS converts 
arginine to NO93. NO production by activated macrophages is known to inhibit tumor growth and 
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to induce tumor cell death94. Elevated levels of NO were detected in various human tumors, yet, 
the role of NOS expression in the tumor environment is still not clear95,96.  
1.2.3 Lipid metabolism 
Here, exclusively the metabolism of arachidonic acid involving cyclooxygenases 1 and 2 (COX1, 
COX2), resulting in the synthesis of prostanoids, which function as mediators of inflammation, will 
be outlined. While COX1 is constitutively expressed in almost every kind of tissue, COX2 
expression is induced by inflammation and oncogenes, like the proto-oncogene RAS, and is 
primarily found in tumors97. Overexpression of COX2 is associated with poor prognosis in breast 
carcinoma98 and seems to be linked to HIF expression, resulting in augmented survival of 
colorectal cancer cells99. Consistently, inhibition of COX2 mitigated tumor growth by preventing 
the infiltration of tumor-promoting MDSCs and impairing their ARG expression100-104. 
1.3 Tumor immunology  
The first observation that neoplastic tissues are infiltrated by leukocytes was made by Rudolf 
Virchow in 1863 and led him to the conclusion that cancer is linked to inflammation105. In 1986, 
Harold F. Dvorak compared tumors to wounds that do not heal, highlighting the contribution of 
stroma cells to tumor growth8. Nowadays, tumor-promoting inflammation is recognized as a 
hallmark of cancer and immune escape mechanisms, utilized by tumors to prevent elimination by 
immune cells, represent a newly discovered trait of human malignancies2. In the following 
chapters, both the role of inflammation in cancer and the interactions between tumor and immune 
cells will be discussed in detail. 
1.3.1 Inflammation and cancer 
Inflammation plays an essential role in all stages of tumorigenesis and is recognized as a hallmark 
of cancer, as described in Chapter 1.12. Only a minority of tumors is caused by germline 
mutations, whereas about 90% of tumors develop due to somatic mutations and environmental 
factors. Among the latter, chronic infections account for almost 20% of tumors. For instance, 
infections with Helicobacter pylori are a common cause for gastric cancer and chronic infections 
with hepatitis B virus or hepatitis C virus increase the risk for hepatocellular carcinoma. 
Accordingly, patients suffering from inflammatory bowel disease have a higher risk to develop 
colorectal cancer106. 
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Other contributing environmental factors are tobacco smoking, inhaled pollutants and an 
unbalanced diet. Exposure to noxae as well as obesity can in turn trigger inflammation. Cigarette 
smoking, for instance, provokes chronic bronchitis which can lead to lung cancer107. 
Inflammation, which is characterized by heat (calor), pain (dolor), redness (rubor) and swelling 
(tumor), occurs in two manifestations: acute inflammation is the physiological and timely limited 
response of the immune system to infections; in contrast, chronic inflammations persist for a long 
time107. However, not all chronic inflammatory diseases increase cancer risk. Psoriasis for 
instance seems to exert the opposite effect108. This suggests that cancer-associated chronic 
inflammation differs from normal chronic inflammation, meaning that solid tumors trigger intrinsic 
inflammation to favor a pro-tumorigenic microenvironment. Cancer-associated inflammation is 
characterized by the overexpression of oncogenes like MYC and RAS, which, besides the 
initiation of hyperproliferation and angiogenesis, induce the production of pro-tumoral cytokines 
and chemokines and thereby facilitate the recruitment of immune cells of myelomonocytic origin, 
like MDSCs109.  
1.3.2 Immune cells in the tumor microenvironment 
The tumor stroma consists of fibroblasts, endothelial cells, pericytes, mesenchymal cells and cells 
of the innate and adaptive immune system. Innate immune cells like macrophages, neutrophils, 
eosinophils, basophils, mast cells, dendritic cells (DCs) and natural killer (NK) cells represent the 
first line of defense against invading pathogens. Tissue-resident macrophages, mast cells and 
DCs diligently police their environment for distress signals and release mediators like cytokines, 
chemokines, histamine, matrix remodeling proteases and ROS to attract the infiltration of 
leukocytes to the site of damage, leading to inflammation. The activation of vascular and fibroblast 
responses by macrophages and mast cells contributes to wound healing. DCs as mediators 
between innate and adaptive immunity, take up foreign antigen, move to the lymphoid organs and 
present their antigens to T cells in a major histocompatibility complex (MHC)-dependent manner. 
NK cells interact with DCs to regulate their maturation and in turn become activated by mature 
DCs110. 
Contrary to the rapid rather unspecific first-line defense by the innate immune system, the 
adaptive immunity is directed against a specific antigen and characterized by a memory function. 
The cells of the adaptive immune system, B and T lymphocytes, undergo clonal expansion upon 
recognition of foreign antigens presented by DCs and, therefore, constitute a much more 
sophisticated but time-consuming immune response110.  
Immune cells present in the tumor microenvironment represent a double-edged sword as they can 
promote or inhibit tumor growth. The balance between these extremes is regulated by tumor-
derived factors which control abundance and activity of different types of immune cells in the 
tumor microenvironment111. The interaction between tumor cells and immune cells, the so-called 
“cancer immunoediting’”, can be categorized in three states: elimination, equilibrium and escape 
(Figure 1-5)112. In the elimination phase, the immune system functions as a tumor suppressor and 
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kills tumor cells. This immunosurveillance is lost in immunocompromised mice reflected by the 
increased incidence of tumors. Similar observations show elevated tumor development in 
immunosuppressed patients after organ transplantation or in case of HIV113. If tumor cells survive 
the attack of immune cells, proliferation can still be controlled by immunological mechanisms, 
which leads to a state of equilibrium114. Tumor immune evasion means that tumors overcome anti-
tumor immunity and become clinically apparent115.  
Several mechanisms leading to tumor immune evasion have been identified. Tumors can evade 
immune recognition via downregulation of MHC class I molecules leading to compromised 
activation of cytotoxic T cells (CD8+ T cells). Furthermore, tumors create an immunosuppressive 
microenvironment by producing factors like TGF-β, interleukin 10 (IL-10) and VEGF, which in turn 
lead to the accumulation of immunosuppressive cells like regulatory T cells (Tregs) and MDSCs. 
Immunosuppression is also achieved via induction of inhibitory receptors like CTLA-4 (cytotoxic T 
lymphocyte-associated protein 4) and PD-1 (programmed cell death 1) on immune effector cells 
and PD-L1 (programmed cell death ligand 1) on tumor cells115. The interplay between tumor cells 
and specific immune cell populations present in the tumor microenvironment will be highlighted in 
the following chapter. 
 
Figure 1-5. Cross-talk of immune and cancer cells: Immunoediting 
Malignant transformed cells are recognized and eliminated by cytotoxic T cells (CD8+), NK cells and innate 
immune cells. Tumor cells, that survive elimination, enter an equilibrium phase, where tumor outgrowth is 
inhibited by cells of the adaptive immune system. Due to constant selection pressure, tumor cell variants can 
emerge, which display reduced immune recognition or suppress immune cell function, leading to tumor 
progression. NKG2D, NK group 2, member D; NK, natural killer cell; MΦ, macrophage; DC, dendritic cell; 
IFN, interferon; IL, interleukin; TNF, tumor necrosis factor; TRAIL, tumor necrosis factor-related apoptosis-
inducing ligand; MDSC, myeloid-derived suppressor cell; Treg, regulatory T cell; CTLA-4, cytotoxic T 
lymphocyte-associated protein-4; PD-1, programmed cell death 1; PD-L1, programmed cell death ligand 1; 
TGF-β, transforming growth factor β; IDO, indoleamine 2,3-deoxygenase; VEGF, vascular endothelial growth 
factor. (Adapted from Schreiber et al., Science 2011116) 
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1.3.2.1 Myeloid cells 
1.3.2.1.1 Macrophages and myeloid-derived suppressor cells 
The most abundant immune cells found in tumors are tumor-associated macrophages (TAMs). 
They originate from circulating monocytes or tissue-resident macrophages and are recruited into 
the tumor microenvironment, e.g., via the chemokine CCL2 (chemokine (C-C motif) ligand 2)117, 
CSF1 (colony-stimulating factor 1) and VEGF118. TAMs are present during all stages of 
tumorigenesis112 and are involved in angiogenesis, invasion and metastasis119. Consistently, high 
numbers of infiltrating TAMs correlate with poor prognosis120. Macrophages can be subdivided in 
M1 macrophages, found during inflammation, and anti-inflammatory M2 macrophages, 
preferentially accumulating in the tumor microenvironment. M1 macrophages develop upon 
stimulation with IFN-γ (interferon γ) and microbial factors (classical activation), and display a pro-
inflammatory phenotype with high expression of TNF-α (tumor necrosis factor α), IL-1, IL-6, IL-12, 
IL-23, MHC molecules and iNOS, thereby promoting an anti-tumor response. In contrast, M2 
macrophages, which differentiate after stimulation with IL-4, IL-10 and IL-13 (alternative 
activation), produce anti-inflammatory cytokines like IL-10, show downregulation of MHC class II 
expression, and express scavenger receptor A and ARG121. However, a strict separation of M1 
and M2 macrophages is not possible as both “types” represent only the extremes of these highly 
plastic myeloid cells, which can rapidly adapt their phenotype to the microenvironment. This 
variable polarization could possibly explain the observation that a high grade of infiltration with 
TAMs can also be related to a favorable prognosis in a minority of human tumors122. 
Another myeloid cell type sharing some characteristics with M2-like TAMs is the so-called MDSC. 
This population mainly consists of immature myeloid cells co-expressing the classical myeloid 
lineage marker CD11b and the granulocytic marker Gr-1 in mice123,124. MDSCs are potent 
inhibitors of T cells via arginine deprivation in the tumor microenvironment due to high ARG1 
expression125. Furthermore, they cause nitration of the T cell receptor (TCR) via excessive ROS 
and peroxynitrite production during direct cell-cell contact126. MDSCs also induce Treg activation 
and expansion. At present, MDSCs can be divided into two main subsets: the more prevalent 
granulocytic MDSCs and the monocytic MDSCs, which are characterized by CCR2 (chemokine 
(C-C motif) receptor 2) expression and show higher immunosuppressive capacity127. Their 
expansion is promoted by granulocyte-macrophage colony-stimulating factor (GM-CSF=CSF2, 
colony-stimulating factor 2)128. 
1.3.2.1.2 Dendritic cells 
DCs are important inducers of an anti-tumor immune response as they cross-present antigens to 
T cells. This task can only be performed by fully mature DCs. Various factors like VEGF and IL-
10, which are released by tumor cells and TAMs can lead to an immature or tolerogenic DC 
phenotype129. Tolerogenic DCs are characterized by IL-10, TGF-β and IDO production, resulting in 
a compromised ability to activate T cells130. The production of angiogenic factors by immature 
DCs directly promotes tumor growth131. Moreover, these cancer-associated DCs augment the 
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expansion of Tregs and cause T cell anergy. Altogether, tumor cells are capable to elicit a 
reprogramming of DCs towards an immunosuppressive and pro-angiogenic phenotype that 
promotes tumor growth132.  
DCs also play a role in NK cell activation, thereby promoting a potent immune response against 
tumors. In addition, direct cytotoxic effects of DCs against tumor cells were observed. However, 
until now, no clear correlation of DC infiltration and prognosis can be demonstrated in human 
tumors133. 
1.3.2.2 Lymphoid cells 
1.3.2.2.1 Natural killer cells 
NK cells, as potent players in cancer immunosurveillance, are not only capable of targeting 
tumors indirectly via the secretion of IFN-γ and activation of M1 and T helper 1 (Th1) anti-tumor 
immune responses134; they can also directly lyse tumor cells irrespective of prior activation and 
without MHC restriction. This process occurs through the release of perforin and granzyme from 
cytolytic granules135 and is controlled by NK cell surface receptors, such as NKG2D (natural-killer 
group 2, member D) which recognizes stress-induced NKG2D ligands on target cells136. NK cells 
also lyse tumor cells that lost MHC class I molecules135 and thereby escaped from the 
immunologic control by cytotoxic T cells137. Thus, high numbers of infiltrating NK cells correlate 
with a favorable prognosis in patients with lung, gastric, colorectal and head and neck 
cancer138,139. However, in melanoma, renal, breast and liver carcinoma, NK cell infiltration is 
impaired140-143 and isolated NK cells from tumor lesions are inactive. These findings suggest that 
NK cell effector functions are inhibited by tumor cells137. Several immune escape mechanisms 
have been identified that help tumor cells to evade NK cell cytotoxicity, e.g., repression of NK cell 
infiltration and effector function, and tumor editing towards a poorly immunogenic tumor 
phenotype130. Tumor cells prevent NK cell attraction via downregulation of chemokines like 
CXCL2 (chemokine (C-X-C motif) ligand 2)134,135 and generate an immunosuppressive tumor 
microenvironment by means of TGF-β production137. Additionally, hypoxia in the tumor 
microenvironment impairs the expression of activating receptors on NK cells, such as NKG2D, 
and thereby limits their ability to kill tumor cells144. Tumor cells’ editing towards a poorly 
immunogenic phenotype involves downregulation of NKG2D ligand expression on tumor cells and 
thereby impedes the recognition by NK cells130,145. Upregulation of MHC class I molecules on 
tumors, a phenomenon observed for instance in melanoma lesions142, also contributes to the 
evasion of tumor cells145. The reprogramming of NK cells towards a tumor-promoting phenotype, 
displaying compromised cytolytic functions and pro-angiogenic properties, was observed in lung, 
colorectal and breast cancer135. In this context, findings linking high NK cell infiltration to poor 
outcome in metastatic ovarian carcinoma and invasive ductal breast cancer are not 
surprising146,147. 
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1.3.2.2.2 T lymphocytes 
Similar to NK cells, cytotoxic T cells possess potent anti-cancer properties, which are based on 
the recognition of tumor-specific antigens or tumor-associated antigens expressed by cancer 
cells, and the consequent induction of a cytotoxic T cell response112. CD8+ effector T cells secrete 
IFN-γ and TNF-α and directly kill tumor cells via the release of perforin or granzyme from lytic 
granules148. Consistently, high numbers of infiltrating CD8+ T cells predict a favorable outcome in 
ovarian cancer, melanoma, colorectal cancer and breast cancer149-152. 
Hence, efforts are made to identify tumor-specific mutations, which implies extensive genome 
sequencing153. The accumulation of mutational epitopes in tumors correlated with increased 
patient survival and was linked to elevated infiltration of cytotoxic T cells154. However, targeting 
tumor-specific antigens by adoptively transferred T cells had only limited success in melanoma, 
lung and bladder cancer155. 
Unlike tumor-specific antigens, tumor-associated antigens are not exclusively expressed on 
cancer cells but also on normal cells112. Recognition of tumor-associated antigens can, therefore, 
lead to mechanisms of self-tolerance, resulting in an inefficient anti-tumor immune response156.  
Tregs are a specific subpopulation of T helper cells (CD4+ T cells) and are characterized by the 
expression of CD4, CD25 and FOXP3 (forkhead box P3). Under physiological conditions, Tregs 
protect against autoimmune diseases via suppression of self-reactive T cells. In the tumor 
microenvironment, Tregs suppress anti-tumor immunity by secreting immunosuppressive factors 
like IL-10 and TGF-β. TGF-β production by tumor cells or Tregs can convert conventional T cells 
into Tregs which then inhibit effector functions of lymphocytes. Furthermore, Tregs compete with 
other lymphocytes for IL-2 and thereby limit T cell proliferation and activation157. However, in 
humans, no clear association has been described regarding Treg infiltration and prognosis, and 
the outcome seems to depend on the type of cancer112. 
The heterogeneous population of CD4+ T cells further consists of Th1 cells and Th2 cells, which 
arise upon stimulation with IL-12 and IL-4, respectively, as well as Th17 cells which are induced 
by IL-6 and TGF-β. Th1 cells secrete IFN-γ and TNF-α, and thereby promote a cytotoxic T cell 
response, whereas the production of IL-4, IL-5 and IL-13 by Th2 cells leads to tumor promotion. 
Th17 cells secrete IL-17, IL-21 and IL-22 and play an ambiguous role in cancerogenesis, 
facilitating either tumor rejection or tumor progression, depending on the type of cancer158. 
1.3.2.2.3 Regulation of the T cell response by checkpoint molecules 
Effector functions of T cells are regulated by the balance of co-stimulatory and co-inhibitory 
signals. T cells recognize (tumor-)antigens presented on MHC molecules of antigen-presenting 
cells, like DCs, via the TCR. Apart from this signal, T cells require additional stimulation by 
antigen-independent co-stimulatory receptors, such as CD28, in order to become fully activated. 
In contrast, the stimulation of an inhibitory co-receptor on T cells, e.g., PD-1 or CTLA-4, leads to T 
cell inhibition. These immune checkpoint molecules limit the extent and duration of the immune 
response. PD-1 is upregulated on a variety of activated immune cells, including T and B cells, NK 
cells, monocytes and DCs, and represents a negative feedback loop to control T cell activation, 
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since T cell cytokines like IFN-γ or IL-4 upregulate PD-1 ligands. PD-L1 is expressed by a variety 
of solid and hematological human tumors and helps tumor cells to evade anti-tumor T cell effector 
functions. Consistently, a link between PD-L1 expression and poor outcome in various types of 
cancer has been demonstrated, which might also partially explain their resistance to adoptive T 
cell therapies112. 
1.3.3 Cytokines in the tumor microenvironment 
The communication of cells in the tumor microenvironment occurs either directly via cell-cell-
contact or via soluble factors such as cytokines and chemokines, which can act in an autocrine 
and paracrine manner111. 
The cytokine and chemokine profile in the tumor microenvironment regulates immune cell function 
and can either promote or inhibit tumor growth111. While anti-tumor immunity is achieved by 
cytokines like IL-12 and IFN-γ as well as by TRAIL (tumor necrosis factor-related apoptosis-
inducing ligand), tumor promotion is mediated through cytokines like IL-1, IL-6, IL-17, IL-23 and 
TNF. Transcription factors involved in cytokine/chemokine production, which are activated in the 
majority of tumors and act as non-classical oncogenes are NF-κB (nuclear factor κB) and STAT3 
(signal transducer and activator of transcription)159. Despite the heterogeneity of human cancer, 
common cytokine patterns could be identified which lead to immunostimulation or are 
accompanied by a cancer-protective immunosuppression160. Some critical components of the 
cytokine profile in the tumor microenvironment of human cancer are presented below (Figure 1-6). 
1.3.3.1 Immunostimulatory cytokines 
Typical immunostimulatory cytokines are IL-2, IL-12, IFN-γ, TNF-α and IL-6.  
IL-2 functions as a growth factor for stimulated T cells, necessary for clonal expansion after 
antigen contact, and is mainly secreted by activated CD4+ T cells but also by naïve CD8+ T cells 
and DCs161. Moreover, IL-2 stimulates the activation of NK cells162 and plays a crucial role in the 
development and expansion of Tregs161.  
IL-12 is critical for the connection between innate and adaptive immune responses163. It is mainly 
produced by DCs and stimulates Th1 cells, which in turn activate CD8+ T cells160. IL-12 induces 
IFN-γ production of T and NK cells163. 
The major cytokine for macrophage activation, IFN-γ, upregulates MHC class I and II expression, 
which is required for antigen recognition by CD8+ and CD4+ T cells, respectively160. IFN-γ is mainly 
produced by cytotoxic T cells, Th1 cells and NK cells, and inhibits the production of the 
immunosuppressive factor TGF-β164.  
TNF-α - as an acute-phase response cytokine like IL-1 - is produced by macrophages as a rapid 
response to inflammatory stimuli. It activates neutrophils and monocytes and recruits them to the 
site of inflammation via regulation of adhesion molecules on endothelial cells. The potent 
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immunostimulatory characteristics of TNF-α contribute to a pro-inflammatory tumor 
microenvironment in established tumors160.  
TNF-α induces the production of IL-6, another pro-inflammatory cytokine, by monocytes and 
macrophages165. IL-6 is also responsible for the recruitment of leukocytes to the site of 
inflammation166. Furthermore, it facilitates T cell differentiation and activation, mediates the 
conversion of B cells into antibody-generating plasma cells and activates fibroblasts to produce 
matrix metalloproteases for ECM degradation160. It blocks Treg development and together with 
TGF-β induces the polarization of Th17 cells167. 
In many types of human cancer, the concentrations of immunostimulatory cytokines like IL-2, IL-
12 and IFN-γ are low, which is often linked to poor prognosis. On the contrary, serum 
concentrations of immunostimulatory cytokines TNF-α and IL-6 are frequently elevated and 
correlate with disease progression or worse prognosis160. 
1.3.3.2 Immunosuppressive cytokines 
Besides immunostimulatory cytokines, immunosuppressive cytokines are present in the tumor 
microenvironment, among which TGF-β and IL-10 play major roles. 
TGF-β, which is produced, e.g., by tumor cells, is known to suppress a range of pro-inflammatory 
cytokines like IL-12, IL-2 and IFN-γ, and thereby limits the function of antigen-presenting cells, T 
cell proliferation and activity of T and NK cells. Besides, B cell proliferation and differentiation is 
impeded. In contrast, TGF-β supports Th17 and Treg differentiation. Thus, TGF-β, as a potent 
immunosuppressive factor exerting various effects on other cytokines and immune cells, is a 
major inducer of local tolerance in the tumor microenvironment160. 
Furthermore, TGF-β upregulates the highly immunosuppressive cytokine IL-10, which in turn 
leads to increased TGF-β production as a positive feedback mechanism168. 
IL-10 is secreted by a wide range of cells, predominantly by Th2 cells, subsets of Tregs, Th1, 
Th17 cells, monocytes, macrophages and subsets of DCs but can also be produced by tumor 
cells. It inhibits the production of the key pro-inflammatory cytokines IL-1, IL-6, IL-12 and TNF-
α169, as well as the production of IL-2 and IFN-γ by Th1 cells. In addition, antigen-presentation of 
DCs is impaired by IL-10, as MHC class II expression and upregulation of co-stimulatory 
molecules CD80 and CD86 are compromised168. 
Elevated serum levels of both TGF-β and IL-10 are detected in patients with various cancer types 
and are correlated with advanced cancer stages, poor outcome or metastases160. 
In summary, the balance between immunoinhibitory and immunostimulatory factors present in 
human cancer seems to determine the activity of immune cells, and thereby patient outcome 
(Figure 1-6)160. 
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Figure 1-6. Cytokine network in the tumor microenvironment 
Simplified scheme of interactions between immunostimulatory (green) and immunosuppressive (purple) 
cytokines present in the tumor microenvironment. Decreased concentrations of IL-2, IL-12 and IFN-γ and 
elevated concentrations of TNF-α, IL-6, TGF-β and IL-10 are often linked to poor prognosis in human cancer. 
1.4 Impact of tumor metabolism on the immune system 
The metabolism of tumors is adapted to provide favorable conditions for tumor growth. This 
phenomenon does not only influence tumor cells themselves but also exerts effects on stroma 
cells like immune cells. Accelerated glucose metabolism for instance was found to be correlated 
with low CD8+ T cell infiltration in renal cell carcinoma170. This is in line with the finding that tumor 
cells deprive the microenvironment of glucose which restricts T cell glycolysis and effector 
function171,172. Several metabolites accumulating in the tumor microenvironment, due to the 
alterations in tumor metabolism, exhibit immunosuppressive properties. Besides glutamate, 
kynurenin and methylthioadenosin, lactate represents a potent immunomodulator173 and is, 
therefore, highlighted in the following. 
In addition to its tumor promoting attributes like the induction of angiogenesis and metastasis59,62 
(Chapter 1.2.1.3), lactate and especially its protonated form lactic acid has been demonstrated to 
exert inhibitory effects on a range of immune cells. In dendritic cells, differentiation and activation 
was impeded by lactic acid174,175, while in human monocytes, TNF secretion was inhibited upon 
lactic acid exposure176. Human T cells showed an impaired proliferation and cytokine production 
upon treatment with lactic acid177. Tumor lactic acidosis further resulted in a compromised function 
of cytotoxic T lymphocytes via inhibition of P38 and JNK (c-Jun N-terminal kinase)/c-Jun 
activation178. In line with this finding, restoration of the physiological pH by buffering or PPI 
overrides T cell dysfunction70,73. In human monocytes and macrophages, lactic acid was shown to 
induce the production of IL-23 and thereby facilitate secretion of IL-17, which is a pro-
inflammatory cytokine involved in Th17 immune responses179. In mice with LDHA-depleted 
tumors, decreased numbers of MDSCs were found in spleens and NK cell function was 
inhibited180. Moreover, it was demonstrated that lactic acid polarizes TAMs towards an M2 
phenotype via the induction of HIF-1α181. 
These findings strongly suggest that lactic acid is a potent immunomodulator. However, little is 
known about the impact of lactic acid on immune cells in vivo.  
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2 Research Objectives 
Metabolic reprogramming of tumor cells is the basis for their excessive proliferation. Changes in 
the glucose pathway remain the most prominent feature of tumor cells and are known as the 
Warburg effect. The increased uptake of glucose, subsequent conversion of pyruvate to lactate 
and the export of the latter in co-transport with protons occurs in the majority of malignant 
neoplasia. Lactate and lactic acid have been shown to exert a range of direct tumor-promoting 
functions and there is evidence that lactic acid compromises various types of immune cells.  
The aim of this dissertation was to clarify the immunomodulatory role of tumor-derived lactic acid 
and its impact on tumor growth. In preliminary studies, Ldha expression was downregulated in 
mouse melanoma cells by means of shRNA technology, which resulted in low-lactate producing 
melanoma tumor cell clones. Tumor growth, immune cell infiltration and activation should be 
analyzed in respective tumors grown from these cells in immunocompetent and immunodeficient 
mice. In parallel, in vitro analyses should be performed to compare in vitro and in vivo effects of 
lactic acid on different types of immune cells. 
Finally, biopsies of melanoma patients should be analyzed regarding lactate production and the 
impact of the latter on immune cell infiltration. 
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3 Material 
3.1 Equipment 
ADVIA 1650 Bayer, Tarrytown, USA 
Autoclave  Technomara, Fernwald, Germany 
Balance LP1200S Sartorius, Göttingen, Germany 
Bioanalyzer 2100 Agilent Technologies, Santa Clara, CA, USA 
Biofuge fresco Heraeus, Hanau, Germany 
BioPhotometer  Eppendorf, Hamburg, Germany 
Bug Box Hypoxic Work Station Ruskinn, Bridgend, UK 
CASY Cell Counter Innovatis/Roche, Basel, Switzerland 
Centrifuge Megafuge 3.0R Heraeus, Hanau, Germany 
Centrifuge Sigma 2 Sartorius, Göttingen, Germany 
Cryo 1 °C Freezing Container Thermo Fisher Scientif ic, Waltham, MA, USA 
Electrophoresis equipment  Biometra, Göttingen, Germany 
Electrophoresis equipment (PFGE) Biostep, Jahnsdorf, Germany 
ELISA plate reader MWG Biotech, Ebersberg, Germany 
EVOS Cell Imaging System Life Technologies, Carlsbad, CA, USA 
FACS Calibur flow cytometer BD Biosciences, Franklin Lakes, NJ, USA 
Forceps Aesculap, Tuttlingen, Germany 
Heat sealer Eppendorf, Hamburg, Germany 
Incubator Shaker I26 New Brunswick Scientific, Edison, NJ, USA 
Incubators  Heraeus, Hanau, Germany 
Laminar Flow Cabinet Clean Air Telstar, Woerden, The Netherlands 
LSR II flow cytometer BD Biosciences, Franklin Lakes, NJ, USA 
Microscopes Zeiss, Jena, Germany 
Microtiter plates washer Thermo Electron Corporation, Waltham, MA, 
USA 
Multifuge 3S-R Heraeus, Hanau, Germany 
Multipipettor Multipette plus Eppendorf, Hamburg, Germany 
NanoDrop 1000 PeqLab, Erlangen, Germany 
Oxygraph-2k Oroborus Instruments, Innsbruck, Austria 
PCR Thermocycler PTC-200 MJ-Research/Bio-Rad, Munich, Germany 
pH Meter  Knick, Berlin, Germany 
pH Meter, portable Hanna Instruments, Kehl am Rhein, Germany 
Picofuge Heraeus, Hanau, Germany 
Pipetboy Integra Biosciences, Fernwald, Germany 
Pipettes Gilson, Milddleton, WI, USA 
Pipettes Eppendorf, Hamburg, Germany 
Power supplies  Biometra, Göttingen, Germany 
Pulsed field electrophoresis equipment GE Healthcare, Chalfont St Giles, UK 
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Pulsed field gel electrophoresis equipment Biostep, Jahnsdorf, Germany 
Realplex Mastercycler epGradient S Eppendorf, Hamburg, Germany 
Rocking plattform HS250 IKA Labortechnik, Staufen, Germany 
Rotilabo mini centrifuge Carl Roth, Karlsruhe, Germany 
Sonorex Ultrasonic Bath Bandelin, Berlin, Germany 
Speed Vac Christ, Osterode, Germany 
Test tube shaker IKA Sigma-Aldrich, St. Louis, MO, USA 
Thermomixer Eppendorf, Hamburg, Germany 
TissueLyser Qiagen, Hilden, Germany 
Vortexer Scientific Industries Ink., Bohemia, NY, USA 
Wallac Betaplate Counter PerkinElmer, Rodgau, Germany 
Wallac Harvester PerkinElmer, Rodgau, Germany 
Water purification system  Merck Millipore, Billerica, MA, USA 
Waterbath Julabo, Seelstadt, Germany 
Western blot chamber Biometra, Göttingen, Germany 
3.2 Consumables 
Cell culture dishes BD, Franklin Lakes, NJ, USA 
Cell culture flasks Costar, Cambridge, MA, USA 
Cell scrapers Sarstedt, Nümbrecht, Germany 
Cell strainer (70 µm, 100 µm) Falcon, Heidelberg, Germany 
Combitips for Eppendorf multipette Eppendorf, Hamburg, Germany 
Cryo tubes  Corning, Corning, NY, USA 
Ep dualfilter T.I.P.S Eppendorf, Hamburg, Germany 
Heat sealing film  Eppendorf, Hamburg, Germany 
Hyperfilm ECL Amersham/GE Healthcare, Chalfont St Giles, UK 
Immobilon-P PVDF membrane Merck Millipore, Billerica, MA, USA 
Micro test tubes (0.5 ml, 1.5 ml, 2 ml)  Eppendorf, Hamburg, Germany 
Micropore filters Sartorius, Göttingen, Germany 
Microtiter plates (6, 12, 24, 96 wells) Costar, Cambridge, MA, USA 
PCR plate Twin.tec 96 well Eppendorf, Hamburg, Germany 
Petri dishes Falcon, Heidelberg, Germany 
Pipette tips Eppendorf, Hamburg, Germany 
Plastic pipettes Costar, Cambridge, MA, USA 
Polystyrene test tubes Falcon, Heidelberg, Germany 
Polystyrene test tubes with cell strainer cap Corning, Corning, NY, USA 
Scalpels (No. 10), disposable Feather, Osaka, Japan 
Syringe Filters, sterile Sartorius, Göttingen, Germany 
Syringes and needles BD, Franklin Lakes, NJ, USA 
Tubes (5 ml, 15 ml, 50 ml, 225 ml)  Falcon, Heidelberg, Germany 
UniFilter plates PerkinElmer, Rodgau, Germany 
Whatman Chromatography Paper Sigma-Aldrich, St. Louis, MO, USA 
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3.3 Media, buffers and solutions 
2-Mercaptoethanol Gibco/Life Technologies, Carlsbad, CA, USA 
Acrylamide Carl Roth, Karlsruhe, Germany 
APS Merck Millipore, Billerica, MA, USA 
Aqua B. Braun Melsungen, Melsungen, Germany 
Biocoll Separating Solution Biochrom/Merck Millipore, Billerica, MA, USA 
Bovine serum albumine Sigma-Aldrich, St. Louis, MO, USA 
CasyTON Roche, Basel, Switzerland 
DMSO Sigma-Aldrich, St. Louis, MO, USA 
FACS clean BD Biosciences, Franklin Lakes, NJ, USA 
FACS flow BD Biosciences, Franklin Lakes, NJ, USA 
FACS rinse BD Biosciences, Franklin Lakes, NJ, USA 
Fetal calf serum PAA/GE Healthcare, Chalfont St Giles, UK 
Glycerin Merck Millipore, Billerica, MA, USA 
Glycine Merck, Darmstadt, Germany 
H2O2 Merck, Darmstadt, Germany 
H2OUSB USB/Affymetrix, Santa Clara, CA, USA 
HBSS Sigma-Aldrich, St. Louis, MO, USA 
HCl Carl Roth, Karlsruhe, Germany 
Isopropanol B. Braun Melsungen, Melsungen, Germany  
L-Alanyl-L-Glutamine Biochrom/Merck Millipore, Billerica, MA, USA 
MEM Non-Essential Amino Acid Solution Sigma-Aldrich, St. Louis, MO, USA 
MEM Sodium Pyruvate Sigma-Aldrich, St. Louis, MO, USA 
MEM Vitamin Solution Sigma-Aldrich, St. Louis, MO, USA 
Methanol Thermo Fisher Scientific, Waltham, MA, USA 
NaCl VWR, Radnor, PA, USA 
Nuclease-free water Gibco/Life Technologies, Carlsbad, CA, USA 
PBS Sigma-Aldrich, St. Louis, MO, USA 
RIPA buffer Sigma-Aldrich, St. Louis, MO, USA 
RPMI 1640 Gibco/Life Technologies, Carlsbad, CA, USA 
SOC medium Invitrogen, Camarillo, CA, USA 
TB medium Interchim, Wörgl, Austria 
TEMED Sigma-Aldrich, St. Louis, MO, USA 
Tris USB/Affymetrix, Santa Clara, CA, USA 
Triton X100 Sigma-Aldrich, St. Louis, MO, USA 
Tween 20 Sigma-Aldrich, St. Louis, MO, USA 
Typsin-EDTA PAN Biotech, Aidenbach, Germany 
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3.4 Enzymes, kits and reagents 
3H-thymidine Hartmann Analytic, Braunschweig, Germany 
Agilent RNA 6000 Nano Kit Agilent Technologies, Santa Clara, CA, USA 
Amersham ECL Prime Western Blotting 
Detection Reagent 
Amersham/GE Healthcare, Chalfont St Giles, 
UK 
BD Comp Beads BD Biosciences, Franklin Lakes, NJ, USA 
BD GolgiPlug BD Biosciences, Franklin Lakes, NJ, USA 
Bio-Rad DC protein assay Bio-Rad, Munich, Germany 
Bromophenol blue Sigma-Aldrich, St. Louis, MO, USA 
Caproic acid Sigma-Aldrich, St. Louis, MO, USA 
Carboxy SNARF-1 AM acetate Life Technologies, Carlsbad, CA, USA 
CD8α+ T cell Isolation Kit Miltenyi Biotec, Bergisch Gladbach, Germany 
Collagenase IV Worthington, Lakewood, NJ, USA 
Collagenase Type IA Sigma-Aldrich, St. Louis, MO, USA 
Cyclosporin A (Sandimmun®) Novartis, Basel, Switzerland 
DAPI Sigma-Aldrich, St. Louis, MO, USA 
DNase I Sigma-Aldrich, St. Louis, MO, USA 
dNTPs GE Healthcare, Chalfont St Giles, UK 
DuoSet ELISA mouse TGF-β1 R&D Systems, Minneapolis, MN, USA 
EDTA Sigma-Aldrich, St. Louis, MO, USA 
FcR-Blocking reagent mouse Miltenyi Biotec, Bergisch Gladbach, Germany 
FoxP3 transciption factor staining buffer set eBioscience, San Diego, CA, USA 
IL-2 (Proleukin) Novartis, Basel, Switzerland 
Intracellular pH Calibration Kit Life Technologies, Carlsbad, CA, USA 
Ionomycin Enzo Life Sciences, Farmingdale, NY, USA 
JetPrime Transfection Reagent Polyplus-transfection, Illkirch, France 
KHCO3 Fluka, Buchs, Switzerland 
L-Lactic acid Sigma-Aldrich, St. Louis, MO, USA 
LPS Enzo Life Sciences, Farmingdale, NY, USA 
Luminol Sigma-Aldrich, St. Louis, MO, USA 
MitoTracker Green Thermo Fisher Scientific, Waltham, MA, USA 
M-MLV Reverse Transcriptase Promega, Madison, WI, USA 
MycoAlert Mycoplasma Detection Kit Cambrex, Rockland, ME, USA 
Myxothiazol Sigma-Aldrich, St. Louis, MO, USA 
NaHCO3 Merck, Darmstadt, Germany 
NH4Cl Merck, Darmstadt, Germany 
NK cell Isolation Kit II Miltenyi Biotec, Bergisch Gladbach, Germany 
p-Coumaric acid Sigma-Aldrich, St. Louis, MO, USA 
Plasmid Maxi Kit Qiagen, Hilden, Germany 
PMA Calbiochem, San Diego, CA, USA 
Propidium iodide Invitrogen, Camarillo, CA, USA 
QIAshredderTM Qiagen, Hilden, Germany 
QuantiFast SYBR® green PCR Kit Qiagen, Hilden, Germany 
Random Decamers Ambion/Life Technologies, Carlsbad, CA, USA 
RNAlaterTM Qiagen, Hilden, Germany 
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RNase-free DNase Set Qiagen, Hilden, Germany 
RNeasy Mini Kit Qiagen, Hilden, Germany 
Rotenone Sigma-Aldrich, St. Louis, MO, USA 
SDS Sigma-Aldrich, St. Louis, MO, USA 
Sodium citrate Merck, Darmstadt, Germany 
Sodium L-lactate Sigma-Aldrich, St. Louis, MO, USA 
3.5 Antibiotics 
Ampicillin Calbiochem, San Diego, CA, USA 
Blasticidin Invitrogen, Camarillo, CA, USA 
G418 Sigma-Aldrich, St. Louis, MO, USA 
Penicillin/streptomycin Gibco/Life Technologies, Carlsbad, CA, USA 
3.6 Molecular weight standards 
Kaleidoscope Prestained Standard from Bio-Rad (Munich, Germany) was used as a molecular 
weight standard for proteins. 
3.7 Oligonucleotides for quantitative real-time PCR 
Unmodified HPLC-purified oligonucleotides were designed as described in Chapter 4.2.2.2 and 
purchased from Eurofins MWG Operon (Ebersberg, Germany). Nos2 was provided in the 
TaqMan® Gene Expression Assay (Life Technologies, Carlsbad, CA, USA). Small letters indicate 
mouse genes, capital letters indicate human genes. 
Gene Primer Sequence (sense and antisense) 
Arg1 5'-GACTCCCTGCATATCTGCCAAAGAC-3' 
5'-GTCTCTTCCATCACCTTGCCAATCC-3' 
Arg2 5'-TGCATTTGACCCTAAACTGGCTCC-3' 
5'-ATTGACTTCAACAAGATCCAGAGCTGAC-3' 
Cd4 5'-ACTCTGACTCTGGACAAAGGGACAC-3' 
5'-GAGTCCATCTTGACCTTATCACCTTCAC-3' 
Cd8a 5'-AACGAAGGCTACTATTTCTGCTCAGTC-3' 
5'-TGTAAATATCACAGGCGAAGTCCAATCC-3' 
Cox1 5'-CGCCTACAGCCCTTCAATGAATACC-3' 
5'-CCAACTCAGCAGCCATCTCCTTCTC-3' 
 
 
Material 
  26 
 
 
Gene Primer Sequence (sense and antisense) 
Cox2 5'-CAATGAGTACCGCAAACGCTTCTCC-3' 
 5'-TGTCACTGTAGAGGGCTTTCAATTCTG-3' 
Csf2 5'-GCCATCAAAGAAGCCCTGAACCT-3' 
5'-CTGCTCGAATATCTTCAGGCGGGTC-3' 
Foxp3 5'-CCCATCCCCAGGAGTCTTGC-3' 
5'-ACCATGACTAGGGGCACTGTA-3' 
Glut1 5'-CGTCCTGCTGCTATTGCTGTG-3' 
5'-GGTGAAGATGAAGAAGAGCACGAGG-3' 
Hk1 5'-GACGACATCAGAACAGACTTCGAC-3' 
5'-CAATCAGGATGTTACGGACGATCTC-3' 
Hk2 5'-GTGGACTGGACAACCTCAAAGTGAC-3' 
5'-GAAGGACACGTCACATTTCGGAG-3' 
Ido1 5'-TCTCTATTGGTGGAAATCGCAGCTTCTC-3' 
5'-TCCAATGCTTTCAGGTCTTGACGCTC-3' 
Ido2 5'-TGCTGCCAAGATCTCTTGCCATTCC-3' 
5'-ACTGCTGCCTTCTCCACCAAGAC-3' 
Ifng 5'-TCAAGTGGCATAGATGTGGAAGAA-3' 
5'-TGGCTCTGCAGGATTTTCATG-3' 
Il10 5'-GGTTGCCAAGCCTTATCGGA-3' 
5'-ACCTGCTCCACTGCCTTGCT-3' 
Il17a 5'-GCTCCAGAAGGCCCTCAGA-3' 
5'-AGCTTTCCCTCCGCATTGA-3' 
Il6 5'-GAGGATACCACTCCCAACAGACC-3' 
5'-AAGTGCATCATCGTTGTTCATACA-3' 
Ldha 5'-TATCTTAATGAAGGACTTGGCGGATGAG-3' 
5'-GGAGTTCGCAGTTACACAGTAGTC-3' 
LDHA 5'-GGTTGGTGCTGTTGGCATGG-3' 
5'-TGCCCCAGCCGTGATAATGA-3' 
Ldhb 5'-TTGTGGCCGATAAAGATTACTCTGTGAC-3' 
5'-AGGAATGATGAACTTGAACACGTTGAC-3' 
Rn18s (18S) 5'-ACCGATTGGATGGTTTAGTGAG-3' 
5'-CCTACGGAAACCTTGTTACGAC-3' 
Tgfb1 5'-CACCGGAGAGCCCTGGATA-3' 
5'-TGTACAGCTGCCGCACACA-3' 
Tnf 5'-CATCTTCTCAAAATTCGAGTGACAA-3' 
5'-TGGGAGTAGACAAGGTACAACCC-3' 
Vegfa 5'-CTGGAGTGTGTGCCCACTGA-3' 
5'-TCCTATGTGCTGGCCTTGGT-3' 
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3.8 Antibodies 
3.8.1 Antibodies for western blotting 
      
Specificity Source Species 
cross-
reactivity 
Molecular 
Weight 
Dilution Manufacturer 
 
     
α-Actin Rabbit Human, 
animal 
42 kDa 1:2,000 Sigma-Aldrich, St. Louis, MO, 
USA 
α-ARD1 Rabbit Human, 
mouse 
31 kDa 1:30,000 Provided by Jacques 
Pouysségur (Institute of 
Research on Cancer and 
Ageing (IRCAN), University of 
Nice-Sophia Antipolis-CNRS-
Inserm, Centre A. Lacassagne, 
Nice, France) 
α-LDHA Rabbit Human, 
mouse, rat, 
monkey 
37 kDa 1:1,000 Cell Signaling Technology, 
Danvers, MA, USA 
α-LDHA 
(for Ldha−/− clones) 
Rabbit Human, 
mouse, rat, 
monkey 
36 kDa 1:1,000 Abcam, Cambridge, UK 
α-LDHB (431.1) Mouse Human 35 kDa 1:1,000 Santa Cruz Biotechnology, 
Dallas, TX, USA 
α-Mouse HRP Goat - - 1:2,500 Dako, Glostrup, Denmark 
α-Phospho-LDHA Rabbit Human, 
mouse, rat 
37 kDa 1:1,000 Cell Signaling Technology, 
Danvers, MA, USA 
α-Rabbit HRP Goat - - 1:2,500 Dako, Glostrup, Denmark 
3.8.2 Antibodies for flow cytometry 
3.8.2.1 Anti-mouse antibodies 
Specificity Isotype Conjugation Clone Manufacturer 
 
    
α-CD11b Rat IgG2b FITC M1/70 eBioscience, San Diego, CA, USA 
α-CD11c Armenian 
Hamster IgG1 
PE HL3 BD Biosciences, Franklin Lakes, NJ, 
USA 
α-CD19 Rat IgG2a PE-Cy7 eBio1D3 eBioscience, San Diego, CA, USA 
α-CD25 Rat IgG1 APC PC61.5 eBioscience, San Diego, CA, USA 
α-CD3ε Armenian 
Hamster IgG 
FITC 145-2C11 eBioscience, San Diego, CA, USA 
α-CD3ε Armenian 
Hamster IgG1 
PerCP 145-2C11 BD Biosciences, Franklin Lakes, NJ, 
USA 
α-CD3ε Armenian 
Hamster IgG1 
APC-Cy7 145-2C11 BD Biosciences, Franklin Lakes, NJ, 
USA 
α-CD4 Rat IgG2a eFluor450 RMA4-5 eBioscience, San Diego, CA, USA 
α-CD45 Rat IgG2b PE 30-F11 BD Biosciences, Franklin Lakes, NJ, 
USA 
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Specificity Isotype Conjugation Clone Manufacturer 
 
    
α-CD45 Rat IgG2b PerCP 30-F11 BD Biosciences, Franklin Lakes, NJ, 
USA 
α-CD45 Rat IgG2b V500 30-F11 BD Biosciences, Franklin Lakes, NJ, 
USA 
α-CD8α Rat IgG2a PerCP 53-6.7 BD Biosciences, Franklin Lakes, NJ, 
USA 
α-CD8α Rat IgG2a FITC 53-6.7 BD Biosciences, Franklin Lakes, NJ, 
USA 
α-Gr-1 Rat IgG2b PB RB6-8C5 BioLegend, San Diego, CA, USA 
α-Granzyme 
B 
Rat IgG2a PE NGZB eBioscience, San Diego, CA, USA 
α-I-Ab Mouse IgG2a APC AF6-120.1 BioLegend, San Diego, CA, USA 
α-IFN-γ Rat IgG1 APC XMG1.2 BD Biosciences, Franklin Lakes, NJ, 
USA 
α-IL-17 Rat IgG2a PE eBio17B7 eBioscience, San Diego, CA, USA 
α-IL-2 Rat IgG2b PE JES6-5H4 BD Biosciences, Franklin Lakes, NJ, 
USA 
α-IL-6 Rat IgG1 PE MP5-20F3 eBioscience, San Diego, CA, USA 
α-NFATc1 Mouse IgG1 PE 7A6 BioLegend, San Diego, CA, USA 
α-NK1.1 Mouse IgG2a APC PK136 eBioscience, San Diego, CA, USA 
α-NK1.1 Mouse IgG2a eFluor450 PK136 eBioscience, San Diego, CA, USA 
α-NK1.1 Mouse IgG2a BV421 PK136 BioLegend, San Diego, CA, USA 
α-NKp46 Rat IgG2a V450 29A1.4 BD Biosciences, Franklin Lakes, NJ, 
USA 
α-PD-L1 Rat IgG2b BV421 10F.9G2 BioLegend, San Diego, CA, USA 
3.8.2.2 Anti-human antibodies 
Specificity Isotype Conjugation Clone Manufacturer 
     
α-CD25 Mouse IgG1 APC 2A3 BD Biosciences, Franklin Lakes, NJ, USA 
α-CD3ε Mouse IgG1 APC SK7 eBioscience, San Diego, CA, USA 
α-CD3ε Mouse IgG1 BV510 SK7 BioLegend, San Diego, CA, USA 
α-CD3ε Mouse IgG2a FITC HIT3a BD Biosciences, Franklin Lakes, NJ, USA 
α-CD45 Mouse IgG1 PE HI30 Invitrogen, Camarillo, CA, USA 
α-CD8α Mouse IgG1 PE-Cy7 SK1 BioLegend, San Diego, CA, USA 
α-CD8α Mouse IgG1 PerCP SK1 BioLegend, San Diego, CA, USA 
3.8.3 Antibodies for the depletion of specific cell populations 
Specificity Isotype Manufacturer 
 
  
α-CCR2 (MC-21) IgG2b (MC-67) Provided by Matthias Mack (Department of Internal 
Medicine II, University Hospital Regensburg, 
Germany) 
α-CD8α (Clone 2.43) Rat IgG2b Bio X Cell, West Lebanon, NH, USA 
α-CD4 (Clone GK1.5) Rat IgG2b Bio X Cell, West Lebanon, NH, USA 
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3.9 Bacteria 
E. coli Provided by Jacques Pouysségur (Institute of Research on Cancer and Ageing 
(IRCAN), University of Nice-Sophia Antipolis-CNRS-Inserm, Centre A. Lacassagne, 
Nice, France) 
3.10 Cell lines 
For animal experiments the mouse melanoma cell line B16.SIY E12 was used. This cell line was 
created by removal of GFP from the SIY-pLeGFP vector (present in B16.SIY E12 cells, containing 
the SIY antigen which is recognized by 2C/RAG2−/− CD8+ T cells182) and subsequently transfected 
into B16.F10 cells by the group of Christian Blank (Division of Immunology, The Netherlands 
Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands).  
Additionally, B16.SIY E12 cells were transfected with a pGeneClip hMGFP plasmid containing 
shRNA sequences against Ldha to generate cells with low Ldha levels (Ldhalow cells), a 
scrambled shRNA sequence for control cells, as well as GFP and an ampicillin resistance gene. 
As parental B16.SIY E12 cells already contained an ampicillin resistance gene against G418 on 
the SIY-pLeGFP vector, a pGene/V5-His vector containing a blasticidin-resistence gene was used 
as a second plasmid, allowing cultivation of Ldhalow cells under antibiotic selection. The generation 
of Ldhalow cells from B16.SIY E12 was performed by Michael Kastenberger183. 
In another approach to decrease LDHA levels, performed at the Institute of Research on Cancer 
and Ageing (IRCAN) of the University of Nice-Sophia Antipolis-CNRS-Inserm, Centre A. 
Lacassagne in Nice, France, under the supervision of Jacques Pouysségur, CRISPR/Cas9, 
targeting Ldha in B16.SIY E12 was used to generate Ldha−/− clones (Chapter 4.7).  
The P815.B71 mastocytoma cell line for priming of 2C/RAG2−/− CD8+ T cells (Chapter 4.4.3.1) 
was provided by Christian Blank (Division of Immunology, The Netherlands Cancer Institute, 
Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands).  
3.11 Mice 
2C/Rag2−/− Provided by Christian Blank (Division of Immunology, The Netherlands Cancer 
Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands) 
C57BL/6J Charles River, Wilmington, MA, USA 
C57BL/6N Taconic, Hudson, NY, USA 
Ccr2−/−   Provided by Uwe Ritter (Institute of Immunology, University of Regensburg, 
Germany) 
Cd8−/−   The Jackson Laboratory, Bar Harbor, ME, USA 
Ifngr1−/−  The Jackson Laboratory, Bar Harbor, ME, USA 
Ifng−/−  The Jackson Laboratory, Bar Harbor, ME, USA 
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Pfp−/− Provided by Petra Hoffmann (Department of Internal Medicine III, University 
Hospital Regensburg, Germany) 
Rag2−/−   Taconic, Hudson, NY, USA 
Rag2−/−γc−/−  Taconic, Hudson, NY, USA 
3.12 Patient material 
After informed consent, biopsies of primary melanoma, melanoma in situ, cutaneous metastases 
of melanoma and adjacent healthy skin or nevi of respective patients, who had undergone surgery 
for skin tumors at the Department of Dermatology at the University Hospital of Regensburg, 
Germany, were obtained. The study was approved by the institutional ethics committee (approval 
number 13-101-0127), designed and conducted in accordance with the Declaration of Helsinki 
and performed in cooperation with Elisabeth Kohl and Sebastian Haferkamp (Department of 
Dermatology, University Hospital Regensburg, Germany). 
3.13 Databases and software 
The following databases and software tools were used to design experiments and process data.  
CorelDraw X4 Corel, Ottawa, Ontario, Canada 
EndNote X7 Thomson Reuters, New York, NY, USA 
FlowJo v9.5.3 FlowJo,LLC, Ashland, OR, USA 
GeneRunner version 3.05 http://www.generunner.com 
GraphPad Prism 5.02 GraphPad Software, La Jolla, CA, USA 
ImageLab v4.0 Bio-Rad, Munich, Germany 
Microsoft Excel 2003/2007/2010 Microsoft Deutschland GmbH 
PerlPrimer version 1.1.14 http://perlprimer.sourceforge.net/ 
PubMed  http://www.ncbi.nlm.nih.gov/entrez 
UCSC Genome Browser http://www.genome.ucsc.edu 
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4 Methods 
4.1 Cell culture methods 
All cells were handled under a laminar flow cabinet with sterile consumables. If not otherwise 
stated, all media used were supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% 
L-glutamine and 0.5% penicillin/streptomycin, cells were incubated at 37 °C/5% CO 2/95% relative 
humidity and centrifugation was performed at 345 g for 7 minutes at 4 °C. 
4.1.1 Cell passaging 
The CRISPR Ldha−/− clones were cultured without selection antibiotics. The Ldha shRNA 
transfected and untransfected B16.SIY E12 mouse melanoma cells were cultured in medium with 
selection antibiotics G418 and blasticidin. Cells were passaged every 3-4 days and, therefore, 
rinsed with PBS and trypsinized for 3-5 minutes with 0.05% Trypsin/0.02% EDTA at 37 °C. To 
inactivate trypsin, medium was added in a 10:1 ratio and cells were centrifuged. After cells were 
resuspended in 1-5 ml of medium, depending on the pellet size, cells were counted with the CASY 
cell counter and 0.5-1 x 106 cells were seeded in fresh medium. 
P815.B71 mastocytoma cells were passaged every 2-3 days by transferring some cells into fresh 
medium (subcultivation ratio of 1:10).  
4.1.2 Freezing and thawing 
For freezing, the volume of 0.5-5 x 106 cells was mixed with freezing medium (FCS 20%, dimethyl 
sulphoxide, DMSO 80%) in cryo tubes in a 1:2 ratio and slow-frozen in cryo freezing containers for 
short-term storage at 80 °C or long-term storage in  liquid nitrogen.  
Frozen cells were thawed at room temperature and immediately added to warm medium. After 
centrifugation cells were seeded in fresh medium. 
4.1.3 Cell counting 
Cell numbers and viability were determined by means of electronic pulse area analysis using a 
CASY cell counter. This method obtains signals when a cell passes in a low-voltage field through 
the system’s high-precision measuring pore. 
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4.1.4 Mycoplasma test 
All cell lines were routinely tested for mycoplasma with the MycoAlert mycoplasma detection kit 
according to the manufacturer’s recommendations. 
4.1.5 3H-thymidine incorporation assay 
To measure proliferation of cell lines, the incorporation of the radioactive nucleoside 3H-thymidine 
into new strands of chromosomal DNA during mitotic cell division was assessed. Therefore, 2.5 x 
104 cells per well were seeded into flat-bottom 96-well microtiter plates, incubated for 2 hours until 
cells were fully adherent, and 0.5 µCi (=0.00185 MBq) [methyl-3H]-thymidine was added. After 20-
22 hours cells were transferred to UniFilter plates with a Wallac Harvester and incorporated 3H-
thymidine was measured with a Wallac Betaplate counter. 
4.1.6 Enzymatic determination of lactate 
To determine lactate concentrations in supernatants, 2.5 x 104 cells were seeded into flat-bottom 
96-well microtiter plates and incubated for 24 hours. Supernatants were analyzed with a routine 
procedure using an ADVIA 1650 analyzer at the Department of Clinical Chemistry (University 
Hospital Regensburg, Germany). By means of an enzymatic assay the hydrogen peroxide, which 
emerges from the oxidation of lactate by lactate oxidase, reacts with a chromogen in presence of 
a peroxidase. The amount of resulting dye is proportional to the lactate concentration and can be 
measured by spectrophotometry. 
4.1.7 Cell cycle analysis 
For cell cycle analysis, 5 x 105 cells were rinsed with ice-cold PBS, resuspended in 300 µl 
propidium iodide buffer (0.1% Triton X100, 0.1% sodium citrate, 50 µg/ml propidium iodide in 
distilled water), vortexed thoroughly and incubated for 24 hours at 4 °C. Cells were then measured 
by flow cytometry at the BD LSR II and cell cycle was analyzed according to “Dean/Jett/Fox” using 
FlowJo software. 
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4.1.8 High-resolution respirometry and analysis of 
mitochondria 
Respiration of cells was determined by high-resolution respirometry using the oxygraph O2-k. 0.5-
1 x 106 cells were analyzed in cell culture medium for routine respiration during 20 minutes. 
Values were corrected for residual oxygen consumption being not related to the respiratory 
system, which was determined after addition of rotenone (0.5 µM) and myxothiazol (2.5 µM). 
To analyze mitochondrial content, 5 x 105 cells were seeded in a 75 cm2 flask. After 72 hours cells 
were drained of medium and medium without additives containing green-fluorescent mitochondrial 
stain MitoTracker Green (25 nM) and cyclosporin A (16 nM), serving as export inhibitor of the dye 
from the mitochondria, was added. After 2 hours incubation at 37 °C, the cells were trypsinized 
(Chapter 4.1.1), centrifuged twice with 1 ml flow cytometry buffer (PBS containing 2% FCS), 
resuspended in 400 µl flow cytometry buffer and measured at the flow cytometer. Unstained cells 
were used to determine autofluorescence. 
4.2 Molecular biology techniques 
4.2.1 Preparation of ribonucleic acids 
To obtain total ribonucleic acids (RNA) of cell lines, 1 x 106 cells/well were incubated in 6-well 
microtiter plates for 24 hours, rinsed with PBS, lysed using the RNeasy Mini Kit, detached with cell 
scrapers and sheared 10 times using a 1 ml syringe. Procedures were performed on ice and RNA 
lysates were frozen at -80 °C for storage. 
To obtain total RNA of tissues, dissected mouse or human tumors were homogenized using 
TissueLyser (3 min, 20 Hz) and QIAshredder columns according to the manufacturer’s 
instructions.  
Subsequent isolation of total cellular RNA and additional on-column DNA digestion with the 
RNase-free DNase Set against potential DNA contamination was performed according to the 
manufacturer’s instructions using the RNeasy Mini Kit. RNA concentration was determined with 
the NanoDrop 1000 spectrophotometer. RNA quantification and integrity was measured on RNA 
Nano LabChips using the 2100 Bioanalyzer. 
4.2.2 Polymerase chain reaction 
Polymerase chain reaction (PCR) is a method to in vitro-amplify specific DNA fragments with the 
help of a DNA template, a thermoresistant DNA polymerase and sequence-specific 
oligonucleotide primers which flank the DNA fragment of interest. The quantitative real-time PCR 
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(qRT-PCR) used here, serves to quantify the expression level of specific genes. Therefore, total 
cellular RNA had to be converted into DNA (=copy DNA, cDNA) by means of reverse 
transcription. 
4.2.2.1 Reverse transcription 
In order to determine gene expression levels, isolated total RNA was transcribed into cDNA using 
a reverse transcriptase derived from the murine moloney leukemia virus (M-MLV), random 
decamer primers and 2’-deoxyribonucleosid-5’-triphosphates (dNTPs). The reaction was 
performed in a PCR thermocycler according to the following protocol (Table 4-1) with a reaction 
volume of 20 µl. 
Table 4-1. Protocol for reverse transcription 
(1) Mix and incubate at 65 °C for 5 min 
 
Total RNA 0.5 µg 
Random decamer primers (10 µM) 1 µl 
dNTPs (10 µM) 1 µl 
H20USB ad 15 µl 
(2) Add and incubate at 42 °C for 2 min 
 
M-MLV buffer (5X) 4 µl 
(3) Add and incubate at 42 °C for 50 min,        
     then at 70 °C for 15 min 
 
M-MLV reverse transcriptase 1 µl 
 
4.2.2.2 Primer design 
For qRT-PCR, oligonucleotide primers with specificity towards the genes of interest (Chapter 3.7) 
were constructed with the help of the ‘PerlPrimer’ software and the UCSC genome browser, 
following the criteria below (Table 4-2). Primers generated in this way were verified by means of 
‘Blat’ and ‘in silico’ PCR (UCSC genome browser) and secondary structure analysis was 
performed with the help of the GeneRunner software. 
Table 4-2. Criteria for primer design 
GC content 40-60% 
Melting temperature (Tm)  65-68 °C 
Length primer 20-28 bp 
Length amplicon 70-250 bp 
Position On 2 different exons spanning an intron 
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4.2.2.3 Quantitative real-time PCR 
In order to quantify gene expression levels, qRT-PCR makes use of a dye which intercalates 
double-stranded DNA and becomes fluorescent in its bound form. The amount of fluorescence is 
proportional to the amount of amplified DNA. Quantification of PCR products takes place in the 
early exponential phase of the PCR reaction, determining the PCR cycle when the fluorescence of 
the sample exceeds the background fluorescence for the first time as cycle threshold (ct)-value. 
By amplification of known amounts of cDNA (positive control) and corresponding ct-values, a 
standard curve can be generated and from measured ct-values of samples the amounts of 
amplified cDNA can be determined.  
With the exception of iNos, which was quantified by the group of Christian Bogdan (Microbiology 
Institute-Clinical Microbiology, Immunology and Hygiene, Erlangen, Germany) using the Nos2 
TaqMan Gene Expression Assay, here the QuantiFast SYBR Green Kit was used for qRT-PCR. 
Reactions were prepared in 96-well PCR microtiter plates at a volume of 10 µl/well with a reaction 
mix depicted in Table 4-3. Samples were pipetted in triplicates and a positive control for 
generation of a standard curve was pipetted in duplicates. 
 Table 4-3. Reaction mix for qRT-PCR 
Reagent Volume 
QuantiFast SYBR Green-mix 5 µl 
cDNA (1:10 in H20USB) 1 µl 
Sense primer (10 µM) 0.5 µl 
Antisense primer (10 µM) 0.5 µl 
H20USB 3 µl 
 
After sealing the microtiter plate with heat-sealing film and quick centrifugation, qRT-PCR was 
carried out by Realplex Mastercycler EpGradient S according to the following program (Table 
4-4). 
Table 4-4. Program for qRT-PCR 
Process Temperature Duration 
Initial denaturation 95 °C 5 min 
Denaturation 95 °C 8 s 
  45 cycles 
Annealing/elongation 60 °C 20 s 
Melting curve 95 °C 15 s  
 65 °C 15 s 
 65-95 °C 10 min 
 
Specific amplification of the expected PCR product was controlled by the pattern of the melting 
curve. By means of the slope of the standard curve and the y-axis intercept, the amount of cDNA 
was calculated by the Realplex software. The amount of messenger RNA (mRNA) which 
corresponds to the calculated amount of cDNA was finally normalized to that of 18S rRNA. 
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4.3 Biochemical methods 
All samples were treated as described in the following, except samples generated in the 
laboratory of Jacques Pouysségur (Institute of Research on Cancer and Ageing (IRCAN), 
University of Nice-Sophia Antipolis-CNRS-Inserm, Centre A. Lacassagne, Nice, France), which 
are described in Chapter 4.7. 
4.3.1 Preparation of proteins 
In order to obtain total protein, 1 x 106 cells were incubated in 6-well microtiter plates for 24 hours. 
Afterwards, cells were rinsed twice with 1 ml PBS and 100 µl RIPA buffer, containing additional 
protease inhibitor, were added. Adherent cells were then detached with cell scrapers and vortexed 
thoroughly for 1 minute. All procedures were performed on ice and protein lysates were stored at  
-80 °C. 
For determining protein concentrations, samples were centrifuged at 13,000 g for 15 minutes at 4 
°C and supernatants were subjected to the Bio-Rad D C Protein Assay according to the 
manufacturer’s instructions. Known concentrations of bovine serum albumin (BSA) were used as 
internal standards to calculate protein content. 
For further procedure, equal volumes of 10 µg protein lysate diluted with the same volume of SDS 
sample buffer (2X) (Table 4-5) were prepared. 
Table 4-5. Composition of SDS sample buffer 
Working reagent Components 
SDS sample buffer (2X) 20% (10 ml) Glycerin 
125 mM (5 ml) Tris/HCl (pH 6.8, 1.25 M) 
4% (2 g) SDS 
10% (5 ml) 2-Mercaptoethanol 
0.02% (10 mg) Bromophenol blue 
  ad 50 ml H2Obidest 
4.3.2 SDS polyacrylamide gel electrophoresis 
Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a technique developed 
by U.K. Laemmli to electrophoretically separate proteins according to their molecular weight using 
the denaturation properties of SDS as an anionic detergent and its feature to coat proteins with 
uniform negative charge. 
As running gel served a 12% acrylamide gel (ideal for 20-60 kDa proteins), as stacking gel a 5% 
acrylamide gel, which were prepared with ammonium persulfate (APS) as oxidizing agent and 
N,N,N’,N’-tetramethylethylenediamine (TEMED) as reaction catalyst. Running gel was mixed 
Methods 
  37 
according to Table 4-6, Table 4-7 and Table 4-8, immediately filled in the casting frames and left 
coated with isopropanol for 30 minutes. Then stacking gel was mixed according to Table 4-6, 
Table 4-7 and Table 4-8, filled on top of running gel and a well-forming comb was placed. The gel 
was led to polymerize at room temperature. 
To perform electrophoresis, the SDS gel was placed in the electrophoresis chamber and bathed in 
electrode buffer (1X). After carefully removing the comb, wells were rinsed with electrode buffer 
and loaded with equal volumes of 10 µg protein lysates (Chapter 4.3.1) which were first heated at 
95 °C for 10 minutes and second cooled on ice. Addi tionally, one well was loaded with 5 µl 
Kaleidoscope Prestained Standard as molecular weight standard. 
Samples were run at voltages of 80-100 V and as soon as they reached the running gel, voltage 
was increased to 120-130 V. Electrophoresis was stopped at the time point when the lowest sign 
of the protein marker reached the lower bottom of the gel. 
Table 4-6. Composition of SDS polyacrylamide gels 
Components 12% running gel 5% stacking gel 
Running gel solution 18 ml - 
Stacking gel solution - 10 ml 
TEMED 18 µl 10 µl 
APS (10%) 90 µl 80 µl 
 
 
Table 4-7. Composition of SDS polyacrylamide gel solutions 
Components Running gel solution (12%) Stacking gel solution (5%) 
Running gel buffer 25 ml - 
Stacking gel buffer - 25 ml 
SDS (10%) 1 ml 1 ml 
Acrylamide (30%) 40 ml 16.65 ml 
H2Obidest ad 100 ml ad 100 ml 
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Table 4-8. Working solutions for SDS-PAGE 
Working solutions Components 
Running gel buffer 1.5 M  (90.83 g) Tris/HCl (pH 8.8) 
   ad 500 ml  H2Obidest 
Stacking gel buffer 0.5 M  (30 g)  Tris/HCl (pH 8.8) 
   ad 500 ml  H2Obidest 
SDS (10%) 10% (10 g) SDS 
   ad 100 ml  H2Obidest 
Acrylamide (30%) 30% 
  ad 100 ml 
(30 ml) Acrylamide 
H2Obidest 
APS (10%)  10% (100 mg) APS 
   ad 1 ml  H2Obidest 
 Freshly prepared for each usage. 
Electrode buffer (5X) 40 mM (15 g) Tris 
 0.95 M  (216 g) Glycine 
 0.5% (15 g) SDS 
  ad 3,000 ml  H2Obidest 
4.3.3 Western blotting 
The western blotting method was applied to detect specific proteins within the range of separated 
proteins by SDS-PAGE. 
In a first step, proteins from the SDS gel were transferred to a polyvinylidene difluoride (PVDF)-
membrane in a semi-dry electro-blotting system. Therefore, the PVDF membrane was cut to a 
size similar to the SDS gel, hydrophilized in methanol for 2 minutes and equilibrated in buffer B 
(buffers used are described in Table 4-9). The SDS gel was removed from the glass plates and 
also placed in buffer B. Meanwhile, three layers of filter paper soaked with buffer A were placed 
on the bottom part of a semi-dry transfer cell (anode), followed by three layers of filter paper 
soaked in buffer B. The wet membrane was put on the filter paper and then the SDS gel was put 
on top of the membrane and it was covered with three layers of filter paper soaked in buffer C. It 
was made sure that the construction was air bubble-free. The system was closed with the upper 
part of the semi-dry transfer cell (cathode) and transfer of the proteins onto the PVDF membrane 
was carried out at 0.8 mA/cm2 gel surface for 30-45 minutes. 
In a second step, the proteins on the membrane were subjected to immunostaining. Each step 
was performed with shaking for maximum accessibility of reagents. To minimize non-specific 
binding, the membrane was incubated in blocking buffer over night at 4 °C. Subsequently, the 
membrane was swirled in a dilution of primary antibody in blocking buffer (Chapter 3.8.1) for 1.5 
hours at room temperature. Then, the membrane was washed three times in Tris-buffered saline 
(TBS) and Tween 20 (TBST) buffer for 10 minutes, each, before incubation with a dilution of a 
secondary antibody in blocking buffer (Chapter 3.8.1), specific to the isotype of the primary 
antibody for 1 hour at room temperature. The membrane was washed again three times in TBST 
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buffer for 10 minutes, each, and proteins were visualized on an imaging film using luminol-based 
enhanced chemiluminescence (ECL) solutions (Table 4-10). Hereby, the horseradish peroxidase 
(HRP) conjugated to the secondary antibody catalyzed the oxidation of luminol, inducing 
chemiluminescence. This emitted light was then captured by the image film and resulting protein 
bands could be qualified by the molecular weight standard and quantified by the protein 
expression of the housekeeping gene Actin.  
Table 4-9. Buffers for western blotting 
Buffers Components 
Buffer A 0.3 M (36.3 g) Tris/HCl (pH 10.4) 
 
20% (200 ml) Methanol 
 
ad 1,000 ml 
 
H2Obidest 
Buffer B 25 mM (3.03 g) Tris/HCl (pH 10.4) 
 
20% (200 ml) Methanol 
 
ad 1,000 ml 
 
H2Obidest 
Buffer C 4 mM (5.2 g) Caproic acid (pH 7.6) 
 
20% (200 ml) Methanol 
 
ad 1,000 ml 
 
H2Obidest 
TBS buffer (2X) 20 mM (9.16 g) Tris/HCl (pH 7.4) 
 
150 mM (35.1 g) NaCl 
 
ad 2,000 ml 
 
H2Obidest 
TBST buffer 1X (500 ml) TBS (2X) 
 
0.1% (1 ml) Tween 20 
 
ad 1,000 ml 
 
H2Obidest 
Blocking buffer 5% (5 g) Non-fat dry milk 
 
ad 100 ml 
 
TBST buffer 
 
Table 4-10. Composition of ECL solutions 
 Solutions Components 
  
ECL solution A 250 mM (100 mg) Luminol 
 
ad 2 ml 
 
H2Obidest 
ECL solution B 90 mM (14.8 mg) p-Coumaric acid 
 
ad 1 ml  
 
DMSO 
ECL mix 2 ml  
 
ECL solution A 
 
0.89 ml  
 
ECL solution B 
 
20 ml  
 
Tris/HCl (pH 8.5, 1 M) 
 
ad 200 ml 
 
H2Obidest 
 
Stored away from sunlight. 
 
ECL working solution 5 ml 
 
ECL mix 
 
1.5 µl 
 
30% H2O2 
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4.4 Mouse experiments 
All mouse experiments were conducted according to the regulations of the government of Upper 
Palatinate, Regensburg, Germany, and in cooperation with Gudrun Koehl (Department of Surgery, 
University Hospital Regensburg, Germany). 
As differences in tumor growth and immune cell infiltration were observed, depending on sex, age 
and housing temperature of the mice (Figure 4-1), unless otherwise indicated, all experiments 
were performed with male age- and housing temperature-matched animals. 
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Figure 4-1. Tumor growth depends on sex and housing temperature of mice 
Tumor growth after subcutaneous injection of 1 x 105 B16.SIY E12 cells transfected with a scrambled shRNA 
sequence in male (m) and female (f) C57BL/6 mice, housed at 25 °C and 21 °C, respectively ( n = 5-8 mice). 
In statistical analyses, tumor growth of mice housed at 25 °C and 21 °C was compared in female mice (p ink 
asterisks) and male mice (blue asterisk). Data are presented as the mean tumor volume and s.e.m. * P < 
0.05 and *** P < 0.001 (unpaired Student’s t-test). 
4.4.1 Tumor inoculation 
To generate tumors in mice, 1 x 104, 1 x 105 or 1 x 106 B16.SIY E12 Ldhalow cells, control and wild 
type cells were injected subcutaneously in the dorsal region of mice. Tumor volumes were 
estimated by measurements of the short (a) and long (b) axis of the mass and the following 
formula: V = pi/6 x 0.5 x a2 x b, starting on the first day when tumors became visible to the naked 
eye (earliest on day 7). Animals were monitored on a daily basis for tumor size and their general 
condition. When the tumor diameter reached 1 cm, mice were killed and blood, spleens, and 
tumors of mice bearing tumors, grown from 1 x 105 B16.SIY E12 cells were prepared for analysis. 
To exclude size effects only tumors with a max. size of 1,000 mm3 were included in analyses. 
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4.4.2 Depletion of specific cell populations using monoclonal 
antibodies 
4.4.2.1 Depletion of monocytes 
Monocytes were depleted by using an α-CCR2 antibody. Therefore, after injection of tumor cells 
into mice (Chapter 4.4.1), 30 or 50 µg of an α-CCR2 monoclonal antibody and the respective 
isotype (Chapter 3.8.3) were administered intraperitoneally into mice, starting treatment from day 
3 until day 7 or 8. Retrobulbar blood was analyzed on days 0, 4, 7 and 10 to confirm depletion of 
monocytes as described in Chapters 4.4.3.4 and 4.6.2. 
4.4.2.2 Depletion of T cells 
CD4+ or CD8+ T cells were depleted using α-CD4 or α-CD8 antibodies. Therefore, 2 and/or 4 days 
prior to injection of tumor cells into mice (Chapter 4.4.1), intraperitoneal injection of 250 µg of α-
CD4 or α-CD8 monoclonal antibodies and respective isotypes (Chapter 3.8.3) was performed. In 
some experiments, the treatment with the depleting antibodies was continued on days 3, 8, and 
13 after tumor cell injection. Analyses of retrobulbar blood (Chapters 4.4.3.4 and 4.6.2) throughout 
the experiments served to confirm depletion of CD4+ and CD8+ T cells. 
4.4.3 Sample preparation for flow cytometry 
4.4.3.1 Isolation and expansion of CD8+ T cells and NK cells 
CD8+ T cells and NK cells were isolated from spleens of 2C/Rag2−/− and C57BL/6 mice, 
respectively by magnetic bead separation using the CD8α+ T cell isolation kit or the NK cell 
isolation kit II according to the manufacturer’s instructions. 
1 x 105 purified CD8+ T cells were stimulated twice with 5 x 105 irradiated (20 Gy) P815.B71 
mastocytoma cells and cultured in 24-well microtiter plates with media containing 10% FCS, 1% 
L-glutamine, 0.5% penicillin/streptomycin, 0.4% vitamins, 1% non-essential amino acids, 1% 
sodium pyruvate, 0.1% 2-mercaptoethanol and 10 U/ml IL-2. Stimulated CD8+ T cells were 
collected and purified by gradient centrifugation.  
NK cells were expanded for 5 days in media as described above, containing 100-1000 U/ml IL-2.  
4.4.3.2 Preparation of tissue samples 
For flow cytometry analyses, tissues of mice had to be processed to single-cell suspensions. For 
maintaining cell viability, tissues dissected from mice were collected in ice-cold PBS and tissue 
preparation was performed on ice. 
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Tumors were injected with 3 ml medium supplemented with 0.5% Collagenase Type IA (10 mg/ml) 
and 0.4% DNase I (10 mg/ml) and incubated for 1 hour in 6-well microtiter plates, being minced 
with a scalpel after 30 minutes. Tumors were then passed through a 70 µm cell strainer and 
centrifuged. 
Spleens were processed to single-cell suspensions by scratching out cells with curved forceps in 
a petri dish containing medium. Afterwards, they were filtered via 100 µm cell strainers and 
centrifuged.  
Erythrocytes in single-cell suspensions of tumors and spleens were lysed with 2 ml ACK lysis 
buffer (0.155 M NH4Cl, 0.1 M KHCO3 and 0.1 mM EDTA, diluted 1:6 with H2O) for 3 minutes at 
room temperature. The reaction was stopped by adding 10 ml medium and cells were centrifuged. 
Pelleted cells were resuspended in 1-50 ml medium (volume dependent on pellet size) and filtered 
via 100 µm cell strainers. After counting the cells with the CASY cell counter, 0.5-3 x 106 cells 
were used for flow cytometry staining. 
4.4.3.3 Preparation of single cells for intracellular staining 
In order to analyze cytokines in tumors of C57BL/6 mice, 3 x 106 single cells obtained under a 
laminar air flow cabinet by the procedure described in Chapter 4.4.3.2 were incubated for 3 hours 
in 6 ml medium in 6-well microtiter plates with Golgi Plug as protein transport inhibitor.  
For assessing cytokines in splenocytes of healthy mice, single cells were incubated as described 
above with addition of phorbol 12-myristate 13-acetate (PMA, final concentration 50 ng/ml) and 
ionomycin (final concentration 750 ng/ml) as stimuli, and in the presence or absence of 10 and 20 
mM L-lactic acid. 20 mM sodium L-lactate and acidification by hydrochloric acid (HCl) 
corresponding to the pH at 20 mM lactic acid (~pH 5.8) were used as controls. 
To analyze the transcription factor nuclear factor of activated T cells (NFAT), 0.5 x 105 CD8+ T 
cells and 1 x 105 NK cells were cultured in U-bottom 96-well microtiter plates in the presence or 
absence of 15 mM L-lactic acid, hydrochloric acid (HCl) corresponding to the pH of 15 mM L-lactic 
acid (~pH 6.4) and 15 mM sodium L-lactate for 24 hours. 30 minutes before harvesting, cells were 
stimulated with PMA (final concentration 20 ng/ml) and ionomycin (final concentration 750 ng/ml). 
4.4.3.4 Preparation of blood samples 
Blood of mice was collected from the vena cava in heparin tubes. 2-3 drops of blood were lysed 
with 1 ml ACK lysis buffer (Chapter 4.4.3.2) for 5 minutes at room temperature. The reaction was 
stopped by adding 2 ml flow cytometry buffer (PBS containing 2% FCS). After centrifugation, 
supernatants were carefully aspired, leaving ~50 µl to avoid disturbing the pellet and ACK lysis 
was repeated until the pellet was colorless. At last, the pellet was resuspended in 1 ml of flow 
cytometry buffer for subsequent flow cytometry analysis. 
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4.4.4 Sample preparation for RNA isolation 
Tissues were dissected from mice and immediately stored in RNAlater according to the 
manufacturer’s instructions. In this way RNA was stabilized and the gene expression profile was 
preserved. RNA isolation was performed as described in Chapter 4.2.1. 
4.4.5 Analysis of growth factors in tumor supernatants 
Single-cell suspensions of tumors were obtained as described in Chapter 4.4.3.2. 5 x 105 cells 
were incubated in 12-well microtiter plates and stimulated with LPS (lipopolysaccharide, 1 µg/ml) 
for 24 hours. Supernatants were analyzed regarding TGF-β concentrations by means of sandwich 
ELISA (enzyme-linked immunosorbent assay) according to the manufacturer’s recommendations. 
Here, the antigen of interest binds to an antibody which is attached to the bottom of a microtiter 
plate and is detected by a specific detection antibody. This detection antibody is coupled to an 
enzyme which induces a color reaction proportional to bound antigen and thereby indicates the 
amount of antigen present in the respective sample. 
4.4.6 Sample preparation for bioluminescence imaging 
For bioluminescence imaging tissues were immediately snap-frozen upon dissection to preserve 
the metabolic profile. 
4.5 Induced metabolic bioluminescence imaging  
To determine intracellular lactate levels of tumors ex vivo, induced metabolic bioluminescence 
imaging (imBI) was performed by the group of Wolfgang Mueller-Klieser (Institute of 
Pathophysiology, University Medical Center of the Johannes Gutenberg University Mainz, 
Germany). Lactate concentrations were measured in serial tumor cryosections by the imBI 
method184. Briefly, reaction solutions containing specific enzymes linking the metabolite of interest 
to the luciferase of Photobacterium fischeri or Photinus pyralis were used. Light emission was 
induced in a temperature stabilized reaction chamber positioned on the stage of a microscope 
(Axiophot; Zeiss) connected to a 16-bit electron-multiplying charge-coupled device camera with an 
imaging photon counting system (iXonEM + DU-888; Andor Technology PLC). Images of the 
spation distribution of light intensities were calibrated by using appropriate standards. Metabolite 
concentrations were acquired exclusively from histologically viable tissue by interactive optical 
microdissection. The concentrations were calculated in micromoles per gram of tumor tissue and 
were displayed in color-coded images. Three sections per metabolite were analyzed for each 
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tumor, and the mean value was used as a parameter for the metabolite concentration of a tumor. 
Further methodological details and representative calibration curves have been reported 
elsewhere57,185. 
4.6 Flow cytometry 
Flow cytometry is the gold standard technique for cell analysis, as it allows counting, examining 
and sorting of individual cells. With the help of monoclonal antibodies which are conjugated to 
fluorochromes, labeling and detection of specific cell populations is possible. 
Therefore, cells separately pass a laser beam, generating scatter light and fluorescence. Scatter 
light indicates size (forward scatter, FSC) and granularity (side scatter, SSC) of the cells; 
fluorescence gives information about a specific cell type. 
Various fluorochrome-conjugated antibodies against components of the immune system were 
used in 6-color measurements (Chapter 3.8.2) performed at the BD LSR II, equipped with a red, 
blue, violet and UV laser. Staining procedures were performed on ice to preserve cell viability. 
Dead cells were excluded by 4',6-diamidino-2-phenylindole (DAPI), which is a blue fluorescent 
dye that binds to double-stranded DNA (dsDNA) after entering cells with damaged membranes. 
Analysis of flow cytometry data was performed the with FlowJo software.  
4.6.1 Compensation 
Compensation is an essential element of adequate experimental set-up for multicolor flow-
cytometry assays. It is based on the overlap of fluorescence emission wavelengths, which can 
occur when two different fluorochrome-conjugated antibodies bind to one cell. This spillover is 
calculated with the help of single-stained controls as so called compensation values by means of 
which fluorescence emission values are properly corrected.  
In this case, compensation values were established using CompBeads, a compensation-particles 
set, according to the manufacturer’s instructions. Unstained cells were used to correct 
autofluorescence. 
4.6.2 Surface staining 
For staining of surface antigens, 0.5-3 x 106 cells were resuspended in 1 ml flow cytometry buffer 
and centrifuged at 523 g for 4 minutes at 4 °C. For  mouse cells, 1 µl FcR blocking reagent was 
added and cells were incubated for 15 minutes at 4 °C. Then, cells were incubated with 
fluorochrome-conjugated antibodies (Chapter 3.8.2.1 and 3.8.2.2, amounts according to the 
manufacturer’s recommendations) for 15-20 minutes at 4 °C in the dark. After addition of 1 ml flow 
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cytometry buffer, cells were centrifuged at 523 g for 4 minutes at 4 °C and the pellet was 
resuspended in 300 µl flow cytometry buffer. Measurement took place on the same day after 
passing cells through a 35 µm cell strainer cap (only for tissues) and adding 10% DAPI for life-
dead staining. For blood and spleens 5,000-200,000 cells were recorded and for tumors the 
maximum possible number of cells was recorded. 
4.6.3 Intracellular staining 
After incubation, adherent cells were detached with cell scrapers and centrifuged at 523 g for 4 
minutes at 4 °C with 1 ml flow cytometry buffer. Su bsequent staining with antibodies against 
surface markers was performed (Chapters 4.6.2 and 3.8.2.1, amount of antibodies used according 
to the manufacturer’s recommendations) for 15 minutes at 4 °C in the dark. Then, cells were 
centrifuged at 523 g for 4 minutes at 4 °C with 1 m l flow cytometry buffer and intracellular staining 
was performed with a Foxp3 staining buffer set. Therefore, 0.5 ml of Fix/Perm Mix (1:4 ratio of 
Fix/Perm concentrate and Fix/Perm diluent) was added to the cells, vortexed thoroughly and 
incubated for 15 minutes at 4 °C in the dark. Cells  were centrifuged twice with 1 ml 
permeabilization buffer (1:10 dilution in H2O) at 523 g for 4 minutes at 4 °C and staining with  
antibodies against cytokines and/or transcription factor NFAT (Chapter 3.8.2.1) was conducted 
followed by 20 minutes incubation at 4 °C in the da rk. After centrifugation at 523 g for 4 minutes at 
4 °C with 1 ml permeabilization buffer and then 1 m l flow cytometry buffer, cells were 
resuspended in 250 µl flow cytometry buffer, filtered through 35 µm cell strainer caps and 
subjected to measurement. 
4.6.4 Quantification of intracellular pH 
0.5 x 106 CD8+ T cells isolated from 2C/Rag2−/− mice (Chapter 4.4.3.1) were centrifuged at 345 g 
for 7 minutes at 4 °C and resuspended in 1 ml Hank’ s balanced salt solution (HBSS, containing 2 
g/l NaHCO3). After adding 10 µM Carboxy SNARF-1 AM acetate, cells were incubated for 30 
minutes in the incubator. Then centrifugation was performed with 1 ml HBSS at 345 g for 7 
minutes at 4 °C. Afterwards, cells were resuspended  in 1 ml HBSS containing different amounts of 
L-lactic acid (0, 10, 15 and 20 mM) or HCl corresponding to the pH of 15 mM lactic acid (~pH 6.4) 
and were incubated at 37 °C for 30 minutes and 7 ho urs, respectively. For in situ pH calibration, 
instead of being treated with lactic acid, cells were incubated with a mix of pH-controlled buffers 
and valinomycin/nigericin according to the manufacturer’s recommendations. Samples were then 
subjected to measurement at the FACS Calibur flow cytometer. For analyses, ratios of emission 
wavelength λ1, transmitted by a 585/42BP filter and wavelength λ2, transmitted by a 670LP filter, 
were calculated.  
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4.7 Generation of Ldha−/− clones with CRISPR/Cas9 
Clustered, regularly interspaced, short palindromic repeats (CRISPR)/Caspase 9 (Cas9) systems, 
originally found in bacteria as defense mechanisms against invading viruses, nowadays serve as 
potent novel tools for genome engineering186. By means of a single guide RNA (gRNA), the Cas9 
endonuclease can be directed to a specific locus in the genome and perform a double-strand 
break at the desired site. This is mis-repaired by error-prone non-homologous end-joining, 
resulting in a gene deletion. To exclude possible off-target activity by the Cas9 endonuclease 
parallel targeting of different sites of the desired gene is recommended. 
For the knockout of Ldha by means of CRISPR/Cas9, two different loci on exon 4 of the Ldha 
gene in B16.SIY E12 cells were targeted by means of two different gRNAs (Plasmid generation by 
Jérôme Durivault, group of Jacques Pouysségur, Centre Scientifique de Monaco, Département de 
Biologie Médicale, Monaco). Successful knockout was determined by LDHA immunoblotting of 
whole-cell lysates from cells cultivated in 1% O2 hypoxia for 24 hours, as described by Marchiq et 
al.187, using 11% SDS polyacrylamide gels and an α-LDHA antibody (Chapter 3.8.1). 
These experiments were performed in the laboratory of Jacques Pouysségur (Institute of 
Research on Cancer and Ageing (IRCAN), University of Nice-Sophia Antipolis-CNRS-Inserm, 
Centre A. Lacassagne, Nice, France). 
4.7.1 Plasmid amplification and isolation 
The CRISPR/Cas9 system was provided by Jérôme Durivault (group of Jacques Pouysségur, 
Centre Scientifique de Monaco, Département de Biologie Médicale, Monaco) as an all-in-one 
plasmid (Figure 10-1) and transformed into E. coli. Therefore, 200 ng of CRISPR/Cas9 plasmid 
were added to E. coli in pre-cooled tubes and incubated for 30 minutes on ice followed by 
incubation at 42 °C in the waterbath for 45 seconds . After 2 minutes incubation on ice, 100 µl 
SOC medium were added and incubated for 15 minutes at 37 °C on a heatblock. Bacteria were 
plated out on ampicillin agar plates and incubated for ~16 hours. One colony was picked and 
incubated in TB medium with ampicillin in the incubator shaker at a 45 °C ankle at 37 °C for 24 
hours. Then, the bacteria were transferred in an Erlenmeyer flask with TB medium containing 
ampicillin and incubated for another 24 h in the incubator shaker. Plasmid DNA was obtained 
using the Qiagen Plasmid Maxi Kit according to the manufacturer’s instructions. 
4.7.2 Transfection and cloning of Ldha−/− cells 
For transfection, 2 x 106 B16 SIY.E12 cells were seeded in small cell culture dishes and incubated 
for 24 hours. After incubation the cells were transfected with 10 µg plasmid DNA using the 
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jetPRIME DNA transfection kit according to the manufacturer’s instructions. Transfection 
efficiency of over 90 % could be achieved. 
Cells were seeded in a low density of 1,000 cells/10 cm cell culture dish and as soon as visible 
colonies formed, clones were picked. 
4.8 Analysis of human biopsies 
4.8.1 Sample preparation for flow cytometry analysis 
In order to obtain single-cell suspensions from human tissue, biopsies were minced with a scalpel 
and incubated in 1 ml medium containing 100 µl Collagenase IV (2100 U) and 45 µl DNase I (10 
mg/ml) in 12-well microtiter plates for 2 hours. Medium with minced tissue was then passed 
through 70 µm cell strainers, and microtiter plates were rinsed with 20 ml medium to collect all 
cells. After centrifugation at 345 g for 7 minutes at 4 °C, cells were resuspended in 1 ml medium 
and subjected to cell counting. If the pellet contained erythrocytes, ACK lysis was performed 
before cell counting with 3 ml ACK lysis buffer (Chapter 4.4.3.2) for 2 minutes at room 
temperature, stopped by addition of 10 ml medium and subsequent centrifugation. Samples were 
then subjected to surface staining (Chapter 4.6.2). 
4.8.2 Sample preparation for RNA isolation and 
bioluminescence imaging 
Freshly dissected human tissues were immediately snap-frozen to preserve the metabolic profile. 
RNA isolation was performed as described in Chapter 4.2.1. Bioluminescence imaging was 
performed according to Chapter 4.5. 
4.9 Statistical analyses 
Results represent the mean and standard error of the mean (s.e.m.). Comparison between groups 
was performed using paired or unpaired Student’s t-test. Correlations were calculated by the 
Pearson test. P-values of < 0.05 were considered statistically significant. All calculations were 
performed using GraphPad Prism software. 
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5 Results 
5.1 Immunomodulatory role of lactic acid in vitro 
Tumor cells are characterized by a highly glycolytic phenotype in order to sustain 
hyperproliferation, which leads to the excessive production of lactate and in turn to the 
accumulation of lactic acid in the tumor microenvironment. As data on the impact of lactic acid on 
mouse immune cells are scarce, here, lymphoid and myeloid cell populations were analyzed after 
exposure to lactic acid. 
5.1.1 Effects on lymphoid cells 
To assess the impact of lactic acid on lymphoid cells, splenocytes from C57BL/6 mice were 
stimulated with PMA/ionomycin and incubated in the absence or presence of pathophysiological 
concentrations of lactic acid57 for 3 hours. In parallel, the effects of sodium lactate and pH 
changes similar to that of 20 mM lactic acid (~pH 5.8) were studied to distinguish between the 
impact of lactate itself and acidification, which is coupled to lactate export. After 3 hours, the 
activity of lymphoid cells was determined by measuring cytokine production using flow cytometry. 
Initially, IFN-γ, as an important cytokine for T and NK cell anti-tumor immunity was analyzed. 
Among CD4+ T cells only 6% IFN-γ producing cells were found (Figure 5-1 A), whereas 25% of 
CD8+ T cells and nearly 40% of NK cells were identified as IFN-γ-producing cells (Figure 5-1 B,C). 
Regarding the impact of lactic acid on IFN-γ, a severe reduction was observed in all three cell 
populations with increasing concentrations of lactic acid. In contrast, incubation with sodium 
lactate showed no effect on IFN- γ production, whereas acidification (~pH 5.8) resulted in a 
decrease of IFN- γ production comparable to that of 20 mM lactic acid. Comparing the inhibitory 
effect of lactic acid on IFN-γ production between T cells and NK cells, CD8+ T cells were found to 
be the most susceptible cell type. Upon treatment with 20 mM lactic acid, IFN-γ production in 
CD8+ T was almost completely abolished, while CD4+ T cells and NK cells were able to maintain a 
residual IFN-γ production. 
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Figure 5-1. Lactic acid suppresses IFN-γ production of T and NK cells 
(A-C) Quantification of IFN-γ+ cells among CD4+ T cells (A), CD8+ T cells (B) and NK cells (C) from 
stimulated splenocytes of healthy C57BL/6 mice after incubation in the absence (untreated) or presence of 
lactic acid (10 and 20 mM LA), acidified medium corresponding to the pH of 20 mM LA (~pH 5.8) as well as 
20 mM sodium lactate (NaL) for 3 hours, by flow cytometry (n = 3, mean and s.e.m., n = 1 for pH 5.8 and 20 
mM NaL). * P < 0.05, ** P < 0.01, and *** P < 0.001 (paired Student’s t-test). 
As the anti-tumor activity of lymphoid cells is not only based on IFN-γ but also implicates 
granzyme B, which is important for cytolytic effector functions of T cells and NK cells, the latter 
was studied as well. Flow cytometry analyses revealed that the number of granzyme B+ cells was 
almost three times higher in NK cells than in CD8+ T cells and the expression did not differ 
significantly after treatment with lactic acid, acidification or sodium lactate (Figure 5-2 A,B), 
suggesting that granzyme B production, unlike IFN-γ production, seems to be lactic acid 
insensitive. 
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Figure 5-2. Granzyme B production of CD8+ T cells and NK cells is not impaired by lactic acid 
(A,B) Quantification of granzyme B+ cells among CD8+ T cells (A) and NK cells (B) from stimulated 
splenocytes of healthy C57BL/6 mice after incubation in the absence (untreated) or presence of lactic acid 
(10 and 20 mM LA), acidified medium corresponding to the pH of 20 mM LA (~pH 5.8) as well as 20 mM 
sodium lactate (NaL) for 3 hours by flow cytometry (n = 3, mean and s.e.m., n = 1 for pH and 20 mM NaL).  
5.1.2 Effects on myeloid cells 
In addition to lymphoid cells, myeloid cells were analyzed regarding their sensitivity towards lactic 
acid by measuring cytokine production as described in Chapter 5.1.1. 
A prominent cytokine produced by myeloid cells is IL-6. Its expression is upregulated in many 
types of cancer and associated with tumor progression and poor prognosis160. Splenocytes were 
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stimulated with PMA/ionomycin and incubated in the absence or presence of pathophysiological 
concentrations of lactic acid57, corresponding acidification and sodium lactate for 3 hours. As 
depicted in Figure 5-3, the number of IL-6+ CD11b+ cells showed no differences in the non-treated 
versus lactic acid-treated cells, i.e. IL-6 production by myeloid cells is not affected by lactic acid. 
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Figure 5-3. IL-6 production of myeloid cells is not affected by lactic acid 
Quantification of IL-6+ cells among CD11b+ cells from stimulated splenocytes of healthy C57BL/6 mice after 
incubation in the absence (untreated) or presence of lactic acid (10 and 20 mM LA), acidified medium 
corresponding to the pH of 20 mM LA (~pH 5.8) as well as 20 mM sodium lactate (NaL) for 3 hours, by flow 
cytometry (n = 3, mean and s.e.m., n = 1 for pH and 20 mM NaL).  
5.2 Immunomodulatory role of lactic acid in vivo 
The previous experiments proved that lactic acid has a negative impact on the IFN-γ production of 
T and NK cells from spleens of healthy C57BL/6 mice. Together with similar findings on human T 
cells177,178,188,189 and human myeloid cells174-176, these data strongly suggest a modulatory role of 
lactic acid on immune cells also in vivo. To investigate this hypothesis, tumor cell lines producing 
different levels of lactic acid were used to generate tumors in immunocompetent and 
immunodeficient mice, which were then analyzed regarding immune cell infiltration and activation, 
and the impact on tumor growth. 
5.2.1 Characterization of B16.SIY E12 Ldhalow cells for in vivo 
experiments 
In order to investigate the role of lactic acid on immune cells in vivo, B16.SIY E12 mouse 
melanoma cells, producing high amounts of lactate, were transfected with Ldha shRNA plasmids 
to generate clones with reduced Ldha expression (Ldhalow) and in this way to decrease lactate 
production of the cells183. Untransfected cells (WT) and cells transfected with a scrambled shRNA 
(Ctrl) served as controls. 
The following chapters describe the characterization of the Ldhalow clones. 
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5.2.1.1 Enzymes and transporters involved in glucose metabolism 
To confirm the knockdown by shRNA technology, Ldha mRNA levels were analyzed in B16.SIY 
E12 cells in comparison to mRNA expression of other enzymes or transporters linked to glycolysis 
which could possibly be influenced by the downregulation of Ldha. 
Wild type cells (WT), cells transfected with a scrambled shRNA sequence (Ctrl) and Ldhalow 
clones (Ldhalow1 and Ldhalow2) were cultured for 24 hours at a cell density of 1 x 106 cells in 6-well 
microtiter plates, total RNA was isolated using the RNeasy Mini Kit and reverse transcription was 
performed. qRT-PCR with primers for Ldha, Ldhb, Glut1, Hk1 and Hk2 was performed and 
normalized to the mRNA expression of 18S rRNA.  
Results revealed that Ldha mRNA expression levels in Ldhalow clones were reduced by almost 
50% compared to controls, suggesting the efficient knockdown of Ldha (Figure 5-4 A). This was 
accompanied by an upregulation of Ldhb in Ldhalow clones (Figure 5-4 B), which could catalyze 
the inverse reaction, i.e. transforming lactate into pyruvate. The expression of Glut1 was not 
affected by the knockdown (Figure 5-4 C), whereas Hk1 mRNA expression was elevated in 
Ldhalow clones compared to control cells, and Hk2 mRNA expression was decreased compared to 
wild type cells (Figure 5-4 D,E). 
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Figure 5-4. Ldhalow clones show downregulation of Ldha mRNA and upregulation of Ldhb 
(A-E) qRT-PCR analysis of Ldha (A), Ldhb (B), Glut1 (C), Hk1 (D) and Hk2 (E) in untransfected cells (WT), 
cells transfected with a scrambled shRNA sequence (Ctrl), and cells transfected with shRNA for Ldha 
(Ldhalow). The results are presented relative to the level of 18S rRNA. Each dot represents an individual 
experiment and horizontal lines indicate the mean. * P < 0.05, ** P < 0.01, and *** P < 0.001 (unpaired 
Student’s t-test).  
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As mRNA levels do not always correspond to protein levels, protein expression of LDHA and 
LDHB was analyzed to investigate changes in the abundance of the enzymes after knockdown by 
Ldha shRNA. Actin served as loading control. 
Results from western blotting revealed that, on protein level, LDHA and its phosphorylated form 
were strongly reduced in Ldhalow clones (Figure 5-5 A), matching the results on mRNA level 
(Figure 5-4 A). In contrast, no change in LDHB protein expression was observed in Ldhalow clones 
compared to controls (Figure 5-5 B).  
    
Figure 5-5. LDHA protein levels are diminished in Ldhalow clones compared to control cells 
(A,B) Western blot analysis of LDHA and its phosphorylated form (p-LDHA) (A) and LDHB (B) in whole-cell 
lysates of cells transfected with a scrambled shRNA sequence (Ctrl), untransfected cells (WT) and cells 
transfected with shRNA for Ldha (Ldhalow). Actin served as loading control. One representative experiment of 
three is shown. 
5.2.1.2 Lactate production 
The efficient knockdown of Ldha on mRNA and protein level, as shown above, does not allow 
conclusions regarding the activity of the LDH-5 enzyme. 
In order to examine the functional consequences of the Ldha knockdown by shRNA, cells were 
cultured at a density of 2.5 x 104 cells in 96-well microtiter plates and lactate levels were assessed 
in cell culture supernatants after 24 hours by an enzymatic assay. Analyses, performed by the 
Department of Clinical Chemistry (University Hospital Regensburg, Germany), revealed that 
lactate production in Ldhalow cells was reduced by ~50% compared to controls (Figure 5-6). This 
result shows that the Ldha shRNA knockdown was successful and the Ldhalow clones represent a 
suitable tool to study the role of lactic acid in immunomodulation. 
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Figure 5-6. Ldhalow clones produce lower amounts of lactate than controls 
Lactate concentrations in the supernatant of 2.5 x 104 untransfected cells (WT), control cells (Ctrl), Ldhalow1 
and Ldhalow2 cells, cultured for 24 h (n ≥ 21 per group, mean and s.e.m.). ** P < 0.01, and *** P < 0.001 
(unpaired Student’s t-test).  
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5.2.1.3 Proliferation 
To ensure that the decrease in lactate production of Ldhalow clones was not due to reduced cell 
growth, proliferation was assessed by a 3H-thymidine incorporation assay. 
After 24 hours incubation, Ldhalow cells did not show an impairment regarding proliferation 
compared to control cells (Figure 5-7). On the contrary, Ldhalow1 cells proliferated even more than 
the control cells and Ldhalow2 cells. Thus, the reduced lactate production of Ldhalow cells was 
independent of cell proliferation. 
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Figure 5-7. Ldhalow clones proliferate similarly to controls 
Proliferation of 2.5 x 104 untransfected cells (WT), control (Ctrl), Ldhalow1 and Ldhalow2 cells, based on 3H-
thymidine incorporation, after 24 h (n ≥ 3 per group, mean and s.e.m.). * P < 0.05 (unpaired Student’s t-test).  
5.2.1.4 Cell cycle 
Ldhalow cells were not only analyzed regarding proliferation but also regarding their cell cycle 
distribution, as cell cycle regulation is interconnected with cellular metabolism, crucial for cell 
survival and proliferation190 and, therefore, important for the stability of the Ldhalow clones. 
In all cell lines analyzed, the majority of cells (~70%) resided in the resting phase (G0/G1), while a 
smaller amount of ~20%, each, resided in the synthesis phase (S) and pre-mitosis phase (G2), 
respectively (Figure 5-8). No differences were observed in the distribution of cells in the cell cycle 
states between Ldhalow, control and wild type cells. Therefore, neither the stability of the Ldhalow 
clones nor the replication properties were affected by the knockdown. 
G0
/G
1 S G2
G0
/G
1 S G2
G0
/G
1 S G2
G0
/G
1 S G2
0
20
40
60
80
Ctrl
WT
Ldhalow1
Ldhalow2
Ce
lls
 
(%
)
 
Figure 5-8. Cell cycle properties do not differ between Ldhalow clones and controls 
Cell cycle analysis of wild type (WT), control (Ctrl) or Ldhalow1 and Ldhalow2 cells after seeding of 5 x 105 cells 
for 24 h and staining with propidium iodide buffer (n = 3-5, mean and s.e.m.).  
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5.2.1.5 Respiration 
The knockdown of Ldha, which is crucial for glycolysis, could possibly impair the energy yield of 
the cell. Thus, it is conceivable that the cell attempts to compensate this energy loss by 
upregulating OXPHOS, in order to maintain energy levels. 
To clarify, whether this hypothesis proves true, cells were analyzed by high-resolution 
respirometry, and the results show that Ldhalow clones exhibit a higher basal respiration compared 
to control cells (Figure 5-9 A). Analysis of mitochondria with the green-fluorescent mitochondrial 
dye MitoTracker Green demonstrated that the higher respiration of Ldhalow clones compared to 
control cells was due to an increased quantity of mitochondria (Figure 5-9 B,C). This allows the 
conclusion that Ldhalow cells compensate their impaired glycolysis by upregulating their 
mitochondrial content and thereby increasing respiratory capacity, whereas control cells, showing 
lower mitochondrial content and lower respiration, seem to rely mainly on glycolysis.  
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Figure 5-9. Ldhalow clones show increased respiratory capacities compared to control cells 
(A) Basal respiration of control (Ctrl), Ldhalow1 and Ldhalow2 cells (n = 5-6, mean and s.e.m.) measured by 
high-resolution respirometry. Values were corrected for residual oxygen consumption. (B) Histogram of 
MitoTracker Green staining by flow cytometry of cells described in A. Dashed peaks show unstained cells. 
One representative experiment of three is displayed. (C) Mean fluorescence intensity (MFI) of MitoTracker 
Green staining normalized to unstained cells as measured in B (n = 3, mean and s.e.m.). ** P < 0.01 and *** 
P < 0.001 (unpaired Student’s t-test).  
5.2.2 Analysis of Ldhalow tumors in immunocompetent C57BL/6 
mice 
The most common way to study human tumors is a tumor xenograft model. In this approach, 
human tumor cells are transplanted subcutaneously or in organs of interest into 
immunocompromised mice like athymic nude mice or severe combined immunodeficient (SCID) 
mice. Thereby, tumor rejection by immune cells is prevented and growing tumors can be analyzed 
regarding invasiveness, metastasis, survival, response to therapeutics and many more 
parameters. 
Although the xenograft model reflects many characteristics of human tumors, the role of the 
immune system is totally neglected. As the complex mutual interactions between the immune 
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system and tumors are important for immunosurveillance or immune escape, we decided to use a 
syngeneic mouse model in order to study the role of tumor-derived lactic acid on immune cells in 
the tumor microenvironment. Here, transplanted cancer cells and the host are MHC matched, 
which prevents transplant rejection. This allows the investigation of a “real-life” situation in the 
tumor microenvironment. 
To generate tumors in immunocompetent C57BL/6 mice, 1 x 105 B16 tumor cells transfected with 
a scrambled shRNA sequence (Ctrl) or Ldhalow clones (Ldhalow1, Ldhalow2) were injected 
subcutaneously into the dorsal region of the mice. Between day 13 and 21, tumors were dissected 
and subjected to various analyses. 
5.2.2.1 Metabolic characteristics of tumors 
Dissected tumors were immediately stored in RNAlater reagent according to the manufacturer’s 
instructions and isolation of total RNA as well as reverse transcription were performed. qRT-PCR 
was conducted with primers targeting genes of glucose metabolism, amino acid and prostaglandin 
metabolism to analyze the impact of the Ldha knockdown on other pathways in vivo. The results 
obtained were normalized to 18S rRNA expression. 
5.2.2.1.1 Glucose metabolism 
To see whether the successful knockdown in vitro (Figure 5-4 A) remained stable under in vivo 
conditions, the expression of Ldha was examined in control and Ldhalow tumors. Results from 
qRT-PCR demonstrated significantly decreased Ldha mRNA levels of Ldhalow tumors compared to 
control tumors (Figure 5-10 A). This finding proved that Ldhalow cells maintain reduced Ldha 
mRNA levels not only in vitro but also in vivo. 
Ldha, the target of the shRNA in Ldhalow clones, codes for an important enzyme of the glucose 
metabolism. It is possible, that by its knockdown, other “players” of the glucose metabolism are 
altered due to the tumor microenvironment in vivo. 
Expression levels of Ldhb, as well as Glut1, being responsible for glucose uptake into the cells 
and Hk1 and Hk2, which are the rate-limiting enzymes in glucose metabolism, were analyzed in 
control and Ldhalow tumors. Ldhb was found to be downregulated in Ldhalow2 tumors but not in 
Ldhalow1 tumors compared to control tumors (Figure 5-10 B). The in vitro results showed an 
upregulation of Ldhb in both Ldhalow cells (Figure 5-4 B). No differences were found in the 
expression levels of Glut1 mRNA in control and Ldhalow tumors (Figure 5-10 C), which matches 
the results in vitro (Figure 5-4 C). Hk1 mRNA levels in vivo were only increased in Ldhalow1 and 
not in Ldhalow2 tumors compared to control tumors (Figure 5-10 D), whereas in vitro both Ldhalow 
clones showed increased Hk1 mRNA expression levels (Figure 5-4 D). Regarding Hk2 mRNA 
expression, in line with the in vitro results (Figure 5-4 E), no differences between control and 
Ldhalow tumors were observed in vivo (Figure 5-10 E). 
These results suggest that the tumor microenvironment can influence certain “players” of the 
glucose metabolism, resulting in changes of mRNA expression levels. However, in our model, 
Ldha mRNA expression remained stable under in vivo conditions. 
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Figure 5-10. Ldha shRNA knockdown remains stable in vivo 
(A-E) qRT-PCR analysis of Ldha (A), Ldhb (B) Glut1 (C), Hk1 (D) and Hk2 (E) mRNA in tumors of C57BL/6 
mice after subcutaneous injection of 1 x 105 control (Ctrl), Ldhalow1 or Ldhalow2 cells. The results are 
presented relative to the level of 18S rRNA. Each dot represents an individual mouse and horizontal lines 
indicate the mean. * P < 0.05 (unpaired Student’s t-test). 
Gene expression could also be linked to differences in tumor size, as large tumors lead to 
hypoxia, which in turn regulates the transcription of a variety of genes. Even though endeavors 
were made to obtain tumors with comparable sizes, this is often not possible due to time- and 
experimental limitations. Hence, in statistical analyses, tumor volumes were correlated to the 
amount of mRNA expression. Results revealed that the mRNA expression of Ldha, Ldhb, Glut1, 
Hk1 and Hk2 was not dependent on tumor volume (data not shown). This suggests that the 
differences between control and Ldhalow clones are predominantly due to the downregulation of 
Ldha. 
5.2.2.1.2 Amino acid and prostaglandin metabolism 
Fast proliferating tumor cells do not only show metabolic alterations in glucose metabolism but 
also exhibit a deregulated tryptophan and arginine metabolism, and changes in prostaglandin 
metabolism. 
Overexpression of the tryptophan-converting enzyme IDO is found in several types of cancer80,81 
and leads to T cell unresponsiveness83. Accordingly, decreased serum tryptophan levels are 
linked to poor prognosis in melanoma82. Similarly, elevated expression of ARG1 and ARG2 leads 
to arginine depletion and subsequent impairment of T cell function93. Alternatively, arginine is 
metabolized by NOS which was detected in various human tumors95,96.  
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While COX1 is constitutively expressed in all cells, COX2 expression is mainly found at sites of 
inflammation and is overexpressed in tumors97. It causes release of prostaglandins, especially 
prostaglandin E2, which is further stimulating inflammation and inducing angiogenesis, and 
thereby promotes tumor growth191.  
Regarding mRNA expression of Ido1, Ido2, Arg1, Arg2, iNos, Cox1 and Cox2 no significant 
differences were observed in Ldhalow tumors compared to control tumors (Figure 5-11 A-G). This 
indicates that the downregulation of Ldha has no impact on other important tumor-promoting 
factors.  
Ct
rl low
1
Ld
ha
low
2
Ld
ha
0.000
0.002
0.004
0.006
0.008
0.010
A
Re
la
tiv
e 
Id
o1
m
RN
A 
ex
pr
es
si
on
Ctr
l
low
1
Ld
ha
low
2
Ld
ha
0.000
0.002
0.004
0.006
0.008
0.010
B
R
e
la
tiv
e
Id
o
2
m
R
N
A
 
ex
pr
e
ss
io
n
Ctr
l
low
1
Ld
ha
low
2
Ld
ha
0.0001
0.001
0.01
0.1
1
C
Re
la
tiv
e
Ar
g1
m
RN
A 
ex
pr
es
si
o
n
Ct
rl low
1
Ld
ha
low
2
Ld
ha
0.000
0.002
0.004
0.006
0.008
0.010
D
Re
la
tiv
e
Ar
g2
m
RN
A 
ex
pr
es
si
on
Ctr
l low
Ld
ha
0.0001
0.001
0.01
0.1
E
Re
la
tiv
e 
iN
o
s
m
RN
A 
ex
pr
es
si
o
n
Ct
rl low
1
Ld
ha
low
2
Ld
ha
0.001
0.01
0.1
F
Re
la
tiv
e
Co
x1
m
RN
A 
ex
pr
es
si
on
Ct
rl low
1
Ld
ha
low
2
Ld
ha
0.000
0.005
0.010
0.015
G
Re
la
tiv
e
Co
x2
m
RN
A 
ex
pr
es
si
on
 
Figure 5-11. Ldhalow tumors show no alterations in the expression of other tumor-promoting enzymes  
(A-G) qRT-PCR analysis of Ido1 (A), Ido2 (B), Arg1 (C), Arg2 (D), iNos (E), Cox1 (F) and Cox2 (G) mRNA in 
tumors of C57BL/6 mice after subcutaneous injection of 1 x 105 control (Ctrl), Ldhalow1 or Ldhalow2 cells. The 
results are presented relative to the level of 18S rRNA. Each dot represents an individual mouse and 
horizontal lines indicate the mean.  
5.2.2.2 Intratumoral lactate levels 
In vitro, Ldhalow cells were shown to have a decreased Ldha expression both on mRNA and on 
protein level (Figure 5-4 A and Figure 5-5 A) and diminished lactate concentrations in the 
supernatant (Figure 5-6). Reduction of Ldha mRNA levels in Ldhalow clones remained stable in 
vivo (Figure 5-10 A). To analyze whether the enzyme activity of LDH-5 is still compromised in 
tumors grown in mice, intratumoral lactate levels were determined. Therefore, tumors were 
immediately snap-frozen upon dissection and induced metabolic bioluminescence imaging was 
performed by the group of Wolfgang Mueller-Klieser (Institute of Pathophysiology, University 
Medical Center of the Johannes Gutenberg University Mainz, Germany). Analyses revealed that 
Ldhalow tumors exhibited two-fold lower intratumoral lactate levels compared to control tumors 
(Figure 5-12 A,B), implying that the Ldha knockdown in Ldhalow clones is stable in vitro and in 
vivo. 
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Figure 5-12. Ldhalow tumors exhibit lower intratumoral lactate levels than control tumors 
(A) Induced metabolic bioluminescence imaging of intratumoral lactate levels in sections of tumors grown 
after injection of 1 x 105 control or Ldhalow cells in C57BL/6 mice. Two representative images are shown. (B) 
Quantification of intratumoral lactate levels identified as in A (n = 3-5 mice per group, mean and s.e.m., 
multiple tumor areas per sample analyzed). ** P < 0.01 (unpaired Student’s t-test).  
5.2.2.3 Lactate levels upon recultivation of cells after tumor excision 
In addition to the induced metabolic bioluminescence imaging technique, lactate levels of tumors 
grown in mice were analyzed by another approach. After excision of tumors, single-cell 
suspensions were generated and cultivated for 7 days in cell culture medium in the absence or 
presence of selection antibiotics. After this period, due to the lack of stimulation and/or survival 
factors for stroma cells, only tumor cells were present. Lactate production of 2.5 x 104 cells 
cultivated for 24 hours was measured in the supernatants by the Department of Clinical Chemistry 
(University Hospital Regensburg, Germany) using an enzymatic assay. Analyses revealed that 
Ldhalow tumor cells showed significantly decreased amounts of lactate compared to control tumor 
cells (Figure 5-13), with values similar to those measured in vitro (Figure 5-6). These results were 
independent of the addition of selection antibiotics, suggesting that the enzymatic activity of LDH-
5 remained unchanged in vivo.  
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Figure 5-13. Cells from Ldhalow tumors produce less lactate than cells from control tumors 
Lactate production of 24 h-single-cell suspension cultures containing 2.5 x 104 cells generated from excised 
tumors grown in C57BL/6 mice after subcutaneous injection of 1 x 105 control (Ctrl) and Ldhalow cells, 
following cultivation for 7 days in the absence or presence of selection antibiotics (n = 3 tumors per group, 
mean and s.e.m.). * P < 0.05 and ** P < 0.01 (unpaired Student’s t-test). 
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5.2.2.4 Growth factors 
One major hallmark of cancer is the sustained proliferation of tumor cells, which is in part based 
on the upregulation of growth factor expression including TGF-β, VEGF and CSF2 in the tumor 
environment. These factors are produced by tumor cells or stroma cells. TGF-β is a potent 
immunosuppressive cytokine160 and VEGF is a key regulator of angiogenesis. Both factors can be 
induced by lactate61,62. CSF2 is responsible for the expansion of pro-tumoral MDSCs128. 
Several studies proved that the accelerated glycolysis and lactate production of tumors are 
favorable for cancer progression. To analyze the impact of compromised glycolysis on growth 
factor expression, mRNA levels of Tgfb1, Vegfa and Csf2 from Ldhalow tumors grown in C57BL/6 
mice were determined by qRT-PCR. While Ldhalow tumors exhibited significantly decreased levels 
of Tgfb1 compared to controls (Figure 5-14 A), Vegfa and Csf2 mRNA expression were similar in 
Ldhalow tumors and control tumors (Figure 5-14 B,C). Tgfb expression, therefore, seems to be 
compromised in a tumor microenvironment with low lactate levels. However, only minor amounts 
of TGF-β protein were detectable in the supernatants of control tumors (mean value 125 pg/ml, 
range 0-430 pg/ml) and Ldhalow tumors (mean value 150 pg/ml, range 0-318 pg/ml) and values did 
not differ significantly.  
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Figure 5-14. Ldhalow tumors are characterized by lower levels of Tgfb1 mRNA 
(A-C) qRT-PCR analysis of mRNA for Tgfb1 (A), Vegfa (B) and Csf2 (C) in tumors of C57BL/6 mice after 
subcutaneous injection of 1 x 105 control (Ctrl), Ldhalow1 or Ldhalow2 cells. The results are presented relative 
to the level of 18S rRNA. Each dot represents an individual mouse and horizontal lines indicate the mean.   
** P < 0.01 (unpaired Student’s t-test). 
5.2.2.5 Chemokine and cytokine profile 
Besides growth factors, being responsible for tumor cell proliferation and angiogenesis, the 
cytokine pattern in the tumor microenvironment is pivotal for tumor outcome. Tumor promotion is 
mediated for instance by TNF, IL-6, IL-10 and IL-17, while anti-tumor immunity is achieved by 
cytokines such as IFN-γ. In order to establish the role of tumor-derived lactate on cytokine 
expression in vivo, mentioned cytokines were analyzed in tumors from C57BL/6 mice by means of 
qRT-PCR. Results revealed that mRNA expression of Tnf, Il6, Il10 and Il17a was similar in Ldhalow 
tumors and control tumors (Figure 5-15 A-D). In contrast, Ifng mRNA expression was significantly 
elevated in Ldhalow1 tumors compared to control tumors (Figure 5-15 E). This is suggestive of an 
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immunosuppressive role of lactate on IFN-γ and in line with the finding of a diminished IFN-γ 
production in lymphocytes upon exposure of lactic acid in vitro (Figure 5-1). 
Ctr
l
low
1
Ld
ha
low
2
Ld
ha
0.0001
0.001
0.01
0.1
A
R
el
at
iv
e
Tn
f
m
RN
A 
ex
pr
es
si
o
n
Ctr
l
low
1
Ld
ha
low
2
Ld
ha
0.00
0.02
0.04
0.06
0.08
B
Re
la
tiv
e
Il6
m
RN
A 
ex
pr
es
si
o
n
Ct
rl low
1
Ld
ha
low
2
Ld
ha
0.00
0.05
0.10
0.15
0.20
C
Re
la
tiv
e
Il1
0
m
RN
A 
ex
pr
es
si
o
n
 
Ctr
l
low
1
Ld
ha
low
2
Ld
ha
0.0000
0.0002
0.0004
0.0006
0.0008
0.0010
D
R
el
at
iv
e
Il1
7a
m
RN
A 
ex
pr
es
si
o
n
Ctr
l
low
1
Ld
ha
low
2
Ld
ha
0.0000
0.0002
0.0004
0.0006
0.0008
0.0010
*
E
R
el
at
iv
e
Ifn
g
m
RN
A 
ex
pr
es
si
o
n
 
Figure 5-15. Ldhalow tumors express higher Ifng mRNA levels compared to control tumors 
(A-E) qRT-PCR analysis of mRNA for Tnf (A), Il6 (B), Il10 (C), Il17a (D) and Ifng (E) in tumors of C57BL/6 
mice after subcutaneous injection of 1 x 105 control (Ctrl), Ldhalow1 or Ldhalow2 cells. The results are 
presented relative to the level of 18S rRNA. Each dot represents an individual mouse and horizontal lines 
indicate the mean. * P < 0.05 (unpaired Student’s t-test). 
5.2.2.6 Tumor growth  
In order to analyze whether Ldha knockdown by means of shRNA technique influences the growth 
of tumors in vivo and to understand the impact of lactate on the immune system, tumor growth in 
immunocompetent C57BL/6 mice was measured. Therefore, 1 x 104, 1 x 105 or 1 x 106 wild type 
(WT) cells, cells transfected with a scrambled shRNA (Ctrl) and Ldhalow tumor cells, each, were 
injected subcutaneously into the dorsal region of C57BL/6 mice. 
After subcutaneous injection of 1 x 104 tumor cells, on day 17, WT and Ctrl tumors reached a 
mean volume between 100 and 200 mm3, whereas no tumors of Ldhalow1 and Ldhalow2 cells were 
detected (Figure 5-16 A). On day 21, 90% of the mice in the Ldhalow1 group, 80% of the mice in 
the Ldhalow2 group, but only 30% of the mice in the WT and Ctrl group were tumor-free (Figure 
5-16 B). This finding suggested that tumor growth control is possible in the Ldha knockdown 
tumors. Since the tumors should be analyzed, the number of injected tumor cells was augmented. 
Results from the injection of 1 x 105 tumor cells in male and female mice revealed that on day 18, 
control tumors reached a mean volume of about 1,400 mm3 (Figure 5-16 C). In contrast, Ldhalow 
tumors only reached a mean volume of about 400 mm3. Although tumor growth was not entirely 
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inhibited, the significant difference in tumor growth between Ctrl and Ldhalow tumors remained, 
irrespective of the gender. In a further experiment, 1 x 106 tumor cells were injected in mice. Here, 
a loss of the growth difference between control and Ldhalow tumors was observed (Figure 5-16 D) 
suggesting that tumor control was not possible with an unphysiologically high tumor load. 
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Figure 5-16. Growth of Ldhalow tumors is suppressed in C57BL/6 mice with low tumor burden 
(A) Tumor growth after subcutaneous injection of 1 x 104 untransfected cells (WT), control cells (Ctrl) or 
Ldhalow cells (Ldhalow1, Ldhalow2) in C57BL/6 mice (n = 10). In statistical analyses WT or Ctrl tumors were 
compared to Ldhalow tumors. (B) Tumor-free survival of mice described in A. (C) Tumor growth after 
subcutaneous injection of 1 x 105 control (Ctrl) or Ldhalow cells in male (m) and female (f) C57BL/6 mice (n = 
4-5). In statistical analyses, growth of tumors was compared between control cells and Ldhalow cells among 
mice of the same sex. (D) Tumor growth after subcutaneous injection of 1 x 106 control (Ctrl) or Ldhalow cells 
into C57BL/6 mice (n = 4-5). Data are presented as the mean tumor volume or mean tumor-free survival and 
s.e.m. * P < 0.05 and ** P < 0.01 (unpaired Student’s t-test). 
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5.2.2.7 Immune cell infiltration 
The observation of diminished growth of Ldhalow tumors compared to Ctrl tumors after injection of 
low numbers of tumor cells in C57BL/6 mice led to the conclusion that tumor immunosurveillance 
was possible in tumors with low lactate levels but not in the presence of higher lactate levels. To 
examine the effect of lactate on the immune cell infiltrate, excised tumors were analyzed by qRT-
PCR and by flow cytometry. 
5.2.2.7.1 T cell marker expression 
As differences in the Ifng expression were observed between Ldhalow and control tumors, T cells 
as major producers of Ifng were analyzed on mRNA level. For this purpose, several T cell marker 
genes like Cd4 for T helper cells, Foxp3 for Tregs and Cd8 for cytotoxic T cells were analyzed. 
Results from qRT-PCR analyses did not show any significant differences between control and 
Ldhalow tumors regarding Cd4, Foxp3 and Cd8a expression levels (Figure 5-17 A-C). 
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Figure 5-17. T cell marker gene expression is similar in Ldhalow and control tumors 
(A-C) qRT-PCR analysis of mRNA for Cd4 (A), Foxp3 (B) and Cd8a (C) in tumors of C57BL/6 mice after 
subcutaneous injection of 1 x 105 control (Ctrl), Ldhalow1 or Ldhalow2 cells. The results are presented relative 
to the level of 18S rRNA. Each dot represents an individual mouse and horizontal lines indicate the mean. 
5.2.2.7.2 Immune cell infiltrate and tumor size 
Analyses from qRT-PCR regarding T cell markers did not reveal any differences in control and 
Ldhalow tumors. However, as mRNA expression does not always correspond to protein levels and 
as T cells are not the only “players” in the tumor microenvironment, tumors were dissociated to 
single-cell suspensions, stained with fluorochrome-conjugated antibodies against various immune 
cell populations and subjected to flow cytometry. 
Antibodies against the following common immune cell markers were used: CD45 as pan-
leukocyte marker, CD11b as myeloid marker, Gr-1 as a marker for MDSCs and NK1.1 as NK cell 
marker. To stain B cells, α-CD19, and for T cells, antibodies against CD3 were used. T cell 
subpopulations were characterized by α-CD4 antibodies for T helper cells and α-CD8 antibodies 
for cytotoxic T cells. Analyses of aforementioned immune cell markers were performed after the 
exclusion of dead cells (DAPI+) and doublets (FSC-Whigh), using the gating strategy illustrated in 
Figure 5-18 (B cells not shown).  
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Figure 5-18. Gating strategy to detect immune cells in the tumor microenvironment 
Gating strategy for leukocytes (CD45+) among total cells in the tumor, living singular cells (DAPI-FSC-Wlow) 
among CD45+ cells and myeloid cells (CD11b+), NK cells (NK1.1+), MDSCs (CD11b+Gr-1+), T cells (CD3ε+), 
CD4+ T cells (CD3ε+CD4+) and CD8+ T cells (CD3+CD8α+) among CD45+DAPI- singular cells in tumors of 
C57BL/6 mice after subcutaneous injection of 1 x 105 control (Ctrl) or Ldhalow cells. Numbers in graphs 
indicate the percentage of cells. Plots of data from one representative Ldhalow tumor are shown. 
As it was not possible to obtain tumors with exactly the same size, and to exclude possible effects 
of tumor size on immune cell infiltration, correlations of specific immune cell populations with 
tumor volumes were calculated. Results demonstrated that, up to a tumor size of 1,000 mm3, 
tumor volume did not correlate with any of the analyzed immune cell populations. Overall 
leukocyte infiltration (Figure 5-19 A), infiltration with myeloid cells (Figure 5-19 B), MDSCs (Figure 
5-19 C), B cells (Figure 5-19 D), T cells (Figure 5-19 E) and NK cells (Figure 5-19 F) were 
independent of tumor volume. In contrast, when bigger tumors with volumes up to 2,000 mm3 
were included in the calculations, tumor volumes strongly correlated with numbers of infiltrating B 
cells (data not shown), indicating that the immune cell pattern in the tumor microenvironment is 
changed after tumors reach a certain size. 
For this reason, all tumors analyzed did not exceed a tumor volume of 1,000 mm3, guaranteeing 
the results to be size-independent. 
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Figure 5-19. Immune cell infiltrate in tumors does not correlate with tumor size 
(A-F) Correlations of immune cells with tumor volume: CD45+ cells among all cells (A) derived from tumors 
grown after injection of 1x105 control (Ctrl) or Ldhalow cells in C57BL/6 mice and myeloid cells (B), MDSCs 
(C), B cells (D), T cells (E) and NK cells (F) among living CD45+ leukocytes in those tumors, determined by 
flow cytometry. Each symbol represents an individual mouse. Correlations were calculated using a Pearson 
test.  
5.2.2.7.3 Composition of the immune cell infiltrate 
Figure 5-20 depicts the immune cell composition in tumors with maximum sizes of 1,000 mm3, 
grown from 1 x 105 and 1 x 106 control and Ldhalow cells, respectively, analyzed as illustrated in 
Figure 5-18. Tumor sizes of tumors analyzed were equally distributed in control and Ldhalow 
groups of tumors grown from 1 x 105 and 1 x 106 cells, respectively (Figure 5-20 A). Both after 
injection of low tumor cell numbers as well as of high tumor cell numbers, the overall leukocyte 
infiltration was elevated in Ldhalow tumors compared to control tumors (Figure 5-20 B). This 
indicates that reduced lactate levels in the tumor facilitate the immigration or survival of immune 
cells. Interestingly, the numbers of intratumoral CD11b+ cells in Ldhalow tumors were significantly 
decreased compared to control tumors only when 1 x 105 tumors cells were injected but not after 
injection of 1 x 106 cells (Figure 5-20 C). Thus, only in tumors grown from lower amounts of cells, 
a low-lactate environment seems to prevent enrichment of CD11b+ in the tumor stroma resulting 
in decreased tumor growth. No differences in cell numbers between control and Ldhalow tumors 
were observed regarding CD11b+Gr-1+ cells, the so-called MDSCs (Figure 5-20 D). Similar to 
CD11b+ cells, lower numbers of B cells were detected in the Ldhalow tumors grown from 1 x 105 
cells but not from 1 x 106 cells (Figure 5-20 E), indicative of a tumor-promoting role of B cells. 
Analyses of NK cells and T cells revealed significantly increased levels of both populations in 
Ldhalow tumors after injection of 1 x 105 cells (Figure 5-20 F,G). This phenomenon was not 
observed for tumors after injection of 1 x 106 cells, suggesting that infiltration of NK cells as well 
as T cells is linked to the decreased tumor growth. Subsets of T cells were analyzed 
subsequently. CD8+ T cell numbers, but not CD4+ T cell numbers, were significantly increased in 
Ldhalow tumors compared to controls after injection of 1 x 105 cells (Figure 5-20 H,I). In contrast, 
tumors derived from 1 x 106 cells showed no significant difference in CD4+ and CD8+ T cell 
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infiltration. Comparing the percentage of immune cells between tumors grown from 1 x 105 and 1 x 
106 cells, it is striking that the infiltration of myeloid cells was decreased in tumors grown from 1 x 
106 (Figure 5-20 C) and T cell infiltration was increased (Figure 5-20 G). However, as tumor 
growth was not different in Ldhalow and control tumors grown from 1 x 106 cells (Figure 5-16 D), 
even a high number of infiltrating effector T cells is seemingly not able to control tumor growth 
when the tumor load exceeds a certain level. 
In contrast, 1 x 105 tumor cells allow tumor control in Ldhalow tumors compared to control tumors 
and these tumors show an immune cell infiltration profile characterized by increased numbers of 
cytotoxic effector cells like NK cells and T cells, and decreased numbers of myeloid cells and B 
cells, which corresponds to the significantly reduced tumor growth of Ldhalow tumors. 
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Figure 5-20. Ldhalow tumors contain higher numbers of anti-tumor effector cells than control tumors 
in C57BL/6 mice with low tumor burden 
(A) Tumor volume of tumors grown after injection of 1 x 105 or 1 x 106 control (Ctrl) or Ldhalow cells in 
C57BL/6 mice at day of excision. (B-I) Percentage of CD45+ leukocytes among all cells (B) derived from 
tumors described in A and percentage of immune cell populations among living singular CD45+ leukocytes: 
myeloid cells (C), MDSCs (D), B cells (E), NK cells (F), T cells (G), CD4+ T cells (H) and CD8+ T cells (I), 
determined by flow cytometry. In statistical analyses, control tumors were compared to Ldhalow tumors in the 
respective groups. Each symbol represents an individual mouse; small horizontal lines indicate the mean. * P 
< 0.05 and ** P < 0.01 (unpaired Student’s t-test). 
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5.2.2.7.4 Immune cells in the periphery 
To investigate whether the knockdown of Ldha, besides causing changes in the tumor immune 
cell infiltration, also influences the immune cell composition in the periphery, blood and spleens of 
tumor-bearing mice were examined by flow cytometry as illustrated in Figure 5-18. In the blood of 
mice bearing control and Ldhalow tumor cells, no differences in numbers of immune cells were 
observed regarding myeloid cells, MDSCs, NK cells and T cells in the two groups (Figure 5-21 A-
D). Though, comparison between immune cell composition of healthy mice and tumor-bearing 
mice revealed significant differences. Numbers of myeloid cells, MDSCs and NK cells were 
elevated in the blood of tumor-bearing mice (Figure 5-21 A-C). In contrast, numbers of T cells 
were severely reduced in the blood of tumor-bearing mice (Figure 5-21 D). In the spleen, similar to 
the blood, immune cell infiltration in mice bearing control cells and Ldhalow cells showed no 
differences for myeloid cells, MDSCs, NK cells and T cells (Figure 5-21 E-H). Alterations in tumor-
bearing mice compared to healthy mice were only observed for NK cells, which were present at 
higher numbers in spleens of tumor-bearing mice (Figure 5-21 G), and for T cells, which were 
diminished in spleens of Ldhalow tumor-bearing mice (Figure 5-21 H). It seems that NK cells as 
well as T cells play a major role in tumor development as their numbers are altered in the 
periphery of tumor-bearing mice, irrespective of the LDHA profile of the tumor. 
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Figure 5-21. Tumor burden leads to systemic changes in the immune cell composition regardless of 
the LDHA profile of B16 tumor cells 
(A-D) Quantification of myeloid cells (A), MDSCs (B), NK cells (C) and T cells (D) among living mononuclear 
cells in the blood of healthy C57BL/6 and C57BL/6 mice after subcutaneous injection of 1 x 105 control (Ctrl) 
or Ldhalow cells by flow cytometry. (E-H) Quantification of myeloid cells (E), MDSCs (F), NK cells (G) and T 
cells (H) among living leukocytes in spleens as described in A-D. Each symbol represents an individual 
mouse; small horizontal lines indicate the mean. * P < 0.05, ** P < 0.01, and *** P < 0.001 (unpaired 
Student’s t-test). 
 
Results 
  67 
5.2.2.7.5 Activity of immune cells in the tumor microenvironment 
Absolute numbers of immune cells present in the tumor microenvironment do not fully explain 
tumor growth control in this model (Figure 5-20 C,G). Therefore, the activity of immune cells was 
analyzed by determining cytokines.  
As T cells and NK cells are known to exert anti-tumor effector functions via the production of IFN-γ 
and granzyme B, both factors were analyzed by flow cytometry. For this purpose, tumors were 
dissociated to single-cell suspensions and incubated with an inhibitor of the Golgi apparatus to 
restrain proteins within the cell. Intracellular levels of IFN-γ and granzyme B were analyzed by 
intracellular staining with fluorochrome-conjugated antibodies. Results revealed that in Ldhalow 
tumors compared to control tumors, higher numbers of IFN-γ+ CD8+ T cells and NK cells were 
present (Figure 5-22 A,B). Regarding CD4+ T cells, no differences were observed between control 
and Ldhalow tumors (Figure 5-22 C). Additionally, granzyme B+ CD8+ T cells were elevated in 
Ldhalow tumors compared to control tumors (Figure 5-22 D). In contrast, no significant difference 
was observed in granzyme B+ NK cells between control and Ldhalow tumors (Figure 5-22 E). IL-17, 
a cytokine mainly produced by Th17 cells, exerting regulatory functions, was equally produced in 
CD4+ T cells of control and Ldhalow tumors (Figure 5-22 F). These results suggest that, apart from 
higher numbers of CD8+ T cells and NK cells in Ldhalow tumors, these immune cell populations 
exhibit higher functional activity in tumor microenvironments with lower lactate levels.  
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Figure 5-22. Ldhalow tumors contain higher numbers of activated CD8+ T cells and NK cells 
(A-C) Numbers of IFN-γ+ cells among CD8+ T cells (A), NK1.1+ cells (B) and CD4+ T cells (C) in tumors 
grown from 1 x 105 control (Ctrl) and Ldhalow cells in C57BL/6 mice, determined by flow cytometry. (D-F) 
Numbers of granzyme B+ cells among CD8+ T cells (D) and NK cells (E), and IL-17+ cells among CD4+ T 
cells (F) from tumors as described in A-C. Each symbol represents an individual mouse; small horizontal 
lines indicate the mean. * P < 0.05 and ** P < 0.01 (unpaired Student’s t-test). 
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Analyses of the myeloid compartment in the tumor microenvironment demonstrated that Ldhalow 
tumors contained less IL-6+ cells than control tumors (Figure 5-23). This is consistent with the 
finding of lower numbers of CD11b+ cells (Figure 5-20 C) and reduced tumor growth of Ldhalow 
tumors (Figure 5-16 C), as IL-6 has been shown to be a tumor-promoting cytokine159. 
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Figure 5-23. Ldhalow tumors contain less IL-6+ myeloid cells than control tumors 
Numbers of IL-6+ cells among myeloid cells (CD11b+) in tumors grown from 1 x 105 control (Ctrl) and Ldhalow 
cells in C57BL/6 mice, determined by flow cytometry. Each symbol represents an individual mouse; small 
horizontal lines indicate the mean. * P < 0.05 (unpaired Student’s t-test). 
5.2.3 Analysis of Ldhalow tumors in CCR2-deficient mice  
Results from flow cytometry analyses in immunocompetent C57BL/6 mice demonstrated a higher 
infiltration with myeloid cells, accompanied by an increased IL-6 production in control tumors 
compared to Ldhalow tumors (Figure 5-20 C and Figure 5-23). These tumors proliferated faster, 
which suggests a link between myeloid cells and tumor growth. To further examine the role of 
myeloid cells in tumor development, CCR2-depletion experiments were performed. CCR2 is a 
chemokine receptor which is mainly expressed on monocytic MDSCs (CD11b+Gr-1+). CD4+ and 
CD8+ T cells, B cells, NK cells and tumor cells, in vitro and in vivo, were CCR2 negative (data not 
shown). A monoclonal antibody against CCR2 and the corresponding isotype (kindly provided by 
Matthias Mack, Department of Internal Medicine II, University Hospital Regensburg, Germany) 
were administered intraperitoneally into C57BL/6 mice, starting on day 3 after injection of 1 x 105 
tumor cells. Antibodies were injected daily for 5 to 6 days. On days 0, 4, 7 and 10, retrobulbar 
blood from mice was analyzed by flow cytometry to confirm the depletion of monocytes. 
Therefore, blood was stained with α-CD11b and α-Gr-1, or α-Ly6C (expressed on monocytes) 
and α-Ly6G (expressed on granulocytes). After administration of the monoclonal antibodies, a 
severe decrease in the CD11b+Gr-1+ and Ly6C+Ly6G- population was observed in the blood of the 
α-CCR2-treated group compared to the isotype control group on day 4 and day 7 (data not 
shown). These results proved the efficient depletion of monocytes by the α-CCR2 monoclonal 
antibody in the blood of the mice. To analyze the impact of CCR2+ monocyte depletion on tumor 
growth, tumor volume was measured. A slight reduction of tumor growth was observed in the α-
CCR2-treated group compared to the control group without antibody injection (Figure 5-24). 
However, tumor growth was also slightly reduced in the mice injected with an isotype control 
antibody, suggesting a CCR2-independent effect of the antibody application on tumor growth and 
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immune cell activation. Therefore, no clear conclusions regarding the impact of monocytes on 
tumor growth can be drawn from these results.  
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Figure 5-24. CCR2-independent effects of antibody application on tumor growth 
Tumor growth after subcutaneous injection of 1 x 105 control cells into C57BL/6 mice and treatment with an 
α-CCR2 monoclonal antibody or the corresponding isotype compared to untreated tumors (Ctrl) (n = 10-15). 
Data are presented as mean tumor volume and s.e.m. In statistical analyses, growth of control tumors was 
compared to isotype-treated tumors (blue asterisk) and α-CCR2-treated tumors, respectively (black asterisk). 
* P < 0.05 (unpaired Student’s t-test). 
In order to circumvent effects of antibody application on tumor growth, Ccr2−/− mice, lacking 
CCR2+ cells, were used to further analyze the role of monocytes in tumor development. 
Therefore, 1 x 105 control tumor cells were injected subcutaneously into the dorsal region of 
Ccr2−/− and C57BL/6 mice and tumor volumes were determined. Until day 14, tumor growth was 
similar between tumors in Ccr2−/− mice and C57BL/6 mice (Figure 5-25). Subsequently, tumors in 
C57BL/6 mice began to grow exponentially, resulting in tumors with an average size of 1,000 mm3 
on day 20. In contrast, tumors in Ccr2−/− mice only reached a mean tumor volume of less than 500 
mm3 on day 20. These findings indicate a tumor-promoting role of CCR2+ monocytes and suggest 
that the balance between both growth-promoting and growth-inhibitory immune cells determines 
tumor growth.  
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Figure 5-25. Tumor growth is impaired in the absence of CCR2+ cells 
Tumor growth after subcutaneous injection of 1 x 105 control cells (Ctrl) into C57BL/6 and Ccr2−/− mice (n = 
9-10). Data are presented as mean tumor volume and s.e.m. * P < 0.05 (unpaired Student’s t-test). 
5.2.4 Analysis of Ldhalow tumors in immunodeficient Rag2−/− 
and Rag2−/−γc−/− mice 
The experiments with Ccr2−/−  mice demonstrated that a lack of pro-tumoral monocytes resulted in 
decreased tumor growth compared to that in C57BL/6 mice, but was not sufficient to abolish 
tumor growth. Other additional “players” of the immune system seem to be involved in tumor 
growth control, among which anti-tumor effector cells like T cells and NK cells are promising 
candidates.  
To investigate the role of T cells, Rag2−/− mice, lacking B and T cells were used. 
Rag2−/−γc−/−  mice, which additionally lack NK cells, were used to examine the role of NK cells. 
Therefore, 1 x 105 control cells or Ldhalow cells were injected subcutaneously in immunocompetent 
C57BL/6 mice, and immunodeficient Rag2−/− and Rag2−/−γc−/−  mice. First, tumor growth was 
determined and second, tumors were excised, dissociated to single-cell suspensions, stained with 
fluorochrome-conjugated antibodies and measured by flow cytometry in order to investigate 
tumor-infiltrating immune cells. 
5.2.4.1 Tumor growth 
Results from measurements of the tumor volume demonstrated that control tumors grew similarly 
in C57BL/6, Rag2−/− and Rag2−/−γc−/−  mice (Figure 5-26 A). In contrast, Ldhalow tumors showed a 
different growth in the three mouse strains (Figure 5-26 B). Ldhalow tumors in C57BL/6 exhibited 
the slowest proliferation with a mean tumor volume of 200 mm3 on day 18, followed by tumors in 
Rag2−/− mice with a mean tumor volume of 400 mm3 and tumors in Rag2−/−γc−/−  mice, which 
reached a mean tumor volume of 700 mm3. Thus, T cells alone and in combination with NK cells, 
can partially control tumor growth of Ldhalow tumors, whereas in their absence, Ldhalow tumors 
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grow similarly as control tumors. In contrast, the growth of control tumors was not influenced by 
the absence of T and/or NK cells. 
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Figure 5-26. Growth control of Ldhalow tumors is lost in Rag2−/−  and Rag2−/−γc−/− mice 
(A,B) Tumor growth after subcutaneous injection of 1 x 105 control (Ctrl) cells (A) or Ldhalow cells (B) into 
C57BL/6 mice, and immunodeficient Rag2−/− and Rag2−/−γc−/− mice (n = 8-10). Data are presented as mean 
tumor volume and s.e.m. In statistical analyses, the growth of tumors in C57BL/6 mice was compared to 
Rag2−/− and Rag2−/−γc−/− mice, respectively (black asterisks), and the growth of Ldhalow tumors in Rag2−/− 
mice was compared to the growth of Ldhalow tumors in Rag2−/−γc−/− mice (red asterisks). * P < 0.05 and ** P < 
0.01 (unpaired Student’s t-test). 
5.2.4.2 Immune cell infiltration 
By means of flow cytometry, immune cell infiltration of tumors from C57BL/6 mice, Rag2−/− and 
Rag2−/−γc−/−  mice was analyzed regarding the following surface molecules: CD45 as pan-
leukocyte marker, CD11b for the detection of myeloid cells, PD-L1 as immune inhibitory protein, 
CD11c and I-Ab as marker for dendritic cells, and NK1.1 as a marker for NK cells. Importantly, as 
Rag2−/− and Rag2−/−γc−/−  mice have a C57BL/6N background, the latter were used as control mice 
here, whereas all other experiments described were performed with C57BL/6J mice. Analyses 
demonstrated elevated numbers of infiltrating leukocytes in Ldhalow tumors compared to control 
tumors but this difference was only significant in C57BL/6 mice (Figure 5-27 A). As expected, the 
percentage of myeloid cells increased in Rag2−/− mice and in Rag2−/−γc−/−  mice, due to the lack of 
T and NK cells. Myeloid CD11b+ and CD11b+PD-L1+ cells were decreased in Ldhalow tumors of 
C57BL/6 mice but not in immunodeficient mice (Figure 5-27 B,C). Regarding dendritic cells, 
slightly increased numbers were found in Ldhalow tumors of C57BL/6 and Rag2−/− mice but not 
Rag2−/−γc−/−  mice (Figure 5-27 D). In C57BL/6 mice, infiltration of NK cells was increased in 
Ldhalow tumors compared to control tumors, although not significantly, whereas the amount of NK 
cells did not differ between control and Ldhalow tumors in Rag2−/− mice (Figure 5-27 F). In 
Rag2−/−γc−/−  mice, immune cell infiltrates were similar in control and Ldhalow tumors, in line with a 
similar tumor growth in these mice. In contrast, immune cell infiltration in C57BL/6 and Rag2−/− 
mice was different in Ldhalow and control tumors, accompanied by a different tumor growth.  
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Figure 5-27. Differences in immune cell infiltration between control and Ldhalow tumors in 
immunodeficient and immunocompetent mice 
(A-F) Percentage of CD45+ leukocytes among all cells (A) derived from tumors grown after injection of 1 x 
105 control (Ctrl) or Ldhalow cells in immunocompetent C57BL/6 mice and immunodeficient Rag2−/− and 
Rag2−/−γc−/− mice, and percentage of immune cell populations among living CD45+ leukocytes: myeloid cells 
(B), myeloid PD-L1+ cells (C), CD11c+ cells (D), MHC class II+ CD11c+ cells (E) and NK cells (F), determined 
by flow cytometry. Each symbol represents an individual mouse; small horizontal lines indicate the mean. * P 
< 0.05 (unpaired Student’s t-test). 
5.2.5 Analysis of Ldhalow tumors in immunodeficient Pfp−/−  mice  
Previous experiments indicated a link between the accumulation of cytotoxic T cells and NK cells 
in tumors with lower lactate levels and reduced tumor growth. To understand the underlying 
mechanism and to clarify whether T cells and NK cells control growth of Ldhalow tumors, 1 x 105 
control and Ldhalow tumor cells were injected subcutaneously into perforin knockout mice (Pfp−/− 
mice). The pore-forming protein perforin is expressed by T cells and NK cells and essential to 
channel cytotoxic substances like granzymes into target cells. Surprisingly, in the absence of 
perforin, tumor growth control was still maintained in Ldhalow tumors (Figure 5-28) indicating that 
immunosurveillance is not linked to perforin. 
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Figure 5-28. Perforin is irrelevant for tumor growth control in Ldhalow tumors 
Tumor growth after subcutaneous injection of 1 x 105 control cells (Ctrl) and Ldhalow cells into Pfp−/− mice (n = 
7-8). Data are presented as mean tumor volume and s.e.m. * P < 0.05, ** P < 0.01, and *** P < 0.001 
(unpaired Student’s t-test). 
5.2.6 Analysis of Ldhalow tumors in mice lacking CD8+ T cells 
To clarify the impact of CD4+ and CD8+ T cells on tumor growth, α-CD4 and α-CD8 monoclonal 
antibodies were used to deplete CD4+ and CD8+ T cells in C57BL/6 mice, respectively. Therefore, 
1 x 105 control and Ldhalow cells were injected subcutaneously into C57BL/6 mice after 
intraperitoneal injection of 250 µg of α-CD4, α-CD8 monoclonal antibodies and the respective 
isotypes as controls. In some experiments, treatment with the depleting antibodies was continued 
on day 3, 8, and 13 after tumor cell injection. Analyses of blood samples confirmed the successful 
depletion of CD4+ and CD8+ T cells, regardless of the treatment scheme (data not shown). 
However, similar to the results obtained during the depletion of CCR2+ monocytes by an α-CCR2 
monoclonal antibody (Figure 5-24), the isotype exerted inhibitory effects on tumor growth (data 
not shown).  
As no reliable conclusions could be drawn from these experiments regarding the impact of CD4+ 
and CD8+ T cells on tumor growth, a different approach was undertaken to study the role of T 
cells. 1 x 105 control and Ldhalow cells were injected subcutaneously into immunocompetent 
C57BL/6 mice and immunodeficient Cd8−/− mice. Analyses revealed that tumor growth in 
Cd8−/− mice did not differ from tumor growth in C57BL/6 mice for both, control and Ldhalow tumors 
(Figure 5-29), suggesting that tumor growth control is not dependent on CD8+ T cells.  
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Figure 5-29. Tumor growth control of Ldhalow tumors is not impaired in Cd8−/− mice 
Tumor growth after subcutaneous injection of 1 x 105 control cells (Ctrl) and Ldhalow cells into C57BL/6 and 
Cd8−/− mice (n = 5-6). In statistical analysis tumor growth of control and Ldhalow cells was compared in 
C57BL/6 mice (black asterisks) and in Cd8−/− mice (grey asterisks). Data are presented as mean tumor 
volume and s.e.m. * P < 0.05 and ** P < 0.01 (unpaired Student’s t-test). 
5.2.7 Analysis of Ldhalow tumors in immunodeficient Ifng−/− and 
Ifngr1−/− mice 
Based on the results with immunocompetent C57BL/6 mice and immunodeficient Rag2−/− and 
Rag2−/−γc−/− mice, T cells and NK cells play an important role in the growth control of Ldhalow 
tumors (Figure 5-26 B), whereas results with Pfp−/− and Cd8−/− mice demonstrated that CD8+ T 
cells and perforin, as effector molecule, seem to be negligible (Figure 5-28 and Figure 5-29). 
Therefore, the role of IFN-γ, which is a major cytokine in the regulation of innate and adaptive 
immunity, predominantly produced by T cells and NK cells and crucial for tumor control192, was 
investigated. 
5.2.7.1 Tumor growth 
To elucidate the impact of IFN-γ on tumor growth, 1 x 105 control and Ldhalow cells were injected 
subcutaneously into the dorsal region of C57BL/6 mice and Ifng−/− mice. Measurements of tumor 
volumes confirmed that Ldhalow tumors showed a slower growth compared to control tumors in 
C57BL/6 mice (Figure 5-30 A). In contrast, Ldhalow tumors grown in Ifng−/− mice showed strikingly 
increased tumor volumes, comparable to those of control tumors. These results demonstrate a 
loss of tumor growth control in the absence of IFN-γ. To assess whether IFN-γ acts directly on 
tumor cells and thereby allows tumor immunosurveillance, subsequent experiments were 
performed in Ifngr1−/− mice, lacking IFN-γ receptors but with a normal IFN-γ production. After 
inoculation of 1 x 105 cells, control tumors showed similar tumor volumes in C57BL/6 mice and 
Ifngr1−/− mice at any time (Figure 5-30 B). Ldhalow tumors, though, grew slowly in C57BL/6 mice 
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but showed the same exponential growth in Ifngr1−/− mice as observed for control tumors. The 
pattern of tumor growth in Ifngr1−/− mice was identical to that of Ifng−/− mice (Figure 5-30 A,B), 
indicative of the importance of IFN-γ receptors on host immune cells for tumor growth control and 
concomitantly excluding a direct role of IFN-γ on tumor cells. 
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Figure 5-30. IFN-γ is responsible for tumor growth control of Ldhalow tumors 
(A) Tumor growth after subcutaneous injection of 1 x 105 control cells (Ctrl) and Ldhalow cells into C57BL/6 
mice and Ifng−/− mice (n = 5). In statistical analysis growth of control and Ldhalow tumors was compared in 
C57BL/6 mice (black asterisks) and growth of Ldhalow tumors in C57BL/6 mice was compared to growth of 
Ldhalow tumors in knockout mice (red asterisks). (B) Tumor growth in C57BL/6 mice and Ifngr1−/− mice as 
described in A. Data are presented as mean tumor volume and s.e.m. * P < 0.05 and ** P < 0.01 (unpaired 
Student’s t-test). 
5.2.7.2 Immune cell infiltration 
As we observed that the lack of IFN-γ significantly increased growth in tumors with reduced lactate 
production, changes in the immune cell infiltration were investigated. To determine the immune 
cell infiltrate, tumors grown as described in Chapter 5.2.7.1 were dissected from the mice, single-
cell suspensions were generated, antibody staining was performed and samples were subjected 
to flow cytometry. Regarding total immune cell numbers in the tumors, Ifng−/− and Ifngr1−/− mice 
exhibited a trend towards an increased infiltration of CD45+ cells comparable to the effects in 
C57BL/6 mice (Figure 5-31 A). Myeloid cells, characterized by CD11b, were present in slightly 
reduced numbers in Ldhalow tumors compared to control tumors in all mice strains (Figure 5-31 B). 
The percentage of infiltrating B cells was significantly decreased in Ldhalow tumors compared to 
control tumors in C57BL/6 mice and a similar trend was observed in Ifng−/− and Ifngr1−/− mice 
(Figure 5-31 C). While in C57BL/6 mice the number of NK cells in Ldhalow tumors was significantly 
higher than in control tumors, this difference was completely lost in Ifng−/− and Ifngr1−/− mice 
(Figure 5-31 D). Surprisingly, the infiltration of cytotoxic T cells differed not only in C57BL/6 mice 
but by trend also in Ifng−/− and Ifngr1−/− mice (Figure 5-31 E). In addition, cytotoxic T cells were 
analyzed regarding their activity by means of CD25 staining. Results revealed that in C57BL/6 
mice, cytotoxic T cells in Ldhalow tumors were more active than in control tumors, illustrated by an 
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increased number of CD25+ cells in Ldhalow tumors (Figure 5-31 F). In contrast, this difference 
was abrogated in mice lacking IFN-γ or its receptor, where Ldhalow tumors contained the same low 
numbers of CD25+ cytotoxic T cells as control tumors. These findings indicate that IFN-γ is not 
only responsible for the recruitment of NK cells into the tumor microenvironment but also for the 
activation of T cells, which in turn leads to tumor growth control.  
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Figure 5-31. Ldhalow tumors in Ifng−/− mice lack NK cells and activated CD8+ T cells 
(A-F) Immune cell infiltration in tumors grown after injection of 1 x 105 control (Ctrl) or Ldhalow cells in 
immunocompetent C57BL/6 mice or immunodeficient Ifng−/− and Ifngr1−/− mice, determined by flow 
cytometry. Percentage of CD45+ leukocytes among all cells of the tumor (A) and percentage of immune cell 
populations among living singular CD45+ leukocytes: myeloid cells (B), B cells (C), NK cells (D) CD8+ T cells 
(E) and percentage of CD25+ cells among CD8+ T cells (F). Each symbol represents an individual mouse; 
small horizontal lines indicate the mean. * P < 0.05, ** P < 0.01 and *** P < 0.001 (unpaired Student’s t-test). 
5.2.8 Molecular pathways involved in the immunomodulation 
by lactic acid 
The above-mentioned results suggest that IFN-γ is a major immunologic player associated with 
the growth control of Ldhalow tumors in vivo. Furthermore, lactic acid suppressed the IFN-γ 
production of T cells and NK cells in vitro (Figure 5-1). Amongst others, the transcription factor 
NFAT is known to be involved in IFN-γ expression193 and is upregulated on mRNA and protein 
levels during activation of T cells194. NFAT activation and translocation to the nucleus is 
calcineurin-dependent193. The activity of calcineurin, a Ca2+-dependent phosphatase, was shown 
to be strongly associated with intracellular pH195. Hence, it was hypothesized that diminished 
amounts of IFN-γ in a high-lactate tumor microenvironment are due to intracellular acidification 
and subsequent downregulation of NFAT signaling. In order to test this hypothesis, the influence 
of lactic acid on intracellular pH and NFAT expression was determined. 
Results 
  77 
5.2.8.1 Analysis of intracellular pH 
Lactate is exported from the cell in co-transport with protons via MCTs67, which leads to the 
subsequent acidification of the extracellular space68. To analyze the impact of extracellular 
acidification on the intracellular pH of T cells, the latter was quantified in CD8+ T cells from 
spleens of 2C/Rag2−/− mice after incubation with different concentrations of lactic acid (0, 10, 15 
and 20 mM) for 30 minutes using a fluorescent pH-sensitive reagent. In situ calibration was 
performed with pH-controlled buffers. Flow cytometry measurements revealed that untreated cells 
exhibited an intracellular pH around pH 7.5, whereas T cells after treatment with lactic acid 
showed an intracellular acidification (Figure 5-32 A). Treatment with 15 mM lactic acid resulted in 
an intracellular pH shift to pH 5.5 and after incubation with 20 mM lactic acid the intracellular pH 
even dropped below pH 4.5. Comparative analyses of CD8+ T cells incubated with 15 mM lactic 
acid or HCl corresponding to the pH of 15 mM lactic acid (~pH 6.4) for 7 hours showed that lactic 
acid leads to a stronger intracellular acidification (Figure 5-32 B).  
 
Figure 5-32. Lactic acid leads to intracellular acidification in CD8+ T cells 
(A,B) Quantification of the intracellular pH of activated CD8+ T cells after incubation with different 
concentrations of lactic acid (0, 10, 15 and 20 mM) for 30 minutes (A) and after incubation with 15 mM lactic 
acid (LA) or HCl corresponding to the pH of 15 mM LA for 7 hours (B) by flow cytometry, using pH-controlled 
buffers for calibration (pH 4.5, pH 5.5, pH 6.5 and pH 7.5). One representative experiment out of three or two 
is shown.  
5.2.8.2 Analysis of NFAT expression 
The intracellular pH has been demonstrated to strongly regulate the activity of calcineurin195, 
which in turn is responsible for nuclear translocation of NFAT193. As intracellular pH changes were 
observed upon incubation with lactic acid (Figure 5-32), NFAT expression was analyzed in the 
following. Therefore, CD8+ T cells from spleens of 2C/Rag2−/− mice and NK cells from spleens of 
C57BL/6 mice were cultured for 24 hours in the presence or absence of 15 mM lactic acid, HCl 
corresponding to the pH of 15 mM lactic acid (~pH 6.4) and 15 mM sodium lactate. 30 minutes 
before harvesting, cells were stimulated with PMA/ionomycin, subjected to intracellular staining 
and analyzed for NFAT expression using flow cytometry. NFAT expression was upregulated upon 
stimulation in CD8+ T cells and NK cells but cultivation in the presence of lactic acid significantly 
decreased NFAT expression in both CD8+ T cells and NK cells compared to untreated cells 
(Figure 5-33 A,B). Acidification corresponding to the pH of 15 mM lactic acid had the same strong 
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inhibitory effect, whereas the treatment with sodium lactate only caused a slight reduction in NFAT 
expression in CD8+ T cells and NK cells. As total protein levels of NFAT were measured, these 
results indicate that lactic acid predominantly inhibits the activation-dependent upregulation of 
NFAT. Further experiments are necessary to clarify whether lactic acid also disturbs the 
translocation of NFAT to the nucleus. 
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Figure 5-33. Lactic acid impairs NFAT expression in CD8+ T cells and NK cells 
(A,B) Quantification of NFAT expression in unstimulated (-) and stimulated (+) CD8+ T cells (A) and NK cells 
(B) after incubation in the absence (untreated) or presence of 15 mM lactic acid (LA), HCl corresponding to 
the pH of 15 mM LA (~pH 6.4), and 15 mM sodium lactate (NaL) for 24 hours by flow cytometry (n = 2-4 per 
group, mean and s.e.m.). Data are shown as changes in % compared to control (untreated, +). * P < 0.05 
and ** P < 0.01 (paired Student’s t-test). 
5.2.9 Characterization of Ldha−/− clones generated with 
CRISPR/Cas9 
To support the results obtained with the Ldhalow clones, which were created using the shRNA 
technique to lower Ldha mRNA levels, additional B16 clones were generated by means of a 
CRISPR/Cas9 approach, which allowed gene editing. Cas9 was directed against two different loci 
in the Ldha gene of B16.SIY E12 cells (CRISPR1 and CRISPR2). These experiments were 
performed under the supervision of Jacques Pouysségur at the Institute of Research on Cancer 
and Ageing (IRCAN) of the University of Nice-Sophia Antipolis-CNRS-Inserm, Centre A. 
Lacassagne in Nice, France. 
Western blot analyses of the clones revealed that the CRISPR/Cas9 approach was successful in 
several clones resulting from both the CRISPR1 and CRISPR2 approach. The absence of the 
LDHA protein was even confirmed under hypoxic conditions, where LDHA is upregulated, as seen 
in controls (Figure 5-34 A,B). Clones 7 and 9 of CRISPR1 and clone 10 of CRISPR2 were 
selected for further experiments. 
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Figure 5-34. A CRISPR/Cas9 approach generates several Ldha knockout clones 
(A,B) Western blot analysis of LDHA in whole-cell lysates of untreated B16.SIY E12 cells (Ctrl) cultured in 
normoxia (Nx) or 1% O2 (hypoxia, Hx) and clones of B16.SIY E12 cells transfected with CRISPR/Cas9 
plasmids against two different loci in the Ldha gene: CRISPR1 (A) and CRISPR2 (B), cultured in 1% O2 
(hypoxia, Hx). Arrest-defective-1 protein (ARD1) served as loading control. Clones in colored boxes were 
chosen for further analyses. 
In order to examine the functionality of the Ldha knockout by CRISPR/Cas9, lactate levels were 
assessed in cell culture supernatants of 2.5 x 104 cells after 24 hours by an enzymatic assay. 
Experiments were carried out in cooperation with Lucia Wunderlich (Bachelor thesis). Analyses, 
performed by the Department of Clinical Chemistry (University Hospital Regensburg, Germany) 
revealed that despite the complete absence of the LDHA protein (Figure 5-34), lactate production 
in Ldha−/− cells was only reduced by ~30% compared to controls (Figure 5-35).  
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Figure 5-35. Ldha−/− clones produce lower amounts of lactate than controls 
Lactate concentrations in the supernatant of 2.5 x 104 untransfected B16.SIY E12 cells (Ctrl) and B16.SIY 
E12 Ldha knockout cells, generated with CRISPR/Cas9 (Ldha−/− clones), cultured for 24 h (n = 4-8 per group, 
mean and s.e.m.). * P < 0.05, and ** P < 0.01 (unpaired Student’s t-test). 
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To investigate the impact of the CRISPR/Cas9 approach on Ldha and Ldhb mRNA expression, 
qRT-PCR analyses of the Ldha−/− cells were performed. Experiments were carried out in 
cooperation with Lucia Wunderlich (Bachelor thesis). Results revealed that the mRNA expression 
of Ldha was about 100-fold reduced in Ldha−/− clones compared to control cells, with clone 7 
showing the lowest amount of Ldha mRNA (Figure 5-36 A). However, levels of Ldhb mRNA 
remained unchanged in the in Ldha−/− clones compared to control cells (Figure 5-36 B). Thus, the 
abrogation of Ldha in Ldha−/− clones does not influence the expression of Ldhb mRNA. 
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Figure 5-36. Ldha mRNA expression is drastically decreased in Ldha−/− cells but levels of Ldhb mRNA 
remain unchanged 
(A,B) qRT-PCR analysis of Ldha (A) and Ldhb (B) in untransfected B16.SIY E12 cells (Ctrl) and B16.SIY 
E12 Ldha knockout cells, generated with CRISPR/Cas9 (Ldha−/− clones). The results are presented relative 
to the level of 18S rRNA. Each dot represents an individual experiment and horizontal lines indicate the 
mean. * P < 0.05 (unpaired Student’s t-test). 
5.3 Immunomodulatory role of lactic acid in human 
melanoma? 
In melanoma tumors of immunocompetent C57BL/6 mice, IFN-γ expression was impaired in the 
presence of high concentrations of tumor-derived lactate and this resulted in the loss of tumor 
growth control, which was maintained in the presence of lower lactate concentrations. For human 
melanoma, serum levels of LDH, the enzyme responsible for lactate generation, are used as a 
prognostic marker and elevated LDH serum levels indicate advanced disease and poor 
prognosis196. Results from immunohistochemical analyses demonstrated a low expression of 
LDH-5 in melanocytic nevi, whereas in melanoma and metastases, a higher expression of LDH-5 
was observed. Consequently, high LDH-5 expression was related to a reduced disease-free and 
overall survival of melanoma patients40. Up to now, high LDH serum levels are often attributed to 
a high tumor load. However, in the light of our data, the link between high LDH-5 expression in 
tumor tissues and poor prognosis in human melanoma could also be attributed to an 
immunosuppression in the melanoma environment. Therefore, LDHA mRNA expression, lactate 
levels and the immune cell infiltrate were investigated in biopsies of melanoma in situ (the earliest 
stage of melanoma), primary melanoma, cutaneous metastases as well as healthy tissue of 
melanoma patients. 
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5.3.1 Analysis of LDHA expression and lactate levels 
In order to assess LDHA expression, qRT-PCR analyses from total RNA of biopsies from 
melanoma in situ (Mis), melanoma lesions (M) and healthy tissue of melanoma patients (Ctrl M) 
were performed. Results revealed that melanoma lesions exhibited a wide distribution of LDHA 
expression but statistical analyses revealed a significantly elevated LDHA mRNA expression 
compared to melanoma in situ patients (Figure 5-37 A). As mere LDHA expression does not 
always correlate with the activity of the enzyme, lactate levels in tumor biopsies were determined. 
Therefore, biopsies of melanoma in situ, melanoma and healthy tissue of melanoma patients were 
snap-frozen after excision and intra-tissue lactate levels were analyzed using bioluminescence 
imaging by the group of Wolfgang Mueller-Klieser (Institute of Pathophysiology, University Medical 
Center of the Johannes Gutenberg University Mainz, Germany). These measurements revealed 
that lactate levels in lesions of melanoma in situ, melanoma and healthy tissue of melanoma 
patients were similar, with mean values of 6.5 µmol/g tissue (Figure 5-37 B). Hence, mRNA levels 
of LDHA and lactate levels were not corresponding. However, this may also be due to the fact that 
it was not possible to analyze the same biopsies in parallel for LDHA mRNA expression and 
lactate levels. 
Mis Ctrl M M
0.0
0.2
0.4
0.6 *
A
R
el
at
iv
e
LD
H
A
m
R
NA
 
ex
pr
es
si
o
n
Mis Ctrl M M
0
5
10
15
B
La
ct
at
e 
(µ
m
o
l/g
)
 
Figure 5-37. LDHA mRNA expression, but not lactate, is elevated in human melanoma biopsies 
compared to melanoma in situ 
(A) qRT-PCR analysis of LDHA mRNA from human biopsies of melanoma in situ (Mis), melanoma lesions 
(M) and adjacent healthy tissue (Ctrl M). The results are presented relative to the level of 18S rRNA. Each 
dot represents one individual patient and horizontal lines indicate the mean. Connections between dots link 
samples of the same donor. (B) Lactate levels from biopsies as described in A assessed by bioluminescence 
imaging. * P < 0.05 (unpaired Student’s t-test). 
In addition, lactate levels of cutaneous metastatic lesions of melanoma patients (M Met) and 
healthy skin of melanoma patients (Ctrl) with metastases were examined by bioluminescence 
imaging as described above. Strikingly, the results revealed that metastases exhibited mean 
lactate levels of 21 µmol/g (Figure 5-38), which represents a tremendous increase compared to 
melanoma lesions exhibiting 6.5 µmol/g (Figure 5-37 B).  
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Figure 5-38. Cutaneous metastases of melanoma patients exhibit high lactate levels compared to 
healthy tissue 
Lactate levels from cutaneous metastases (M Met) and healthy skin (Ctrl) of human melanoma patients, 
determined by bioluminescence imaging. Each dot represents one individual biopsy and horizontal lines 
indicate the mean (Ctrl: n = 4). Connections between dots link samples of the same donor. * P < 0.05 
(unpaired Student’s t-test). 
5.3.2 Analysis of the immune cell infiltrate 
Cutaneous melanoma metastases displayed significantly higher lactate levels than healthy tissue 
of the same donors. In order to analyze possible correlations between lactate levels and immune 
cell infiltration in metastases of melanoma patients, immune cells in biopsies were investigated by 
flow cytometry. Based on the results obtained in the mouse melanoma model, the activation 
status of cytotoxic T cells was investigated. Analyses revealed that higher numbers of infiltrating 
leukocytes were present in melanoma metastases than in adjacent tissue of the same donors 
(Figure 5-39 A). T cells represented the most abundant cell type among all leukocytes (65%), but 
levels of T cells did not differ in metastases and control tissue (Figure 5-39 B). CD8+ T cells 
represented 35% of all T cells, in healthy tissue and a slightly increased amount of 45% was 
detected in metastatic lesions (Figure 5-39 C). Interestingly and in accordance with previous 
observations in the B16 mouse melanoma model, the numbers of CD25+ cells among CD8+ T 
cells were dramatically reduced in melanoma metastases compared to healthy control tissue of 
the same donor, ranging from 40% in healthy biopsies to values below 1% in metastatic lesions 
(Figure 5-39 D). 
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Figure 5-39. Cutaneous metastases of melanoma patients are highly infiltrated with inactive CD8+ T 
cells 
(A-D) Flow cytometry analyses of leukocytes among all cells of the tumor (A), T cells among all leukocytes 
(B), CD8+ T cells among all T cells (C) and CD25+ cells among CD8+ T cells (D) in cutaneous metastases (M 
Met) and healthy skin (Ctrl) of human melanoma patients. Each dot represents one individual patient and 
horizontal lines indicate the mean. Connections between dots link samples of the same donor.  
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6 Discussion & Perspectives 
6.1 Immunomodulatory role of lactic acid in vitro 
Tumors are characterized by a rapid deregulated cell division and in order to maintain 
hyperproliferation, tumor cell metabolism is altered. The most prominent metabolic change is the 
switch from OXPHOS to aerobic glycolysis, termed Warburg effect. The Warburg phenotype 
exhibits excessive glycolysis and subsequent generation of high amounts of lactate. Lactate, 
which was previously regarded as a mere waste product of glycolysis, has recently emerged as a 
multifunctional player in tumorigenesis197. Its export from the cell in co-transport with protons via 
MCT1 and MCT467 leads to the extracellular accumulation of lactic acid and acidification of the 
tumor microenvironment. Tumor-derived lactic acid exerts direct tumor-promoting effects via the 
generation of tumor acidosis, which enhances the degradation of the ECM and thereby fosters 
tumor invasiveness18. Additionally, tumor-derived lactate functions as a promoter of 
angiogenesis62,198,199.  
Besides the direct effects of lactic acid on tumor progression, there is evidence that lactic acid 
modulates immune cell function. Only few papers investigated the effect of lactic acid on lymphoid 
cells in vitro. Fischer et al. revealed that lactic acid inhibited both the cytokine production and 
cytotoxic activity of human CD8+ T cells177. The ablation of cytokine production was accompanied 
by an impaired lytic granule exocytosis of cytotoxic T cells upon lactic acid exposure178. Lactic 
acid production was further linked to a diminished ability of cytotoxic T cells to recognize tumor-
associated antigens188. Besides lactic acid, lactate was shown to diminish the motility of T helper 
and cytotoxic T cells. Lactate polarized CD4+ T cells into Th17 cells, producing IL-17, and lactic 
acid reduced the cytolytic capacity of CD8+ T cells189. NK cells treated with lactic acid showed a 
diminished production of perforin and granzyme, and thereby blunted cytolytic activity180. 
The finding that lactic acid impaired the cytokine production in human T cells was confirmed for 
mouse T cells by the results obtained in this work. Starting from a concentration of 10 mM, which 
is in the lower range of pathophysiological concentrations measured in human tumor lesions57, 
lactic acid provokes a striking decrease in IFN-γ production of CD4+, CD8+ T cells and NK cells. A 
similar effect was observed upon incubation in an acidic environment independent of lactate, 
whereas upon exposure of sodium lactate no impairment of IFN-γ production was observed. This 
dependence of lymphoid cells’ cytokine production on the extracellular pH was also demonstrated 
by Mendler et al.178. On the other hand, granzyme B production by mouse CD8+ T cells and NK 
cells was neither affected by lactic acid nor by acidosis or sodium lactate. As only intracellular 
granzyme B levels were assessed, it is conceivable that lactic acid interferes with the lytic granule 
exocytosis, as observed by Mendler et al.178, and in this way impairs cytolytic functions of CD8+ T 
cells189. Moreover, it is described that the production of IFN-γ facilitates the cytolytic function of NK 
cells via improving adhesion to target cells200. The impaired production of IFN-γ by lactic acid-
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treated T or NK cells could, therefore, be another explanation for the compromised cytolytic 
activity observed by Haas et al.189. 
However, Fischer et al. and Husain et al. demonstrated the inhibition of perforin and granzyme 
production by lactic acid in human T cells177,180. The discrepancy between the observations 
regarding perforin and granzyme could be due to differences regarding the experimental settings. 
In this dissertation, mouse T cells were incubated with lactic acid only for a short time while in the 
cited publications long-time incubation was performed. To clarify the effects of lactic acid on 
cytolytic molecules, additional experiments will have to be performed. 
The impact of lactic acid on myeloid cells has been investigated by several groups. Dietl et al. 
demonstrated an impeded production of both TNF and IL-6 in human monocytes upon lactic acid 
exposure176. Accordingly, DCs treated with lactic acid showed a tolerogenic phenotype, secreting 
diminished amounts of IL-12 and exhibiting an altered antigen expression profile174. Lactic acid 
also stimulated human monocytes to increase their production of IL-23179, which is crucial for the 
generation of Th17 cells. A direct effect of lactate on Th17 generation was reported by Haas et 
al.189. Shime et al. reported an increase of the IL-6 production from human monocytes upon lactic 
acid exposure which contradicts the observations of Dietl et al.176,179. However, Shime et al. used 
a different experimental setting where monocytes were preincubated with lactic acid179. Yabu et al. 
demonstrated that lactic acid did not influence Il6 mRNA expression in co-cultures of mouse 
CD11b+ cells and CD4+ T cells after incubation for 12 hours201, which is consistent with the finding 
in this work that IL-6 production of myeloid cells was not affected by lactic acid or acidification. 
The discrepancy between the results could be due to a later onset of IL-6 regulation by lactic acid. 
Another plausible explanation would be differences in the immune regulation between mouse and 
human myeloid cells.  
Furthermore, lactic acid was described to elevate ARG1 expression in mouse macrophages, 
which is known to impede T cell proliferation and activity. Interestingly, this feature was also 
attributed to the acidification caused by lactic acid202. 
Concluding, the impact of lactic acid on myeloid cells is not entirely clear. Controversial results 
could likely be related to the high plasticity of myeloid cells, depending on the cytokine profile in 
their environment and thereby on the stimulation and cultivation conditions during experiments. 
Regarding lymphoid cells, increasing evidence suggests that lactic acid exerts immunoinhibitory 
effects on CD4+ and CD8+ T cells and NK cells. 
6.2 Immunomodulatory role of lactic acid in vivo 
In vitro analyses suggest an immunomodulatory role of lactic acid, yet, the investigation of single 
immune cell populations under cell culture conditions is not sufficient to mimic the complex 
situation in the tumor microenvironment. Tumors are composed of tumor cells themselves and 
stroma cells, including fibroblasts, endothelial cells, pericytes, mesenchymal cells and cells of the 
innate and adaptive immune system. The cross-talk between stroma cells and tumor cells 
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determines tumor growth. To elucidate the role of tumor-derived lactic acid in the tumor 
environment, its impact was studied in a mouse melanoma model.  
6.2.1 Characterization of B16.SIY E12 Ldhalow cells for in vivo 
experiments 
By means of shRNA technology, Ldha, coding for the lactate-producing enzyme LDH-5, was 
downregulated in B16.SIY E12 mouse melanoma cells in order to obtain tumor cells with a 
diminished lactate production (Ldhalow cells). Ldha expression as well as other (metabolic) 
properties of these model cell lines were examined. Results from qRT-PCR revealed a 
downregulation in Ldha mRNA expression of about 50% in Ldhalow clones accompanied by a 
decrease in LDHA protein expression compared to untransfected cells and control cells which 
were transfected with a scrambled shRNA sequence. Consequently, Ldhalow clones produced 
about 50% less lactate than untransfected cells and control cells. Thus, the Ldha shRNA 
approach created tumor cells with low lactate production. Additional analyses of the Ldhalow clones 
revealed that the decrease in Ldha mRNA expression was linked to increased mRNA levels of 
Ldhb which, though, did not result in a change of LDHB protein levels. We also investigated other 
marker genes of glycolysis. Glut1 mRNA expression, coding for the main glucose transporter of 
tumor cells, was not impaired by the knockdown of Ldha. In contrast, Hk1 mRNA expression was 
upregulated in Ldhalow clones compared to control cells, probably to compensate for the impaired 
lactic acid production. This hypothesis could be confirmed, as Ldhalow clones showed higher 
mitochondrial respiration due to increased mitochondrial content compared to control cells. 
Despite the metabolic differences in Ldhalow clones and control cells, proliferation and cell cycle 
properties were similar. The elevated mitochondrial respiration after Ldha attenuation was already 
observed in mouse mammary tumor cells by Fantin et al.49, yet, associated with an impairment of 
proliferation under hypoxic conditions. In this work, for both Ldhalow and control cells, a similar 
proliferation even under hypoxic conditions was observed (data not shown). Consistent to the 
findings of Fantin et al.49, an impaired proliferation even under normoxic conditions, decreased 
glycolysis along with increased OXPHOS and elevated levels of ROS were observed in mouse 
metastatic breast cancer LDHA-knockdown cells by Rizwan et al.53, and Le et al. and Wang et al. 
who further observed increased apoptosis due to elevated ROS levels in LDHA-knockdown cells 
of human lymphoma and breast cancer50,54. A decreased proliferation and invasion, together with 
enhanced apoptosis after LDHA silencing, was additionally observed in prostate cancer cells and 
glioblastoma cells203,204. 
Thus, the metabolic switch towards OXPHOS seems to be a common feature of tumor cell lines 
with disrupted LDHA, while effects on proliferation and apoptosis are likely to be cell-type specific. 
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6.2.2 Analysis of Ldhalow tumors in immunocompetent C57BL/6 
mice 
In a next step, the Ldhalow clones were injected subcutaneously into immunocompetent C57BL/6 
mice and tumors were analyzed regarding their metabolic profile and cytokine pattern. Most 
importantly, the Ldha mRNA expression was still downregulated in Ldhalow tumors, accompanied 
by an almost 50% diminished concentration of intratumoral lactate levels compared to control 
tumors. Moreover, after recultivation of cells from dissociated tumors, the difference in the lactate 
production between Ldhalow tumor cells and control tumor cells was still persistent. This clearly 
proved that the Ldha knockdown in the Ldhalow clones is not only stable in vitro but also in vivo. 
The expression of glycolysis-associated genes remained unchanged in Ldhalow tumors compared 
to the in vitro analyses, with the exception of Ldhb mRNA expression which was downregulated 
only in one Ldhalow clone in vivo. Besides LDHA, several other enzymes play roles in 
immunomodulation, among them IDO1 and IDO2, ARG1 and ARG2, COX1 and COX2 as well as 
iNOS. Their mRNA expression was assessed in Ldhalow tumors and no differences were found 
compared to control tumors, ensuring that the observed immunoregulatory effects were caused by 
lactate.  
Since tumors are known to create an immunosuppressive microenvironment, not only by changes 
in their metabolism, but also by the production of pro- and anti-inflammatory cytokines, gene 
expression of crucial tumor-promoting factors was analyzed by qRT-PCR. Analyses of Ldhalow 
tumors in comparison with control tumors did not show alterations in mRNA levels of pro-tumoral 
Vegfa, Csf2, Il6, Il10, Tnf and Il17a. Therefore, the described lactic acid-induced production of 
VEGF by endothelial cells62 seems to play no role in the analyzed Ldha shRNA tumor model. Csf2 
mRNA expression, which is linked to MDSC function and expansion of the highly 
immunosuppressive monocytic MDSC subset127,128 was also not affected by lactic acid. The 
induction of IL-17 by lactic acid, which was described by Shime et al.179, was not observed on 
mRNA levels in B16.SIY E12 control tumors, most likely due to the limited number of Th17 cells in 
tumors. As the main fraction of cells within tumor samples are tumor cells, and stroma cells 
represent only a minor fraction, it is conceivable that possible differences in the expression of 
cytokines, which are produced by immune cells, are concealed and not detected by qRT-PCR. 
However, the results revealed significant differences in Tgfb1 and Ifng mRNA expression, the 
former being significantly downregulated in Ldhalow tumors, while the latter was found to be 
increased. Lactic acid was shown to increase TGFB1 mRNA and protein levels in co-cultures of 
fibroblasts and endothelial cells in a pH-dependent manner205. Knockdown of LDHA by means of 
siRNA was shown to decrease TGFB2 mRNA and protein levels in glioma cells206. In the light of 
these findings and the results obtained in this work, it is likely that both TGFB1 and TGFB2 
expression are induced by lactic acid. However, only little amounts of TGF-β protein were 
detectable in supernatants of control and Ldhalow tumors, with no significant differences between 
the two groups.  
The heightened Ifng mRNA expression observed in Ldhalow tumors is a hint for a less 
immunosuppressive tumor microenvironment in the absence of high lactate levels. Analysis of     
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T cell markers by means of qRT-PCR measurements did not show differences regarding Cd4, 
Foxp3 and Cd8a mRNA expression in Ldhalow tumors compared to controls, which is in contrast to 
the actual protein levels analyzed by flow cytometry, as discussed below.  
To get an impression of the actual immune cell infiltration in tumors derived from Ldhalow cells and 
control cells, intratumoral immune cells were stained with antibodies against surface and cytokine 
markers. To exclude effects linked to tumor size, only tumors with a maximum volume of 1,000 
mm3 were included in the analyses. The size distribution of tumors derived from Ldhalow and 
control cells was similar. Analyses revealed that tumors contained about 5% of immune cells. 
Ldhalow tumors were infiltrated with increased numbers of leukocytes compared to control tumors. 
Among the infiltrating leukocytes, myeloid cells were the most abundant cells in both Ldhalow 
tumors and control tumors. The majority of myeloid cells represented MDSCs, which were present 
in similar amounts in Ldhalow tumors and control tumors. MDSCs share many characteristics with 
M2 macrophages, whose development can be promoted by lactic acid181. As MDSC numbers did 
not differ between Ldhalow and control tumors in C57BL/6 mice and the expression of the M2 
marker gene Arg1 was similar, there is no hint that lactic acid promotes M2 or MDSC 
development in this model. Further analyses of the immune cell infiltration demonstrated that 
about 10% of all leukocytes in control tumors were B cells, whereas their infiltration in Ldhalow 
tumors was significantly reduced. In contrast, the number of T cells among all immune cells was 
increased in Ldhalow tumors compared to control tumors. T helper cell numbers were not altered 
significantly in Ldhalow tumors compared to controls whereas significantly more cytotoxic T cells 
were found in Ldhalow tumors compared to control tumors. The most striking difference between 
Ldhalow tumors and control tumors was the amount of infiltrating NK cells. Ldhalow tumors 
contained about twofold more NK cells among all leukocytes. Thus, local immunomodulation by 
tumor-derived lactic acid could be confirmed.  
To gain inside into possible systemic effects of tumor-derived lactic acid, blood and spleens of 
tumor-bearing mice were analyzed. The results revealed that tumor burden in mice increased the 
levels of circulating myeloid cells, MDSCs and NK cells accompanied by decreased levels of T 
cells in comparison to healthy mice. In spleens, the increase of NK cells and the decrease of T 
cells were observed. However, no differences of immune cell numbers between mice bearing 
Ldhalow tumors and control tumors were detectable in the blood or the spleens, suggestive of a 
locally restricted immunomodulation by tumor-derived lactic acid. In contradiction with this 
hypothesis is the finding of Husain and colleagues that MDSCs occurred less frequently in 
spleens of mice bearing LDHA-silenced tumors180. As T cells and NK cells play major roles in 
tumor suppression, their effector functions were assessed by means of cytokine analyses. The 
activity of T helper cells remained unaffected by lactic acid, as IFN-γ and IL-17 production of CD4+ 
T cells from Ldhalow tumors and control tumors did not differ. In contrast, IFN-γ production of 
cytotoxic T cells and NK cells from Ldhalow tumors was significantly increased, along with elevated 
granzyme B production. Decreased expression of perforin, granzyme B and IFN-γ by T cells and 
NK cells was observed in malignant tissue of lung cancer patients compared to non-cancer tissue 
and could partially be attributed to alterations in the COX2 pathway207. Recent observations from 
Zelenay et al. unfold that COX2 seems to be responsible for tumor-promoting inflammation and 
Discussion & Perspectives 
  88 
immunosuppression in mouse melanoma tumors, and that its ablation leads to a decreased 
expression of IL-6, along with an increased expression of IFN-γ and immune-dependent tumor 
eradication208. In contrast, the results obtained in this dissertation attribute the impaired release of 
IFN-γ and granzyme B from tumor-infiltrating T and NK cells to tumor-derived lactic acid, while no 
differences in Cox mRNA expression between control and Ldhalow tumors were observed. The 
negative impact of lactic acid on IFN-γ production in CD8+ T cells and NK cells was further 
supported by in vitro experiments. Moreover, enhanced cytolytic properties of NK cells in LDHA-
silenced tumors were confirmed by Husain et al.180. In line with this finding is the observation that 
soluble LDH-5 impairs NK cell activity via induction of ligands for the activating receptor NKG2D 
on myeloid cells, and thereby subsequent downregulation of NKG2D on NK cells209. 
Conflicting results between in vitro and in vivo experiments were obtained regarding IFN-γ, IL-6 
and granzyme B production. Lactic acid exposure suppressed IFN-γ in CD4+ T cells in vitro, but 
not in vivo, indicating a decreased sensitivity of CD4+ T cells towards lactic acid in vivo, compared 
to CD8+ T cells. The opposite holds true for granzyme B production, which was impaired in tumors 
with higher lactate levels, but lactic acid did not inhibit granzyme B expression under cell culture 
conditions, suggesting that other factors besides lactic acid are involved in granzyme B 
downregulation in vivo. Furthermore, IL-6 production by myeloid cells was diminished in Ldhalow 
tumors but lactic acid did not promote IL-6 secretion by myeloid cells in vitro, indicating that other 
factors besides lactic acid are necessary to upregulate IL-6 expression in vivo. These results 
highlight that in vitro experiments, especially in the field of tumor immunology, where a multitude 
of different cell types interact with one another, often do not portray the actual (patho-) 
physiological situation.  
Here, it could be shown that tumor-derived lactate impedes infiltration of CD8+ T cells and NK 
cells into tumor sites, along with an inhibition of effector functions by circumventing the production 
of cytokines and other effector molecules. Cytotoxic lymphocytes are major players involved in 
tumor suppression. Besides their direct cytolytic effects on tumor cells via secretion of perforin 
and granzyme135,148, their release of IFN-γ leads to the activation of Th1 cells and 
macrophages134. IFN-γ further inhibits the production of TGF-β164, which could be observed in 
Ldhalow tumors on mRNA level, displaying elevated Ifng and decreased Tgfb1 expression.  
IL-6 has been shown to exert a dual role in tumorigenesis, counteracting tumor growth in early 
stages of melanoma, while possessing stimulatory capacities in later stages of melanoma210-212. 
Yet, in a model of spontaneous melanoma, IL-6 deficient mice formed less and smaller tumors 
compared to immunocompetent mice, indicative of IL-6 being implicated in both the development 
of precursor lesions and subsequent growth of melanomas213. Accordingly, Ldhalow tumors 
containing diminished amounts of IL-6 showed a restricted tumor growth compared to faster 
proliferating control tumors in which higher amounts of IL-6 were present.  
The increased abundance and higher activity of cytotoxic lymphocytes should limit tumor growth 
in a low-lactate tumor microenvironment. And in fact, Ldhalow cells, which proliferate similarly as 
control cells in vitro, showed a significantly decreased tumor growth compared to control tumors 
after injection into immunocompetent C57BL/6 mice. However, this result was dependent on the 
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number of injected tumor cells. When 1 x 104 cells were injected, tumor formation from Ldhalow 
cells was completely prevented until day 17. Injection of 1 x 105 tumor cells still allowed tumor 
growth control in Ldhalow tumors. In contrast, upon injection of 1 x 106 tumor cells, the growth 
difference between Ldhalow tumors and control tumors was lost. The unphysiologically high tumor 
load seems to have overcome any possible anti-tumor immunity. Flow cytometry analyses of the 
immune cell infiltrate in those tumors revealed that differences between Ldhalow tumors and 
control tumors regarding myeloid cells, B cells and T cells were lost.  
B cells have been shown to contribute to tumor growth110,214,215, which is in accord with the finding 
of elevated levels of B cells in rapidly proliferating control tumors after injection of 1 x 105 cells. 
The observed increase in the number of infiltrating B cells in control tumors suggests an 
insensitivity of B cells towards lactic acid, but further experiments have to be performed to confirm 
this hypothesis.  
Numbers of infiltrating cytotoxic T cells and NK cells were increased in Ldhalow tumors, which was 
associated with a decreased tumor growth after injection of low numbers of tumor cells. 
Surprisingly, after injection of high numbers of tumor cells, the majority of infiltrating immune cells 
represented T cells. These findings seem to be contradictory to the observations that infiltration 
with cytotoxic T cells is associated with favorable prognosis in several kinds of cancer, including 
colon carcinoma216 and melanoma217. Regarding NK cells, despite high infiltration, a similar 
proliferation was found in Ldhalow tumors compared to control tumors after the injection of high 
numbers of tumor cells. NK cell infiltration, besides T cell infiltration, is also associated with 
improved outcome in various human tumors138,139. However, tumor-promoting NK cell phenotypes 
with compromised cytolytic functions and pro-angiogenic properties were observed in a range of 
tumors135. Therefore, not the abundance but the activity of immune cells in the tumor 
microenvironment is decisive.  
6.2.3 Analysis of Ldhalow tumors in CCR2-deficient mice 
Monocytic, as well as granulocytic MDSCs have been described as potent inhibitors of T cells, 
and their amount correlates to a poor outcome in various types of cancer127. Furthermore, myeloid 
cells can be influenced by lactic acid174-176,179,181 and thereby could contribute to tumor immune 
escape. Lesokhin et al. demonstrated that the monocytic subset of MDSCs, expressing CCR2, 
regulates the infiltration of CD8+ T cells into the tumor microenvironment128. Therefore, we tried to 
elucidate a possible link between monocytic MDSCs, regulation by lactic acid and tumor growth. 
For this purpose, we used an α-CCR2 antibody and the respective isotype control. However, the 
administration of the isotype antibody already resulted in a reduction of tumor growth compared to 
control tumors. Powerful anti-tumor effects of IgG administration have been described in cancer218 
and high-dose infusion of IgG serves as an anti-inflammatory therapeutic agent in several 
autoimmune and inflammatory diseases219.  
To circumvent any unspecific effects of immunoglobulins, further experiments were conducted 
using CCR2-deficient mice in order to examine the role of monocytic MDSCs in tumor growth. 
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Results showed that the absence of monocytes led to diminished tumor growth compared to that 
of wild type mice. These findings suggest that monocytes play a role in tumor-promotion in the 
B16 mouse melanoma model, which needs to be further investigated.  
6.2.4 Analysis of Ldhalow tumors in immunodeficient 
Rag2−/− and Rag2−/−γc−/− mice 
The presence of monocytic MDSCs seems to promote tumor growth, indicating that tumor 
immunosurveillance is based on the balance between pro-tumor and anti-tumor effector cells. To 
further prove the (lactate-dependent) role of T and NK cells in tumor immunosurveillance, Ldhalow 
and control tumor cells were injected in T and B cell-deficient Rag2−/− mice, and lymphocyte-
deficient Rag2−/−γc−/−  mice. As previously observed, tumor growth of Ldhalow tumors in 
immunocompetent C57BL/6 mice was slow. In Rag2−/− mice, the lack of T and B lymphocytes led 
to accelerated growth of Ldhalow tumors. Tumor growth in Rag2−/−γc−/−  mice, in the absence of 
both T, B and NK cells, outpaced growth of Ldhalow tumors in C57BL/6 and Rag2−/− mice. In 
contrast, similar growth was observed for control tumors, irrespective of the presence or absence 
of lymphocytes in C57BL/6 mice, Rag2−/− mice and Rag2−/−γc−/−  mice. These findings confirm that 
tumor immunosurveillance in our model is dependent on tumor-derived lactate and that it involves 
both T and NK cells. In a tumor environment containing low amounts of lactate, T and NK cells 
together are able to attenuate tumor growth. This is impossible in a tumor environment containing 
high amounts of lactate. Likewise, the absence of T and NK cells obviates tumor growth control, 
even in a low-lactate environment.  
Analyses of immune cell infiltrates in the tumor specimen revealed that in Rag2−/−  mice, the 
difference of NK cell numbers between Ldhalow tumors and control tumors, which was observed in 
C57BL/6 mice, was lost. In addition, higher levels of myeloid cells were detected in Rag2−/− mice 
and Rag2−/−γc−/−  mice, as the fraction of lymphoid cells is missing. Immune cell infiltration was 
representative for tumor growth, as in Rag2−/−γc−/−  mice, in the absence of lymphocytes, Ldhalow 
and control tumors grew similarly, along with no observed differences regarding infiltrating 
immune cells. In Rag2−/−  mice, pro-tumoral expression of PD-L1 on myeloid cells was decreased 
in Ldhalow tumors, a higher abundance of DCs was found, and growth of Ldhalow tumors was 
diminished in comparison to controls. This suggests that PD-L1 expression on myeloid cells may 
be regulated by NK cell activity. NK cells might additionally be responsible for elevated levels of 
DCs in Ldhalow tumors in Rag2−/−  mice. In fact, there is evidence that NK cells are able to induce 
and enhance DC maturation220,221. As previous observations demonstrated higher IFN-γ 
production of NK cells in tumors with impaired lactate production, it is conceivable that this leads 
to the increased infiltration of DCs in Ldhalow tumors of Rag2−/−  mice and C57BL/6 mice, and likely 
contributes to dampened tumor growth. Activated DCs, in turn possess the capability to activate 
NK cells or exert direct cytotoxic effects against tumor cells and in this way can contribute to 
tumor immunosurveillance133. 
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6.2.5 Analysis of Ldhalow tumors in immunodeficient 
Pfp−/−  mice 
Previous experiments proved that activated cytotoxic T cells and NK cells together are capable to 
control tumor growth in a low-lactate tumor microenvironment. To understand the mechanism of 
tumor growth control by T and NK cells, one major effector molecule, the pore-forming protein 
perforin, which is necessary to channel cytotoxic substances like granzymes into target cells, was 
further investigated. Results from tumor cell inoculation experiments into perforin knockout mice 
(Pfp−/− mice) revealed that despite the ablation of perforin production, tumor growth in Ldhalow 
tumors was significantly compromised compared to controls. This shows that in our model, 
perforin is not implicated in tumor suppression, even though perforin-dependent tumor control was 
described for several tumors and metastases222-225. However, there is evidence that tumor 
regression by cytotoxic T cells can occur also independently of perforin226.  
6.2.6 Analysis of Ldhalow tumors in mice lacking CD8+ T cells 
As the cytotoxic effector molecule perforin secreted from both cytotoxic T cells and NK cells was 
not involved in tumor inhibition, the question arose whether another T cell-derived factor leads to 
the suppression of tumor growth. Therefore, an attempt was made to deplete CD4+ or CD8+ T cells 
by administering monoclonal antibodies prior to injection of tumor cells into C57BL/6 mice. Blood 
analyses proved that the depletion of T cells was successful. However, similar to the results 
obtained during the depletion of CCR2+ monocytic myeloid cells with an α-CCR2 monoclonal 
antibody, the control antibody itself exerted suppressive effects on tumor cell proliferation and 
excluded interpretations regarding the role of CD4+ or CD8+ T cells in tumor growth. In further 
experiments, tumor growth was analyzed in Cd8−/− mice lacking CD8+ effector T cells, but 
surprisingly, the difference in tumor growth between Ldhalow and control tumors was comparable 
to that in immunocompetent C57BL/6 mice. Thus, tumor growth control of Ldhalow tumors was still 
possible in the absence of cytotoxic T cells. These data are concordant with a study which 
describes that NK cells and CD4+ Th1 cells together with IFN-γ are essential for tumor rejection in 
mice lacking CD8+ T cells227. CD4+ T cell numbers and activity were similar in Ldhalow tumors and 
control tumors from C57BL/6 mice, which suggests that lactate-dependent tumor growth control is 
independent of CD4+ T cells. Yet, in the absence of CD8+ T cells, CD4+ T cells seem to take over 
CD8+ T cell effector functions and contribute to tumor growth suppression in a low-lactate tumor 
microenvironment, alongside with cytotoxic NK cells. 
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6.2.7 Analysis of Ldhalow tumors in immunodeficient Ifng−/− and 
Ifngr1−/− mice 
Since both the results obtained in this dissertation and data from the literature suggest that IFN-γ 
plays a crucial role in tumor immunosurveillance, its role was investigated by using mice that lack 
IFN-γ. As expected, control tumors showed similar growth in C57BL/6 and Ifng−/− mice, indicating 
that in a high-lactate tumor microenvironment IFN-γ is dispensable, as tumor-promoting factors 
seem to overrule anti-tumor effector mechanisms. Strikingly, tumor control in a low-lactate tumor 
microenvironment, i.e. reduced proliferation of Ldhalow tumors, was completely abolished in the 
absence of IFN-γ. Ldhalow tumors in Ifng−/− mice showed similar growth as control tumors in 
C57BL/6 and Ifng−/− mice. Hence, IFN-γ is a crucial mediator of tumor control by immune cells and 
modulated by tumor-derived lactate. The contribution of IFN-γ to tumor immunosurveillance is well 
described228 and impaired IFN-γ signaling caused by the loss of function of the tumor suppressor 
interferon regulatory factor 1 (IRF-1) is linked to human leukemia and gastric cancer229,230. IFN-γ 
has also been shown to limit tumor growth by inhibiting tumor-induced angiogenesis231, by 
promoting anti-tumor host responses or by directly impeding tumor cell proliferation232,233. The 
question whether tumor immunosurveillance of Ldhalow tumors in C57BL/6 mice is due to direct 
effects of IFN-γ on tumor proliferation was clarified using Ifngr1−/− mice. In these mice, IFN-γ 
receptors are absent on host cells, but injected tumor cells still express IFN-γ receptors. Analyses 
of these experiments demonstrated a similar growth pattern as observed in Ifng−/− mice, with 
Ldhalow tumor proliferation being accelerated in the absence of host IFN-γ receptors. This result 
excludes the possibility that IFN-γ controls tumor growth via direct effects on tumor cells, as the 
presence of IFN-γ receptors on tumor cells would allow tumor suppression in Ldhalow tumors. IFN-γ 
dependent tumor growth inhibition, therefore, rather seems to be related to the activation of anti-
tumor responses by immune effector cells. In order to confirm this hypothesis, the immune cell 
infiltrate in C57BL/6 mice, Ifng−/− and Ifngr1−/− mice was investigated. Total leukocyte numbers 
were consistently higher in Ldhalow tumors compared to controls, irrespective of the mouse strain, 
but a statistically significant difference was only detected in C57BL/6 mice. Among infiltrating 
leukocytes, myeloid cells showed slightly decreased numbers in Ldhalow tumors of all mouse 
strains in comparison to control tumors. B cells were also slightly diminished in Ldhalow tumors in 
Ifng−/− and Ifngr1−/− mice, whereas a significant reduction was observed in C57BL/6 mice. As this 
immune cell pattern of diminished amounts of infiltrating myeloid cells and B cells in Ldhalow 
tumors compared to controls was present in all mice strains but tumor growth was only delayed in 
Ldhalow tumors in C57BL/6 mice, these immune cell populations seem to play no role in tumor 
suppression. Interestingly, exponential tumor growth in control tumors and Ldhalow tumors of both 
Ifng−/− and Ifngr1−/− mice was accompanied by diminished NK cell infiltration. Consistently, limited 
growth of Ldhalow tumors in C57BL/6 mice was associated with higher numbers of infiltrating NK 
cells. Not only were the levels of NK cells significantly elevated in slowly growing Ldhalow tumors, 
but also the percentage of activated CD8+ T cells was markedly increased. In contrast, tumors 
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with excessive proliferation derived from Ldhalow and control cells in Ifng−/− and Ifngr1−/− mice as 
well as control tumors from C57BL/6, only contained marginal amounts of activated T cells. 
Surprisingly, Ldhalow tumors from Ifng−/− and Ifngr1−/− mice exhibited higher numbers of infiltrating 
CD8+ T cells compared to C57BL/6 mice but the majority of these T cells were inactive as they 
showed no expression of CD25. Expansion of CD8+ T cells could have served as a mechanism to 
compensate for their decreased activity.  
In summary, IFN-γ was necessary for both NK cell recruitment into the tumor microenvironment 
and activation of CD8+ T cells, and thereby seems to represent the central factor for tumor growth 
suppression in this model. The IFN-γ-mediated tumor immunosurveillance was compromised by 
the excessive production of lactate from tumor cells. Thus, these findings demonstrate that lactate 
is a potent immunomodulatory factor in highly glycolytic tumors which promotes tumor growth via 
the suppression of IFN-γ production by T and NK cells (Figure 6-1). 
However, in none of the performed tumor inoculation experiments, the growth of Ldhalow tumors 
could be prevented completely. Even in the absence of excessive lactate production by tumor 
cells, where recruitment of NK and CD8+ T cells into the tumor microenvironment and activation 
via IFN-γ was feasible, residual tumor proliferation was observed. Results from Ccr2−/− mice, 
displaying diminished tumor growth compared to controls, suggest that monocytic myeloid cells 
exhibit tumor promoting effects and thereby are responsible for residual Ldhalow tumor proliferation 
in C57BL/6 mice. This notion is corroborated by the finding that IFN-γ fosters immunosuppression 
driven by monocytic MDSCs234. Results obtained in this dissertation also indicate that the function 
and activity of MDSCs seem not to be directly regulated by lactate but rather develop in 
dependence of cytotoxic effector cells which are sensitive to the lactate abundance in the tumor 
microenvironment. 
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Figure 6-1. Tumor-derived lactic acid leads to tumor immune escape 
In a low-lactate tumor microenvironment, the abundance of CD8+ T cells and NK cells and the subsequent 
production of IFN-γ and activation of CD8+ T cells (CD25) leads to tumor immunosurveillance and tumor 
growth control. In contrast, high amounts of lactate in the tumor microenvironment compromise IFN-γ 
production of NK cells and CD8+ T cells via intracellular acidification and downregulation of NFAT and 
thereby inhibit CD8+ T cell activation and NK cell infiltration. This further leads to tumor immune escape and 
tumor progression. MDSC, myeloid-derived suppressor cell; B, B cell; DC, dendritic cell; CD4+, T helper cell. 
6.2.8 Molecular pathways involved in the immunomodulation 
by lactic acid 
Tumor-derived lactate has been shown to drive tumor growth via compromising tumor 
immunosurveillance by impairing the IFN-γ production of CD8+ T cells and NK cells. Analyses on 
the mechanism of the IFN-γ inhibition by lactate or its protonated form lactic acid revealed that 
lactic acid led to a concentration-dependent intracellular acidification in CD8+ T cells. The 
intracellular pH of pH 7.5 in untreated cells decreased to pH 5.5 upon exposure with 15 mM lactic 
acid within 30 minutes after treatment. The effect was lactate-dependent, as the sole incubation 
with HCl led to a decrease in the intracellular pH but did not reach the same low pH values 
observed upon lactic acid exposure. This is likely based on the fact that in the presence of lactate, 
proton transport is not only possible via sodium-proton exchangers and bicarbonate transporters, 
but also through the activity of MCTs, which maximizes proton transport into the cell. Consistent 
with these findings, Fischer et al. observed a decrease in intracellular pH upon lactic acid 
incubation in human CD8+ T cells177. In pmel mouse T cells, however, exposure to low 
extracellular pH levels did not change the intracellular pH73. This discrepancy to the 
aforementioned findings could possibly be due to a significantly longer incubation time of pmel 
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mouse T cells compared to experiments with mouse and human CD8+ T cells. It is possible that 
after long-term incubation, T cells find ways to block proton influx and/or buffer their intracellular 
pH.  
The activity of enzymes depends on an optimal pH and it has been shown that lowering the pH 
strongly decreased the activity of calcineurin195. Calcineurin is responsible for the activation and 
nuclear translocation of NFAT, which is involved in IFN-γ expression193. NFAT is upregulated on 
mRNA and protein levels during activation of T cells194. Flow cytometry analysis revealed that 
NFAT upregulation in CD8+ T and NK cells during activation was inhibited upon lactic acid 
exposure. Acidification by HCl revealed similar results, whereas incubation with sodium lactate 
only resulted in slightly reduced NFAT levels. This indicates that generation of lactate during 
excessive glycolysis in tumors and subsequent accumulation of lactic acid in the tumor 
microenvironment leads to intracellular acidification of T cells and NK cells. Thereby, the 
upregulation of NFAT is disturbed. Furthermore, inhibition of the calcineurin activity prevents 
translocation of NFAT into the nucleus195, resulting in impaired IFN-γ production by CD8+ T and 
NK cells (Figure 6-1).  
Yet, NFAT is not only involved in IFN-γ regulation but also in the regulation of genes from the 
granule exocytosis pathway, including perforin and granzyme193. This may explain that granzyme 
B expression was diminished in tumor-infiltrating lymphocytes in a high-lactate tumor 
microenvironment. Besides the granule exocytosis pathway, lymphocyte-mediated cytotoxicity is 
executed by a “death-ligand” mechanism. Here, binding of FASL on NK or T cells to FAS receptor 
on target cells induces apoptosis of tumor cells. Since FASL expression has also been shown to 
be regulated by NFAT235 and lactic acid was demonstrated to influence NFAT expression, a 
possible role of FAS/FASL interactions in the B16 Ldhalow setting cannot be excluded. 
6.2.9 Characterization of Ldha−/− clones generated with 
CRISPR/Cas9 
In order to support the findings on the immunomodulatory role of lactic acid, additional B16 clones 
were generated by means of Ldha-gene editing using CRISPR/Cas9. In the respective clones, a 
total absence of the LDHA protein was observed under hypoxic conditions, which cause Ldha 
upregulation. Strikingly, despite the complete absence of LDHA, the lactate production of these 
Ldha−/− clones was only reduced by 30% compared to the control cells. Analyses by qRT-PCR 
further revealed a 100-fold lower Ldha mRNA expression in Ldha−/− clones compared to control 
cells, whereas no differences were observed regarding Ldhb expression. These results suggest 
that the LDH-1 enzyme, formed by the LDHB tetramer, is capable to replace LDH-5 enzyme 
activity. Accordingly, attempts with zinc-finger nuclease-mediated targeting of Ldha in Chinese 
hamster ovary cells failed to create cells without lactate production. However, the authors exclude 
the possibility of compensation by other LDH isoforms and attributed the lactate production to the 
recovery of heterozygous mutants and the lethality of cells with complete Ldha deficiency236. 
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Although further characterization of the Ldha−/− clones will be necessary to clarify the source of 
lactate production, these cells will serve as an additional system to confirm the immunomodulatory 
role of tumor-derived lactate in future experiments. 
6.3 Immunomodulatory role of lactic acid in human 
melanoma? 
Results from metabolic flux analyses revealed that human melanoma cell lines, unlike 
melanocytes, exhibit the Warburg phenotype237. BRAF, an oncogene mutated in about 50% of 
melanomas238, and more specifically, the mutation of V600EBRAF, which accounts for the broad 
majority of BRAF mutations detected in melanoma239, has been demonstrated to upregulate 
glycolysis-related genes. Consistently, knockdown of V600EBRAF in melanoma cells reversed the 
Warburg phenotype and reduced glycolysis240, and treatment with the V600EBRAF inhibitor 
vemurafenib resulted in improved survival of patients with V600EBRAF-positive metastatic 
melanoma241.  
Moreover, serum LDH levels have long been used as a prognostic marker in human melanoma, 
with elevated levels being indicative of an advanced disease and poor prognosis196. Additionally, 
higher LDH-5 expression was observed in melanoma and metastasis compared to melanocytic 
nevi and was associated with reduced survival of melanoma patients40.  
High numbers of CD8+ T cells, on the contrary, are considered as a positive prognostic marker150. 
Furthermore, adoptive immunotherapy with tumor-infiltrating lymphocytes seems to be a 
promising therapeutic approach in metastatic melanoma242, whereas immunotherapy of other 
tumors seems to be difficult. Due to challenges in T cell isolation, attempts have been made to 
genetically engineer TCRs of isolated T cells or to generate chimeric antigen receptors (CARs), in 
order to boost T cell anti-tumor functions243-247. The tremendous potential of immunotherapy was 
demonstrated using CAR T cells against CD19 for acute lymphoblastic leukemia patients, leading 
to a remission rate of 90% and durable remission up to 2 years248.  
Despite the widely recognized negative association of LDH serum levels with the outcome of 
human melanoma and the observation of high numbers of infiltrating CD8+ T cells, the possible 
connection between human LDH levels and immune cell infiltrate has not been investigated up to 
now. Therefore, experiments were carried out to establish a link between LDHA expression, 
lactate levels and immune cell infiltrate in human melanoma. Analyses revealed that in lesions of 
primary melanoma, LDHA was overexpressed compared to early melanoma stages, i.e. 
melanoma in situ, though LDHA expression was not different compared to adjacent healthy tissue. 
This was not consistent with the intra-tissue lactate concentrations detected, which showed similar 
levels in melanoma in situ, melanoma lesions and adjacent healthy tissue. Thus, lactate levels do 
not always correlate with LDHA expression and as lactate levels are similar in healthy tissue and 
primary melanoma, lactate seems to play no role in immunoregulation in primary melanoma. 
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However, with regard to metastases, lactate levels were significantly higher. Cutaneous 
metastatic lesions of melanoma patients revealed lactate concentrations ranging from 16 µmol/g 
to 38 µmol/g, whereas healthy tissue of the respective patients exhibited lactate levels around 10 
µmol/g. Subsequent analyses of the immune cell infiltrate demonstrated similar high numbers of 
infiltrating T cells, representing about 65% of all leukocytes, in both control and metastatic tissue. 
The numbers of cytotoxic T cells were slightly elevated in melanoma metastases compared to 
controls. Therefore, T cell migration into the tumor microenvironment does not seem to be 
influenced by extracellular lactate levels. Numbers of activated CD8+ T cells, however, were 
drastically diminished in melanoma metastases compared to adjacent healthy tissue. This is in 
line with the finding of reduced amounts of activated CD8+ T cells in high-lactate mouse 
melanoma tumors. 
In conclusion, the attenuation of CD8+ T cell activation by tumor-derived lactate observed in the 
mouse melanoma model partially mirrors the situation in cutaneous metastases of human 
melanoma patients. Results from the mouse melanoma model suggest the intracellular 
acidification, subsequent downregulation of NFAT and the reduction of IFN-γ in cytotoxic 
lymphocytes as a possible underlying mechanism. Further analyses are needed to clarify the 
importance of these findings for other tumor entities.  
6.4 Perspectives 
It has been known for many years that the excessive generation of lactate by highly glycolytic 
tumors and the subsequent accumulation of lactic acid in the tumor microenvironment exert direct 
pro-tumoral effects. This dissertation demonstrates a link between lactic acid accumulation and 
suppression of cytotoxic effector functions of immune cells, which allows evasion from 
immunosurveillance and thereby promotes tumor progression.  
Thus, it seems likely that lactate, which plays a critical role in tumorigenesis, can be relevant as a 
prognostic marker249. Walenta et al. established a link between lactate metabolism and 
aggressiveness of cancer by demonstrating that lactate accumulation correlates with decreased 
survival of cervical cancer patients57. The negative outcome of high lactate levels in tumors with 
regard to patient survival was likewise described for head and neck squamous cell carcinoma and 
glioblastoma multiforme185,250,251. Furthermore, intratumoral lactate content was shown to be 
associated with the incidence of metastasis185.  
Besides lactate, LDHA, which as a tetramer forms LDH-5, a crucial enzyme of the glucose 
metabolism responsible for the generation of lactate from pyruvate, also represents a potential 
prognostic marker in cancer38,39. In renal cell carcinoma, gastric cancer, pancreatic cancer and 
melanoma, overexpression of LDHA is associated with poor prognosis38-40,252. In pancreatic 
cancer, LDHA expression also correlated inversely with CD8+ T cell infiltration252. 
Immunohistochemistry analyses demonstrated the correlation of LDH-5 overexpression with 
unfavorable outcome in non-small cell lung cancer and colorectal cancer253,254. 
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These results underline the importance of glycolysis and subsequent lactate production for tumor 
progression and metastasis. Hence, increasing attempts are being undertaken to therapeutically 
target tumor glycolysis and lactate accumulation in order to dampen tumor progression and 
metastasis. The application of the small-molecule LDHA inhibitor FX11, a gossypol derivative, 
succeeded to obstruct tumor growth of human cancer xenografts50. Moreover, the combination of 
novel LDHA inhibitors and the chemotherapeutic agent gemcitabine in hypoxic pancreatic cancer 
cells, which are characterized by increased chemoresistance, led to synergistic cytotoxic effects 
with increased apoptosis and impaired cell migration255. Since LDH-5 inhibition appears to 
selectively affect highly glycolytic tumor cells, drugs targeting LDH-5 are likely safe agents 
counteracting tumor growth and invasiveness. Accordingly, research on potent and selective LDH-
5 inhibitors is conducted by several groups across academia and industry. However, the high 
polarity and small size of its natural substrate, and the rather large and open active site of LDH-5 
make it a difficult target. Thus, the commonly poor pharmacokinetic profile of novel LDH-5-
inhibiting molecules and low penetration into cells are the reasons why only a small number of 
LDH-5 inhibitors have progressed to preclinical and clinical trials. The development of more potent 
and selective LDH-5 inhibitors with a high bioavailability will, therefore, be a major future 
challenge36. 
Importantly, besides glycolysis and lactate production, lactate uptake and subsequent OXPHOS 
have been described as a feature of some tumor cell populations in heterogeneous tumors58. 
Consequently, the efficacy of LDHA inhibitors could be further increased by the treatment with 
anti-diabetic drugs such as pioglitazone or metformin, which drive tumor cells towards 
glycolysis256. 
Diclofenac, a non-steroidal anti-rheumatic drug, has been shown to inhibit Ldha expression and 
lactate production in mouse glioma cells in vitro. In vivo, diclofenac treatment resulted in 
decreased intratumoral lactate levels and repressed glioma growth, accompanied by a recovered 
IL-12 production of DCs. Although diclofenac impaired mouse T cell activation and proliferation, it 
likely represents a promising anti-glycolytic cancer drug257. 
Targeting MCTs represents another promising tool in anti-cancer treatment as lactate is exported 
from the cell via MCT1 and MCT467 and elevated levels of MCT1 and/or MCT4 are typical 
features of several human malignancies197,258. A second-generation MCT1 inhibitor, AZD3965, is 
currently undergoing phase I clinical trials for patients with solid tumors, prostate and gastric 
cancer and diffuse large B cell lymphoma259. Results from Marchiq et al. revealed that the 
treatment with the OXPHOS inhibitor phenformin induced cell death of MCT4 knockout cells due 
to a rapid drop in intracellular ATP and a subsequent metabolic catastrophe. Similar effects were 
observed for cells depleted of the MCT chaperone basigin187. These data suggest that combined 
targeting of glycolysis via MCT inhibitors or LDHA inhibitors, and OXPHOS via phenformin 
provides a powerful anti-cancer strategy. 
However, it has to be considered that targeting glucose metabolism may also inhibit the 
proliferation and activation of T cells, as upregulation of glycolysis is a common feature of 
activated T cells260. Impaired activation of tumor-infiltrating T cells was recently attributed to the 
glucose-deprivation by tumor cells leading to dampened T cell effector functions171,172.             
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Anti-glycolytic strategies for cancer therapy have, therefore, to be carefully evaluated, as they 
might act not only on tumor cells but as well on T cell metabolism and function260. Furthermore, 
off-target effects of anti-glycolytic drugs on other benign cells are possible. Thus, drug-delivery 
strategies like bi-specific antibodies, which redirect immune effector cells to the tumor 
microenvironment261, transporter-mediated drug uptake, e.g., a glucose-conjugated LDHA 
inhibitor262 and nanoparticle-based delivery systems to increase permeability and retention in the 
tumor263 are being investigated. 
The export of lactate from the cell via MCT1 and MCT4 is executed in co-transport with protons67 
and the accumulation of lactic acid in the tumor microenvironment leads to a subsequent 
acidification of the extracellular space68. Tumor acidosis is associated with increased invasiveness 
of tumors18. Neutralization of tumor acidity with bicarbonate monotherapy was previously shown to 
diminish tumor growth and to improve the anti-tumor responses to immunotherapy73. Regulators 
of pH, like the proton pump, sodium-proton exchangers and bicarbonate transporters could 
thereby also serve as potential targets for anti-tumor therapy71,72,264. 
In the light of the findings obtained in this dissertation, the strategies described above could lead 
to the reduction of immunosuppression by tumor-derived lactate and lactic acid, and thereby 
improve immunotherapeutic approaches in cancer treatment. In line with this hypothesis is the 
observation that serum LDH levels of patients with metastatic melanoma represent a selection 
criterion for immunotherapy with ipilimumab, a monoclonal antibody blocking CTLA-4. CTLA-4 
represents an immune checkpoint, as this receptor downregulates immune cell function. In case 
of baseline serum LDH concentrations exceeding twice the upper limit of normal values, 
ipilimumab treatment was unlikely to cause long-term benefits265. Another inhibitory checkpoint 
receptor is PD-1, which is predominantly expressed on activated T cells266. Metastatic melanoma 
has been linked to extensive infiltration with cytotoxic T cells which are hyporesponsive and 
cannot inhibit tumor progression. Tumor immune evasion was attributed, amongst others, to PD-
L1 expression267. PD-L1 is expressed on tumor cells and represents the ligand for PD-1266. 
Concordantly, preclinical studies have demonstrated that interfering with PD-1/PD-L1 interactions 
improved effector functions of tumor-specific cytotoxic T cells in the tumor microenvironment and 
thereby supported tumor rejection268,269. Hence, two anti-PD-1 antibodies, nivolumab and 
pembrolizumab, have been approved for the treatment of advanced melanoma and therapy-
refractory metastatic non-small cell lung cancer, and various other PD-1 or PD-L1 inhibitors are 
currently undergoing clinical trials266. Treatment with nivolumab and pembrolizumab has led to 
increased response rates and improved progression-free and overall patient survival in 
comparison to chemotherapy and ipilimumab treatment270-275. However, the data obtained from 
clinical trials for solid tumors revealed low response rates of PD-1 inhibitors266. Tang et al. 
demonstrated that induction of immune checkpoint blockade responses requires sufficient T cell 
infiltration276. 
Strikingly, serum LDH levels in patients with metastatic melanoma can predict clinical outcome 
early after anti-PD-1 therapy, with elevated LDH concentrations being linked to poor survival277. 
These observations, together with the data from this work on the immunomodulatory role of lactic 
acid, might serve as an explanation not only for the low response rates of PD-1 inhibitors in 
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advanced malignancies, but also for limitations of cancer immunotherapies in general. 
Consequently, combination therapies of promising immunotherapeutic agents and anti-metabolic 
drugs have to be developed in order to overcome immune tolerance and improve the anti-tumor 
immune response for the successful treatment of human cancer. 
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7 Summary 
Tumors show alterations in their metabolism to fulfill the requirements of excessive proliferation. 
The most prominent metabolic change is the switch from OXPHOS to aerobic glycolysis, termed 
Warburg effect. The increased uptake of glucose, subsequent conversion of pyruvate to lactate 
and the export of lactate in co-transport with protons lead to the extracellular accumulation of 
lactic acid and occur in the majority of malignant neoplasia. Extracellular lactic acid has been 
shown to exert a range of direct tumor-promoting effects and there is evidence that various 
immune cells are impaired by lactic acid. The aim of this dissertation was to clarify the 
immunomodulatory role of tumor-derived lactic acid. 
Ldha expression, coding for the lactate-generating enzyme LDH-5, was downregulated by means 
of shRNA technology in B16.SIY E12 mouse melanoma cells, resulting in low-lactate producing 
clones (Ldhalow). Cells transfected with scrambled shRNA were used as a control. Ldhalow clones 
showed higher OXPHOS than control cells due to increased mitochondrial content. Despite the 
metabolic differences in Ldhalow clones and control cells, proliferation and cell cycle properties 
were similar in vitro. In immunocompetent C57BL/6 mice, however, tumor growth of Ldhalow 
clones was significantly decreased compared to that of control cells. Bioluminescence analyses 
revealed 50% lower intratumoral lactate concentrations, along with reduced Ldha mRNA 
expression in Ldhalow tumors compared to control tumors. As other enzymes involved in 
tumorigenesis and immunosuppression, including IDO, ARG, COX and iNOS, did not show any 
differences in mRNA expression in Ldhalow tumors and control tumors, reduced tumor growth of 
Ldhalow clones could be attributed to their diminished lactate production.  
Ldhalow tumors contained more leukocytes and among them lower numbers of myeloid cells and B 
cells, which are said to be pro-tumorigenic, whereas the amount of infiltrating anti-tumoral 
cytotoxic T cells and NK cells was increased compared to control tumors. Moreover, cytotoxic T 
cells and NK cells from Ldhalow tumors produced significantly greater amounts of IFN-γ, thereby 
showing a higher activity than T cells and NK cells from control tumors. Consistently, IFN-γ 
production of T cells and NK cells was inhibited by lactic acid in vitro. This suggests that tumor 
immunosurveillance by activated T and NK cells is possible in a low-lactate tumor 
microenvironment but compromised in the presence of high amounts of lactate. 
Accordingly, in the absence of T cells and/or NK cells, tumor growth of Ldhalow clones was 
accelerated and became similar to that of control cells. Growth control of Ldhalow tumors was also 
lost in the absence of IFN-γ. This was accompanied by a diminished infiltration of NK cells and 
activated cytotoxic T cells, indicating a lactate-dependent regulation of IFN-γ production. 
In vitro analyses of cytotoxic T cells revealed a lactic-acid induced drop of intracellular pH, and 
subsequent compromised NFAT expression resulting in a diminished IFN-γ production.  
In summary, this dissertation highlights tumor-derived lactic acid as a potent immunomodulatory 
metabolite which limits effector cell recruitment into the tumor and impairs IFN-γ production of 
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cytotoxic T and NK cells in highly glycolytic tumors. Thereby, tumor immunosurveillance is lost 
and tumor progression is facilitated.  
Interestingly, analyses of cutaneous metastases from melanoma patients displayed high lactate 
levels along with a reduced infiltration of activated cytotoxic T cells. These findings suggest that 
lactic acid has immunomodulatory relevance, not only in the mouse model but also for human 
malignancies. 
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8 Zusammenfassung 
Tumoren weisen verschiedene Veränderungen in ihrem Stoffwechsel auf. Der Warburg-Effekt, die 
wohl bedeutendste metabolische Veränderung, ist durch gesteigerte aerobe glykolytische Aktivität 
charakterisiert. Hierbei wird vermehrt Glukose in die Zelle aufgenommen und zu Laktat 
umgewandelt. Dieses wird im Co-Transport mit Protonen aus der Zelle ausgeschleust, was zu 
einer Anreicherung von Laktat und Protonen (Milchsäure) im Tumormikromilieu führt. Neben einer 
Reihe direkter tumorfördernder Effekte gibt es Hinweise auf eine Immunregulation durch 
Milchsäure. Ziel dieser Arbeit war die Untersuchung der immunmodulatorischen Rolle 
tumorassoziierter Milchsäure. 
Dafür wurde die Expression von Ldha, welche für das laktatproduzierende Enzym LDH-5 kodiert, 
in B16.SIY E12 Mausmelanom-Zellen mittels shRNA-Technologie herunterreguliert. Auf diese 
Weise generierte Klone (Ldhalow) zeigten eine verminderte Laktatproduktion im Vergleich zu 
Kontrollzellen, die mit einer “scrambled”-shRNA transfiziert wurden. Ldhalow-Klone wiesen eine 
erhöhte oxidative Phosphorylierung auf, die der höheren Anzahl an Mitochondrien zuzuschreiben 
war. Trotz metabolischer Unterschiede der Ldhalow-Klone und der Kontrollzellen differierten diese 
nicht in Proliferation und Zellzyklus. Jedoch war das Tumorwachstum der Ldhalow-Klone in 
immunkompetenten C57BL/6-Mäusen deutlich vermindert. Biolumineszenz-Messungen von 
Ldhalow-Tumoren zeigten eine um 50 % verringerte intratumorale Laktatkonzentration im Vergleich 
zu Kontrolltumoren. Eine erniedrigte Ldha mRNA-Expression in Ldhalow-Klonen wurde sowohl in 
vitro als auch in vivo beobachtet. Dies bestätigte die stabile Herrunterregulation der Ldha in den 
Ldhalow-Klonen. Da sich die mRNA-Expression von anderen in Karzinogenese und 
Immunsuppression involvierten Enzymen wie IDO, ARG, COX und iNOS, zwischen beiden 
Gruppen nicht unterschied, wurde das verminderte Tumorwachstum der Ldhalow-Klone der 
verringerten Laktatproduktion zugeschrieben. 
In durchflusszytometrischen Analysen der Ldhalow-Tumoren wurde, im Vergleich zu den 
Kontrolltumoren, eine erhöhte Infiltration mit Leukozyten gefunden, darunter eine geringere 
Anzahl an myeloiden Zellen und B-Zellen, welche als protumoral gelten. Antitumorale 
Immunzellen, wie zytotoxische T-Zellen und NK-Zellen, waren jedoch vermehrt vorhanden. 
Zudem produzierten zytotoxische T-Zellen und NK-Zellen aus Ldhalow-Tumoren signifikant höhere 
Mengen an IFN-γ, was ein Zeichen erhöhter Aktivität darstellt. In Übereinstimmung damit ergaben 
in vitro-Experimente, dass die IFN-γ-Produktion von T- und NK-Zellen durch Milchsäure gehemmt 
wird. Dies legte nahe, dass eine Tumorimmunkontrolle durch aktivierte T- und NK-Zellen in einer 
Tumorumgebung mit niedrigen Laktatmengen möglich ist, ein hoher Laktatspiegel dies jedoch 
verhindert. In Abwesenheit von T- und/oder NK-Zellen wiesen Ldhalow-Tumoren ein vergleichbar 
schnelles Tumorwachstum auf wie Kontrolltumoren. Die immunologische Wachstumskontrolle von 
Ldhalow-Tumoren war in Abwesenheit von IFN-γ ebenfalls nicht mehr möglich. Entsprechend 
waren in diesen Tumoren eine geringere Anzahl infiltrierender NK-Zellen und aktivierter 
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zytotoxischer T-Zellen nachweisbar, was auf eine laktatabhängige Regulation der IFN-γ-
Produktion sowie der Rekrutierung von NK-Zellen und aktivierten T-Zellen hindeutet. In vitro-
Experimente zeigten, dass Milchsäure eine intrazelluläre Ansäuerung in T-Zellen bewirkt, was die 
NFAT-Expression beeinträchtigt und so zu verminderter IFN-γ-Produktion führt. 
Zusammenfassend zeigt diese Arbeit, dass die LDHA-assoziierte Anreicherung von Milchsäure im 
Tumormilieu die Rekrutierung und Aktivierung von zytotoxischen Effektorzellen limitiert. 
Insbesondere scheint die IFN-γ-Produktion zytotoxischer T-Zellen und NK-Zellen in 
hochglykolytischen Tumoren beeinträchtigt zu sein. Auf diese Weise kommt es zum Verlust der 
Tumorimmunkontrolle und zu gesteigertem Tumorwachstum.  
Interessanterweise zeigten erste Analysen von Biopsien kutaner Metastasen des humanen 
Melanoms ebenfalls einen Zusammenhang zwischen hohen Laktatspiegeln und einer geringen 
Infiltration mit aktivierten zytotoxischen T-Zellen. Diese Erkenntnisse deuten darauf hin, dass 
Milchsäure nicht nur im Mausmodel sondern auch in humanen Tumoren immunmodulatorische 
Effekte hat. 
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Plasmid used for the generation of Ldha−/− clones with 
CRISPR/Cas9 
 
 
Figure 10-1. Plamid map of pSpCas9(BB)-2A-GFP (PX458) 
Plasmid used for the knockdown of Ldha in B16.SIY E12 mouse melanoma cells with CRISPR/Cas9 
(CRISPR Ldha−/− clones). Two guide RNAs (gRNAs) targeting different loci on exon 4 of the Ldha gene were 
included in the vector to obtain CRISPR1 plasmid and CRISPR2 plasmid. pSpCas9(BB)-2A-GFP (PX458) 
was purchased from Addgene, Cambridge, MA, USA. 
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